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Abstract 
Neural stem cell grafts can potentially repair damage or degeneration of the human central 
nervous system (CNS). However, the only neural cells reported to provide any benefit to date 
have been immature neural precursors derived from aborted foetuses. Recent studies suggest 
that neural cells can be derived from non-neural and non-embryonic tissues such as bone 
marrow, peripheral and umbilical cord blood, and umbilical cord matrix (Wharton’s jelly). 
These tissues may therefore represent a more accessible source of cells for therapeutic repair 
and regeneration of the brain and spinal cord. Furthermore, they could potentially be obtained 
and grafted autologously, thereby reducing the risk of tissue rejection. 
At present, little is known about the origin, frequency and phenotypic characteristics of 
stem cells from the umbilical cord matrix. This aim of this study was to characterise and 
analyse the neurogenic potential of a potentially novel source of mesenchymal stem cells 
(MSCs) derived from the Wharton’s jelly (WJ) of human umbilical cord, and compared to 
foetal blood-derived MSCs. Cell division rates determined by serial passaging and CyQuant 
proliferation assay, senescence, antigenic profiles, and mesodermal (osteogenic and adipogenic) 
or neural differentiation potentials were assessed. 
MSCs from both sources showed typical fibroblastic morphology and formed 
monolayers in culture with foetal bovine serum (FBS). Most WJ (more than 82%) MSCs 
expressed characteristic markers, including CD105 (SH2), CD73 (SH3), prolyl-4 hydroxylase 
(5B5) and vimentin (V9). The doubling times of the foetal blood MSCs and WJ cells were 30 
and 36 hours, respectively. Furthermore, WJ and foetal blood MSCs demonstrated osteogenic, 
adipogenic and chondrogenic differentiation potential in vitro. The neural differentiation 
potential of these cells in a range culture conditions was assessed with varying results. 
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1 INTRODUCTION 
One in four people worldwide suffer some form of neurodegenerative disorder. The World 
Health Organisation (http://www.who.int/research/en/) estimates that there are currently 4 million 
people worldwide with Parkinson’s disease, 37 million with Alzheimer’s disease (4.5 million in the 
USA), and that 5.5 million die each year as a result of cerebrovascular events. In the USA, more than 
50 million people are affected by various CNS diseases. Each year, 11 000 people sustain spinal cord 
injury, adding to more than 400 000 already affected. Two million people have been disabled by head 
injuries with 1.5 million people a year suffering traumatic brain injury (TBI), adding to the 5.3 million 
already living with disabilities resulting from TBI. The number of people with neurodegenerative and 
cerebrovascular conditions continues to grow with an ageing global population, as does the cost to the 
health service. 
Although there are varying degrees of functional recovery, the adult CNS has only a limited 
capacity for self-repair, because, as the brain matures it loses its ability to support the growth of axons 
and consists of a cellular environment largely dominated by growth-inhibitory molecules, including 
myelin (227, 238).  Neuronal loss is central to most neurodegenerative conditions; therefore, clinical 
therapy has until recently been limited to symptomatic relief. 
Developmental cues may persist in the adult brain; however long-distance axonal growth and 
regeneration and precise target-seeking by growth cones within established neuronal circuitries do not 
appear to occur under physiological conditions (225). This is an obstacle to cellular replacement 
therapy, which is designed to address the restoration of neural circuitries damaged either as a result of 
traumatic events or progressive neurodegeneration. 
Different strategies have been attempted both in the laboratory and at the clinical level, 
especially for Parkinson’s disease (given its localised and well characterised aetiology), which has 
served as a platform for testing cell-based restorative therapies. These include the implantation of 
adrenal cells (93), Sertoli cells (36, 222), and foetal mesencephalic cells (161). 
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Unlike their less developed counterparts, mature or differentiated neural cells are mitotically 
quiescent and do not survive well after intracerebral implantation. Therefore, alternative expandable 
sources of neural stem cells are needed for regenerative therapy. The use of human foetal 
mesencephalic tissue, despite providing some promising early results, is constrained by ethical and 
practical concerns surrounding the availability and survival of CNS tissue from elective abortions. 
Stem cells from alternative sources have the potential to overcome these obstacles. 
 
1.1 Stem Cells 
Although a universal definition of stem cells has yet to be agreed, the following criteria 
represent the current consensus : they are karyotypically normal, undifferentiated cells (lacking 
a specific morphology and not expressing antigens of mature cells) with extensive proliferative 
capacity, long-term self-renewal, and multi-potentiality/pluripotency (capable of giving rise to 
multiple cell lineages). It is not always possible to assess all these parameters simultaneously. 
Pluripotent stem cells can be derived from embryonic, foetal and adult tissues (Figure 1-1). At 
least three different types of mammalian stem cell have been identified in the embryo : 
embryonal carcinoma cells, embryonic stem (ES) cells derived from the inner cell mass of 
blastocysts and embryonic germ cells obtained from post-implantation embryos. 
In the early 1990s, several groups (195, 214) reported the existence of a subset of stem 
cells which could be isolated from foetal and adult CNS. However, these cells were more 
restricted in their differentiation potential than ES cells, giving rise only to the three major cell 
types of the CNS: neurones, astrocytes and oligodendrocytes, and were therefore named neural 
stem cells (NSCs) (87). These can be isolated from both foetal and adult CNS. 
More recently, ‘mesenchymal stem cells’ (MSCs) with apparent neurogenic potential have 
been derived from non-neural tissues such as blood, bone marrow, umbilical cord matrix (Wharton’s 
jelly), liver, skin, muscle and adipose tissue. During embryonic development, MSCs are derived from 
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the mesoderm and give rise to connective tissue in the adult, which retains a population of MSCs 
throughout life (218).  
 
 
Figure  1-1 : Derivation of stem cells from embryonic, foetal and adult tissues.  
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1.2 Embryonic Stem Cells 
Embryonic stem (ES) cells are pluripotent, giving rise to all tissues in the body, including 
those of the nervous system (254), and represent a potential source of material for therapeutic 
applications. Undifferentiated ES cells express genes such as Oct-4, SSEA-1, 3 and 4, TRA 1-
60 and 1-81, and nanog (188). ES cells can be engineered to express therapeutic genes and 
maintained in long-term culture, retaining their ability to differentiate into cell types of the three 
germ layers. 
The first demonstration that mouse ES cells could be differentiated into multiple neural 
phenotypes in culture was reported by Bain and colleagues (18), using retinoic acid. The newly 
formed neurones not only expressed lineage-specific markers, but were also capable of 
generating action potentials. Several groups have now enriched neural progenitors from murine 
and human ES cells (32, 42). 
Van der Kooy’s group later reported the existence of an ES cell-derived population of early 
(primitive) NSCs distinct from definitive NSCs generated later in embryonic development. The 
former were leukaemia inhibitory factor (LIF)-dependent, whilst their definitive counterparts 
were either EGF- or FGF2-dependent for proliferation and the maintenance of their 
undifferentiated state in culture. Furthermore, primitive NSCs retained non-neural 
differentiation potential, unlike definitive ones (109, 257). 
Several groups have found that enriched neural precursors from human ES cells can 
incorporate into brain tissue and differentiate in vivo (213). Zhang et al. transplanted neural 
precursors enriched from ES cells into the lateral ventricles of newborn mice, and observed 
migration to multiple brain regions, followed by differentiation into cells with mature neuronal 
and astrocytic phenotypes, although interestingly no mature oligodendrocytes were identified 
(285). 
Such in vivo studies are important in two respects : firstly, they suggest that transplanted 
cells do have the potential to populate the brain, and secondly, they highlight the fact that more 
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manipulation may be necessary before the required neural cell types are efficiently generated 
(75, 245).  
Early successes in neural differentiation of ES cell grafts in vivo has led to further work in 
injury models to demonstrate that transplanted ES cells can integrate and functionally improve 
outcome following CNS injury (179, 246). However, the precise mechanism required to direct 
neuronal differentiation of ES cells in vivo has yet to be determined. 
 
1.2.1 Advantages of ES Cells 
Embryonic stem cells provide the most promising alternative source of cells for therapeutic 
transfer into neural tissue. They are pluripotent, can be propagated in vitro and can be 
engineered to express therapeutic genes. They migrate and differentiate into regionally 
appropriate cell types, and do not appear to interfere with normal brain development (75). ES 
cells can also be differentiated in vitro into oligodendrocyte precursors that effectively 
myelinate host axons in animal models of human demyelinating disease (31, 162). As shown in 
a large number of studies, ES cells can be readily differentiated into neural cells (32, 42). 
 
1.2.2 Disadvantages of ES Cells 
In addition to the ethical considerations restricting the therapeutic use of ES cells, their 
capacity for unlimited growth in culture is reflected in their tendency to form teratomas after 
implantation (219). Until reliable means of completely eliminating undifferentiated ES cells from 
populations intended for implantation are developed and tested, ES cells remain an experimental tool 
with which to explore proof-of-principle therapies for neurodegenerative conditions. Thus, there are 
more than just ethical reasons for using adult stem cells rather than those derived from embryos (139).  
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1.3 Neural Stem Cells 
Neural stem cells (NSCs) are found in both the developing (embryonic and neonatal) (273) 
and adult mammalian CNS (148, 214-216) mostly in two main active neurogenic/germinal 
zones - the subgranular zone of the dentate gyrus (which generates hippocampal interneurones 
throughout life), and the sub-ventricular zone (SVZ) (Figure 1-2)  and/or the ependymal layer 
(7, 180, 251, 269). 
A sub-population of rapidly proliferating multipotent SVZ-derived NSCs from the anterior 
portion of the lateral ventricles generates interneurones that migrate to the olfactory bulb 
through the rostral migratory stream (RMS) throughout life (194). 
 
 
Figure   1-2 : Anatomical distribution of neural stem cells in the rodent CNS, and their 
growth factor responsiveness (251). A wide and heterogeneous array of neural precursors is 
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generated at specific stages of development in various CNS regions. Cells from different gestational 
ages and anatomical sites are not identical, displaying different growth characteristics, trophic factor 
responsiveness and specific patterns of differentiation (178, 191, 192, 202, 211). This is due to spatio-
temporal variations in NSC growth factor receptor expression patterns and expression levels 
(especially EGF-R and FGF-R) (34, 258). 
Undifferentiated foetal and adult NSCs typically express nestin, PSA-NCAM, Sox1 and 
2, and Bcrp1 (188). Rodent NSCs also express developmentally-regulated genes in vitro, such 
as the Pax family, which is influenced by the extracellular matrix (ECM) molecules they are 
exposed to. However, the gene expression of isolated neural stem/progenitor cells seems 
unaltered within the neurospheres they generate in culture (37, 137, 158, 159). 
Although the bulk of experimental data has been obtained using rodent NSCs, similar 
multipotent cells have been identified in the human, with the antigenic phenotype CD133+, 
CD34-, CD45-, CD24-/lo, and 5E12+. CD34, CD45 and CD24 are haematopoietic cell markers, 
whilst CD133 and 5E12 are NSC markers. These cells have been shown to generate 
neurospheres, self-renew and differentiate into neurones and glia (41, 207). When transplanted 
into the lateral ventricles of immunodeficient newborn NOD/SCID mice they engraft, migrate 
and differentiate into region-specific neuronal cells detectable up to seven months later (260).   
There are important similarities between the in vivo and in vitro properties of rodent and human 
NSCs but there are also significant differences (91). One of the most evident is that 
differentiation of rat neurospheres generates large proportions of oligodendrocytes, whereas 
human NSCs generate relatively few. The reason for this is not clear and further research is 
required to determine which signals influence cell phenotype and to identify the specific cues 
needed for differentiation and maturation. 
An important potential source of human NSCs is the adult brain. NSCs can be 
recovered from human cadavers up to five days post-mortem (204). At present, however, NSCs 
derived from adults are difficult to isolate, are found in smaller numbers with a more limited 
proliferative capacity and appear to have a more restricted differentiation potential than their 
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foetal counterparts. In the light of current knowledge, it appears that foetal NSCs are likely to be 
more useful for cell therapy. Nonetheless, the highly controversial nature of this source of 
neural tissue has provided an impetus for understanding adult NSCs in more detail, with 
promising results (40). 
Whether foetal or adult NSCs are used in cerebral transplants, little is known about the 
cell-intrinsic and external factors that influence proliferative capacity and fate choice. By 
careful examination of the effects of defined neurotrophic factors and an accurate description of 
the factors in the transplant microenvironment, it may well be possible to improve the potential 
of NSC therapy in the future. 
Although the discovery and isolation of NSCs has been vital to understanding brain 
development and repair, the basic biology of NSCs is still poorly understood. Indeed, the 
unequivocal identification of the true NSC remains difficult, as there are no specific markers for 
this cell type. Nestin, for example, is a widely used marker and is highly expressed in the 
developing neuroepithelium and NSCs (148, 255), but is also found in other cell types such as 
endothelial cells, developing myoblasts, reactive astrocytes (160) and even human mesenchymal 
stem cells from different sources. Moreover, the apparent continuum of stem, precursor and 
progenitor cell subtypes hinders a straightforward classification of cell lineages (97). Therefore, 
the identification of NSCs in culture relies on their functional attributes, including their growth 
factor responsiveness, their multilineage differentiation potential (ability to generate one or 
more cell types) and their capacity for proliferative self-renewal (104, 208, 225, 261, 262). 
Other characteristics of undifferentiated NSCs that allow them to be identified in vitro 
include the formation of neurospheres through proliferation. Only a small proportion of the cells 
within a neurosphere are likely to be multipotent and can normally be isolated by their ability to 
form further neurospheres, in the presence of the appropriate growth factor stimulus.  
Differentiation of NSCs in culture can be driven towards defined lineages by growth factor 
withdrawal or by the use of specific inductive signals  The roles of EGF and FGF (Figure 1-2) 
themselves have been investigated using intraventricular infusions. In animal models, these 
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growth factors cause an increase in the size of the ventricular zone, and promote cell division 
defined by BrdU incorporation. Vigorous division of EGF-responsive cells precedes 
differentiation into predominantly glial cells (104). In contrast, FGF directs modest cell division 
and promotes a more neuronal phenotype (104, 105). It thus seems likely that distinct stem cell 
populations are programmed to differentiate into specific cell types during development in 
response to growth factor signals.  
1.3.1 Effect of Extracellular Matrix Molecules on NSC Proliferation 
and Differentiation. 
The cellular response to growth factors is not predefined or fixed, but rather depends on other 
cell intrinsic (such as receptor expression levels and function, genetic disposition and differentiation 
status) and extrinsic influences. For instance, growth factor signalling can be regulated by extracellular 
matrix (ECM) proteins and proteolytic enzymes. An increasing number of growth factors has been 
found to associate with ECM molecules. Rapid and localised changes in the activity of these factors 
can be induced by the release from matrix storage and/or by the activation of latent forms. These 
growth factors, in turn, control cell proliferation and differentiation, and the function, synthesis and 
remodelling of the extracellular matrix (248). However, the role of ECM molecules on NSCs is poorly 
understood (272). Their presumed functions during neural development are largely derived from 
circumstantial evidence, such as spatio-temporal expression coincident with developmental events. 
Changes in ECM expression levels are seen in proliferative neuroepithelial stem/progenitor 
cells in the ventricular germinal matrix during brain development, and might be crucial in determining 
the fate of proliferative SVZ neuroepithelial stem/progenitor cells (239). 
In culture, ECM molecules produced by more committed progeny can be crucial for the 
proliferation and/or differentiation of less mature cells (including NSCs) within neurospheres. This 
hypothesis is supported by the observation that precursor cells implanted into the CNS differentiate 
according to characteristic region-specific ECM cues present within the recipient/host tissue (88, 212, 
263). 
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Despite the uncertainties surrounding the biology of NSCs and the ethical implications of 
their use in the clinic, foetal neural cell transplantation has been tested with some success in 
several adult brain injury models. Foetal cortical grafts survive in the infarct area following 
focal forebrain injury in adult rats and appear to receive connections from the surrounding brain 
resulting in an improvement in motor function (236). Foetal hippocampal tissue transplanted 
into adult rat hippocampus damaged by global ischaemia improves spatial learning and memory 
(110). 
Cortical neurones undergoing injury-induced apoptosis can be replaced by transplanted 
foetal NSCs which can also differentiate in situ into region-specific neuronal and glial subtypes 
when implanted into the lesioned hippocampus, neocortex or striatum in adult rodents (235). In 
the developing brain, stable clones of NSCs can participate in aspects of normal brain 
development when injected into the germinal zones of newborn mice (75). 
 
1.3.2 Advantages of Foetal NSCs 
Comparisons of foetal stem cells with those derived from defined developmental niches in 
the mature brain seem to indicate that NSC plasticity decreases with developmental age. 
Although the precise mechanisms for this are not fully understood, there is evidence that many 
of the fate decisions may be cell intrinsic (190). For example, EGF receptor expression 
increases in cortical stem cells with increased passage number and this may result in an 
increased responsiveness to EGF (34), inducing proliferation and a gliogenic bias in their 
differentiation. 
Human foetal NSCs have been successfully isolated from fresh post-mortem brain tissue 
by exploiting the unique expression of the cell surface marker CD133 together with the absence 
of CD34 and CD45. Not only can single cells with this antigenic phenotype form neurosphere 
cultures that differentiate into both neurones and glia, but they can also be successfully 
transplanted into the brains of immune-deficient neonatal mice (260). Importantly, such studies 
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have been extrapolated to non-human primates (203). Ourednik et al observed that 
transplantation of BrdU-labelled human NSCs into the developing primate forebrain resulted in 
their integration into both the mature cerebral cortex and the subventricular zone. 
A further advantage of foetal NSCs is that they can be rapidly propagated in vitro with 
little or no apparent change in their plasticity. In one study, human neural progenitors isolated 
from embryonic forebrain were expanded for up to a year in culture using EGF, FGF and 
leukaemia inhibitory factor (LIF). Subsequent injection of these cell lines into the developing rat 
brain showed extensive migration and integration (71, 72). 
 
1.3.3 Disadvantages of Foetal NSCs 
Clinical use of foetal tissue for stem cell transplantation is made difficult by ethical 
constraints. Confronted with the moral problems of conceiving for the sole purpose of obtaining 
aborted brain tissue for the treatment of the parent or siblings, scientists have turned to other 
sources of NSCs. Investigators have claimed to isolate NSCs from adult post-mortem brain 
tissue as late as 5 days after death (204). Although it is believed that adult NSCs have a more 
limited capacity to form all neural subtypes than their foetal counterparts, they may still have a 
broader potential than first thought. For example, using a chick-mouse chimera approach 
(involving the injection of NSCs into the amniotic cavity of chick embryos), adult mouse NSCs 
were reported to readily give rise to cells in all the germ layers, demonstrating a high degree of 
plasticity and indicating that their application may go beyond the treatment of CNS disorders 
(56).  
Although it is known that stem cells in the subventricular zone of the adult mammalian 
brain can proliferate, migrate to the olfactory bulb and ultimately differentiate into mature 
neurones, are these cells functional ? In an elegant study from Frisen's research group, labelled 
stem cells were shown to respond to a specific odour-induced signal in the olfactory bulb by 
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upregulating expression of the c-Fos proto-oncogene. These results indicate that newly formed 
adult neurones can functionally integrate into the synaptic circuitry of the mature brain (40). 
However, technical difficulties and ethical constraints in isolating and propagating adult 
NSCs make them unlikely to be used in cell therapy until these obstacles can be overcome. 
 
1.4 Stem cells from Non-Neural Tissues 
Recent studies have suggested that mesenchymal stem cells (MSCs) from certain adult and 
foetal tissues have the potential both in vitro and in vivo to exhibit phenotypic characteristics of 
cells not expected within the tissue of origin (112, 182), including neural phenotypes. These 
tissues include bone marrow (224), peripheral blood (2, 187, 287), umbilical cord blood (101, 
102, 145), umbilical cord matrix (Wharton’s jelly) cells (189, 268), amniotic fluid (113), 
amniotic epithelium (259), endothelium (58, 77), adipose tissue (15, 253), muscle (117, 174), 
liver (64), dental pulp (98) and skin (157). 
As well as representing a plentiful, ethically acceptable and easily accessible source of 
neural tissue for therapeutic brain and spinal cord repair and regeneration, these cells could 
potentially be used autologously, thereby reducing the risk of tissue rejection. 
To date, however, little is known about the source(s), frequency and characteristics of cells 
with the potential to adopt neural lineages. 
 
1.4.1 Bone Marrow 
Adult haematopoiesis takes place in the bone marrow within the vascular sinuses of flat 
and short bones, which contain two stem cell types - haematopoietic (HSCs) and mesenchymal 
(MSCs)/stromal (209). HSCs self-renew and continually generate blood cells throughout life. 
They express CD34, CD45, c-kit/CD117 and HLA-DR, are typically non-adherent in cell 
culture and can be maintained in long-term culture using a bone marrow stromal cell (BMSC) 
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feeder layer. Until recently, they were thought to be tissue-specific stem cells able to 
differentiate into blood-lineage cells only. However, recent evidence suggests that HSCs may 
have greater differentiation potential (225, 249) since they have been found to express neural 
genes (94, 116). 
Bone marrow-derived mesenchymal stem/stromal cells (BMSCs) are non-haematopoietic 
cells also referred to as colony forming unit fibroblasts (CFU-f) which provide the structural and 
functional support for the generation of blood lineages from HSCs (Sanchez224). They also 
have the potential to differentiate into a range of morphologically distinct cell types representing 
all three germ layers (ectoderm, mesoderm and endoderm), including adipocytes, osteoblasts, 
macrophages, chondrocytes, tendon, hepatocytes, muscle, cardiac myocytes, endothelial cells 
and possibly neural cells (224, 249). 
BMSCs are present within the bone marrow at a very low frequency (less than one per 
million mononuclear cells) (30, 39), hence the need for expanding them in culture before 
phenotypic characterisation and/or implantation. The various enrichment and expansion 
methods used to achieve this do not appear to influence the immunophenotype and proliferation 
rate of BMSCs (163). Expression of several adhesion-related antigens, including the integrin 
subunits 4, 5, 1, integrins 3 and 5, ICAM-1 and CD44H permits proliferative 
BMSCs to be enriched or purified by spontaneous adherence to tissue culture plastic, but only in 
the presence of serum. BMSCs were first isolated by Friedenstein et al. in the early 1970s using 
this method (78-84, 138, 169). Similarly to NSCs, there is as yet no single specific antigenic 
marker for BMSCs. However, they express non-haematopoietic cell markers such as CD29, 
CD44 and CD166, and lack HSC-associated markers. They do not express antigenic markers of 
mature blood lineages either : CD14 (monocytes/macrophages), CD31 (endothelial cells) and 
CD11a (lymphocytes). They also express STRO-1. 
With regard to their isolation and expansion, the replacement of serum with a defined 
formulation for BMSC expansion in vitro is an important challenge if human BMSCs are to be 
used in clinical transplantation, since serum of bovine origin may contain as yet unidentified 
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xenogeneic pathogens potentially harmful to Man and serum of human origin may transmit 
prions (122, 123, 135). 
There is still debate as to whether BMSCs are bona fide stem cells - in addition to 
displaying the characteristics described above, are they capable of self-renewing in long-term 
culture and pluri- or multipotent lineage specification and differentiation ? In this respect, some 
groups have successfully passaged BMSCs for 60 to 120 population doublings (as in the case of 
multipotent adult progenitor cells, MAPCs), with little or no apparent change in their 
multipotency (118). The differentiation potential of BMSCs has not been well studied at the 
clonal level due to the difficulty in generating clonal BMSC lines. Colonies of BMSCs derived 
from several cells may consist of a number of clones each capable of differentiating into 
specific lineages. 
Although the antigenic purification/enrichment of neurones and their progenitors from 
embryonic stem cells has been reported (42), the same has not yet been attempted for bone 
marrow cells after the induction of differentiation into a specific lineage. This would allow the 
subsequent evaluation of their in vivo efficacy. 
The generation of neural cells from bone marrow could be either due to the presence of a 
minute subpopulation of highly pluripotent cells in the marrow, or may be explained by the 
reprogramming (trans- or de- differentiation) of an already committed blood progenitor. Indeed, 
Verfaillie’s group has described the ‘multipotent adult progenitor cell’ (MAPC) as a bone 
marrow-derived cell that has multi-tissue potential (119), including neural lineages. When 
transplanted, these cells have been shown to ameliorate neurological deficits in a rat model of 
cerebral ischaemia (286). 
 
1.4.2 Foetal Mesenchymal Stem Cells 
Mesenchymal stem cells (MSCs) can be isolated by cardiocentesis from the human first-
trimester foetal blood and have been characterised by Fisk’s group (38). Similarly to adult bone 
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marrow-derived MSCs, they express prolyl-4-hydroxylase (a marker of fibroblasts), CD73, 
vimentin, CD29, 44 and 106, and fibronectin. A minority (10-15%) express CD105 (an 
endothelial cell marker), and they are negative for haematopoietic lineage markers (CD14, 31, 
34, 45 and 68) and collagen type 1 (another fibroblastic marker). MSCs are highly proliferative 
and have a typical spindle-shape fibroblastic morphology when cultured in 10% FBS on 
untreated tissue culture plastic. These cells cannot be isolated from samples of the umbilical 
cord blood of second and third trimesters foetuses under similar conditions. Comparatively few 
adherent fibroblastic cells can be isolated at these stages (from the same source) by plating cells 
at 25-fold higher concentration. MSCs can also be isolated from first, second and third-trimester 
foetal liver and bone marrow. 
These MSCs (from all three sources) support the survival of CD34+ haematopoietic 
stem/progenitor cells in culture. They also have mesodermal (adipogenic, osteogenic and 
chondrogenic) differentiation potential. Although their immunological properties have been 
documented (95) and found to be similar to bone marrow-derived MSCs, since their first 
description, no study has yet been published on the neurogenic potential of blood-derived first-
trimester foetal human MSCs. 
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1.4.3 Wharton’s Jelly (WJ) Cells of the Umbilical Cord 
The human umbilical cord consists of an outer layer of amniotic epithelial cells (E) 
enclosing a gelatinous matrix referred to as Wharton’s jelly (WJ), first described by Thomas 
Wharton (Figure 1-3) (237). The latter encases a single vein (A) and two arteries (B & C)  and is 
composed of myofibroblast-like stromal cells, collagen fibres and proteoglycans (130). WJ cells 
are highly proliferative and can be propagated for over 80 population doublings, whilst 
maintaining high levels of telomerase activity (189). They reportedly express a number of  stem 
cells markers, including c-kit and Oct-4, as well as telomerase, an enzyme that inhibits cell 
senescence by maintaining telomere length. They are also reported to have osteogenic, 
chondrogenic, adipogenic and neurogenic potentials (189). 
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Figure  1-3 : Haematoxylin & Eosin stain (H&E)  human 
umbilical cord in transverse section. 1 (Loupe) : A - umbilical vein; B 
& C - umbilical arteries; D - matrix or Wharton’s jelly; E - amniotic 
epithelium. 2 : Low magnification (x4) of transverse section through the 
umbilical vein and Wharton’s jelly. 3 : Higher magnification (x40) of 
Wharton’s jelly and matrix cells . Adapted from: 
(http://www.lab.anhb.uwa.edu.au). 
 
WJ cells can survive for at least 6 weeks following 
intracerebral transplantation or systemic infusion without the need 
for immunosuppression of the host rat. The enhanced green 
fluorescent protein (eGFP) labelled cells migrated extensively following implantation and co-
expressed neuronal filament 70 (NF70) (268). To date, WJ cells have not been used in a disease 
model and no electrophysiological confirmation of neuronal differentiation or behavioural 
assessment of transplanted animals has been reported. 
 
1.4.4 Advantages of MSCs 
MSCs (foetal and adult) offer a number of advantages over neural stem cells (NSCs) and 
embryonic stem (ES) cells for clinical implantation. They may : 
1. Be more easily and ethically isolated than NSCs. Umbilical cords can be stored for at least 
one week in sterile PBS before isolating Wharton’s jelly cells. 
2. Have a greater ability to migrate to the brain than NSCs following intravenous infusion, 
although no systematic comparison has yet been performed (29, 54, 67, 183, 184). 
3. Negate the need for immunosuppression in the case of autologous transplants and possibly 
even in the case of heterologous transplants (142, 143, 268). The same may not be true of 
NSCs (12, 111). MSCs have already been used in several clinical trials of autologous 
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transplantation for a wide range of conditions and were found to be well tolerated with 
minimal side-effects (122, 123). 
4. Present fewer ethical constraints, unlike NSCs isolated from human foetal CNS tissue and 
human embryonic stem (ES) cells. 
5. Be subject to fewer regulatory obstacles. Autologous transplantations of BMSCs are 
already performed and such cells from postnatal tissue would open up the possibility of 
using autologous transplants to treat neurodegenerative conditions (224). 
6. Might have a greater differentiation potential than NSCs, which may be restricted to neural 
fates (108, 125, 170, 171, 201, 209). 
Similarly, there are advantages to the use of umbilical cord blood and WJ cells over that of 
bone marrow- and blood-derived cells : 
1. Negligible risk of contamination of umbilical cord blood (UCB) or WJ cells by leukaemic 
cells. 
2. May have greater self-renewal capacity, proliferation rate and differentiation potential than 
adult bone marrow (BM) and peripheral blood (PB) cells (150), although no systematic and 
thorough comparison of different non-neural sources of neural cells has yet been reported 
(99). 
3. No ethical objections to their isolation and use, unlike foetal MSCs, which are invasive 
and/or require an elective abortive procedure on the donor foetus. 
 
1.4.5 Disadvantages of MSCs 
There are a number of drawbacks of using non-neural sources of neural-like cells for 
intracerebral implantation. Foetal human MSCs, for instance, are obtained by cardiocentesis 
during an elective abortive procedure, hence major ethical obstacles surround their use as a 
research tool and potential clinical use. 
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A report was made recently of tumour formation after BM cell intra-cerebral implantation 
in rats (D. Bonnet, pers commun., Nov 2003). To date there is only one report of tumour 
formation following neural stem cell implantation (288). Furthermore, neural-like cells derived 
from non-neural tissue may not respond appropriately to positional signals within the recipient 
brain, as indicated by their presence in inappropriate areas (H. Mehmet, pers commun., Nov 
2003). This latter observation contrasts with reported observations of the fate of donor-derived 
BM cells in the human CNS (185, 186) and BM-derived multipotent adult progenitor cells 
(MAPCs) implanted into the blastocyst-stage mouse embryos (124). These reports suggest that 
MAPCs may respond to local positional and migrational signals within the recipient brain, 
highlighting the need for caution during the design of transplantation studies and the subsequent 
interpretation of results. 
 
1.4.6 Transdifferentiation 
Multipotent stem cells undergo a progressive restriction of their lineage potential as 
development or differentiation proceeds until the terminal final fate is specified. This developmentally-
driven lineage restriction operates within all stem cell systems (210, 270) and is concomitant with a 
reduction in proliferative capacity (262). The stage of development at which fate specification occurs 
and the regulatory mechanisms involved are poorly understood, although both extrinsic or epigenetic 
(extracellular matrix and growth factor availability, cell-cell contact) and intrinsic genetic influences 
are likely to operate (258). Differentiation involves the sequential expression of specific genes leading 
to a mature phenotype in a temporally-defined manner. The maturation of stem cells involves a 
progressive loss of pluripotency, increased phenotypic commitment and finally terminal differentiation 
into a specific cell type or sub-type (190). 
Transdifferentiation (Figure 1-4) is the genetic reprogramming of a differentiated cell 
into a pluripotent one (118, 119, 224) and occurs in reproductive cloning when a somatic 
nucleus is transferred into an enucleated egg. It also describes a switch in cellular phenotype or 
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lineage fate without genetic reprogramming such as occurs in the conversion of cells of 
mesodermal lineage (such as osteoblasts) into cells of ectodermal origin, including neural cells 
(132). A further example of transdifferentiation is the expression of neurogenic phenotypes 
(including neurone-specific enolase, neurofilament and neurotrophic growth factor receptor) in 
bone-derived ‘Ewing’ sarcomas, which are rare neoplastic growths of bone and extra-osseous 
tissue (55, 89, 241). This has important implications for brain regeneration and repair after 
traumatic injury and degenerative disease, since it suggests that bone-derived cells are capable 
of generating neural cells under certain circumstances and may therefore represent an 
alternative, more easily accessible source of neural tissue for therapeutic implantation than 
neural or embryonic stem cells. 
 
Figure  1-4 : Different mechanisms by which observed ‘transdifferentiation’ could occur.  
The three models shown represent mechanisms of differentiation from bone marrow derived cells into 
an alternate phenotype. A) Consistent with a paradigm that cells always travel from a less differentiated 
to a more differentiated state, this model predicts that there is a highly pluripotent cell that has not yet 
committed to the haematopoietic lineage and maintains the ability to differentiate into multiple diverse 
cells types. B) In direct transdifferentiation, a HSC may be able to directly change its gene expression 
pattern from that of a haematopoietic stem cell into an alternate cell type. C) If cell fusion is the 
mechanism by which HSCs acquire a non-haematopoietic phenotype, a marrow-derived cell, perhaps a 
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macrophage, fuses with a non-haematopoietic cell and the nucleus of the marrow-derived cell assumes 
the gene expression pattern of the non-haematopoietic cell type. The 2 nuclei do not necessarily need to 
fuse. Note that these models are not mutually exclusive, and may all reflect the in vivo mechanisms 
involved. These models apply equally well to MSCs, which may be highly pluripotent stem cells with 
the ability to differentiate directly into multiple cell types, transdifferentiate into non-mesenchymal cell 
lineages, or have the ability to fuse with different cell types (108). 
 
There are several reports of non-neural stem cells undergoing transdifferentiation to a pro-
neural form. Some of these have demonstrated the presence of cells expressing markers of 
differentiated neural lineages within bone marrow (183, 184, 224) and Wharton’s jelly cell 
cultures (189), although only few have shown the presence of putative neural stem cells. These 
neural-like cells from bone marrow and Wharton’s jelly have yet to be isolated, purified or 
enriched. The use of non-physiological (toxic and carcinogenic) stimuli to induce or promote 
the emergence of neural-like cells may cause these cell populations to react non-specifically 
with a range of antigenic neural markers (168) and may limit their clinical application. 
A range of physiological and non-physiological agents which have direct or indirect 
effects on gene transcription have been used to induce neural specification of BMSCs in vitro 
(277). Furthermore, co-culture with neural tissue or with differentiated neural cells (astrocytes, 
oligodendrocytes or neurones) has been used as an attempt to increase the proportions of 
BMSC- (118, 119, 224) and umbilical cord blood (UCB) cell-derived (35) neural antigen-
expressing cells. No study has yet examined the effect(s) of co-culturing NSCs with BMSCs in 
order to generate neural-like cells from the latter. Similarly, WJ cells have not been co-cultured 
with other cell types for the purposes of directed differentiation. 
The precise identity of the cell types or subpopulations of BM and WJ cells with the 
potential to generate neural-like cells remains unknown since most studies have used 
heterogeneous or poorly characterised starting populations (264). For example, it is not certain 
whether only BMSCs (putatively CD34-) have the ability to express neural antigenic markers or 
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HSCs (putatively CD34+ or c-kit/CD117+) also have this potential. This is complicated by the 
finding that HSCs can be both CD34+ or CD34- (66). This uncertainty also applies to studies on 
umbilical cord blood. Two recent studies on stem cells from cord blood have reported 
conflicting data with regard to their expression of CD133 (102, 145). This controversy may in 
part be the result of different isolation and culture protocols prior to characterisation. 
Nevertheless, a number of haematopoietic (26, 106) and non-haematopoietic bone marrow-
derived cell populations (including cells expressing SSEA1, a marker of embryonic stem cells) 
(D. Bonnet, pers. commun., Nov 2003) have been shown to express neural antigens both in 
vitro and in vivo. The in vitro expression of neural antigens by cells derived from HSCs has 
only very recently attracted attention (2, 94, 106), although in vivo observations of their 
transdifferentiation potential have previously been reported (26, 134). Haematopoietic c-
kit/CD117+ cells from murine bone marrow were shown to generate oligodendrocytes in vivo 
after transplantation (26). However, no account was taken of the possibility of spontaneous 
donor-host cell fusion (252, 281) and therefore confirmatory tests remain outstanding. 
The concept of stem cell transdifferentiation is not universally accepted (10). In one study, 
Bjornson et al intravenously injected clonally derived NSCs into the tail veins of irradiated 
mice and found that they generated significant numbers of haematopoietic cells (24). However, 
this could not be reproduced by Morshead et al (193) who failed to detect significant numbers 
of haematopoietic cells arising from the injection of labelled neurospheres into the tail vein. 
The long-term culture of stem cells in the earlier experiments might account for this apparent 
discrepancy. 
More recently, two independent studies have provided an alternative explanation for 
transdifferentiation. In the first,  co-culturing GFP labelled neurones with hygromycin-resistant 
ES cells generated undifferentiated hybrid cells with molecular characteristics of both neurones 
and ES cells (281). In the second study, co-culture of bone marrow cells (labelled with GFP) 
with ES cells resulted in fused cells that were GFP-positive and expressed a number of ES cell 
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genes. Significantly, the majority of hybrid cells were tetraploid demonstrating that bone 
marrow cells can fuse spontaneously with other cell types and adopt their phenotype (252, 281).  
Cell fusion can also influence in vivo observations. It has been claimed that donor-derived cells 
do not represent ‘transdifferentiation’ of donor cells but are the result of cell fusion. In the case 
of female patients who received bone marrow transplants from male donors and revealed a 
small proportion (0.1%) of Purkinje cells carrying the Y chromosome, this fusion would be 
between endogenous Purkinje cells and donor cells forming stable heterokaryons that express 
markers of both recipient and donor tissue. This possibility has been confirmed in murine 
models and it is thought that the fusion event reprogrammes the donor cell (Alvarez8). 
Fusion of donor cells with host brain cells may explain the apparent transdifferentiation of 
blood to brain in vivo but does not explain the in vitro data. There are now several published 
protocols for directing bone marrow stromal cells to neural lineages (20, 25, 118, 122, 123, 
224, 277). The approaches used are different and range from using chemical demethylating or 
reducing agents to more physiological growth factors. Although controversial, much of the 
transdifferentiation data is tantalising and is not easily explained by the fusion of stem cells 
with more differentiated cells. 
In these experiments, the generation of neural cells from blood could result from: 
1. Reprogramming of the gene expression profile of a tissue-specific committed 
progenitor or fully differentiated cell into that of a pluri- or multipotent cell. This could operate 
through a process of transdifferentiation in response to local microenvironmental cues or 
through cell fusion, although some investigators consider the latter simply as a possible 
mechanism of plasticity rather than a distinct phenomenon (Figure 1-4B, C); or 
2. Proliferation or differentiation of a pluripotent progenitor cell residing within an adult 
tissue either after migrating into the tissue early in development or at a later stage from a 
different tissue (181) (Figure 1-4A). Verfaillie’s group has described the ‘multipotent adult 
progenitor cell’ (MAPC) as a bone marrow-derived cell that has multi-tissue differentiation 
potential including neural lineages (286).  
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Therefore, cell fusion, although unable to increase the number of cells in a damaged CNS, 
may contribute to replacing damaged cells. If the mechanisms of reprogramming could be 
understood in detail and the frequency of fusion increased, this approach could still be useful 
for therapy, although the possible genomic instability of heterokaryotic cells would have to be 
taken into consideration.  
Another problem with the majority of transdifferentiation studies is that the starting 
population of cells is heterogeneous and there remains the possibility that small numbers of 
contaminating neural cells or more multipotent cells account for the result. 
Ethically, the transdifferentiation debate is of particular interest, since if adult stem cells 
can be induced to differentiate into any cell type, the need for embryonic stem cell research is 
reduced (271). However, a large body of research still suggests that foetal stem cells are 
significantly more plastic than their adult counterparts (139). 
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1.5 The Use of Stem Cells in Brain Disease & Injury 
While therapeutic replacement with stem cells is some way off, bone marrow 
transplants are routinely used to treat immune deficient patients and tentative steps are being 
taken to repair neurodegenerative diseases such as Parkinson’s disease with neural cell grafts. 
The treatment of localised diseases (such as Parkinson’s disease, Huntington’s disease, stroke 
and trauma) and global or disseminated diseases (such as multiple sclerosis, Alzheimer’s 
disease and metastatic brain tumours) require different approaches (217). The latter do not 
preclude the use of cellular therapy since stem cells are able to migrate extensively within the 
mature brain and migrate to sites of injury and degeneration (107). Furthermore, since in 
Parkinson's disease it has been estimated that more than 80% of striatal dopamine has been lost 
as a consequence of more than 50% nigral neuronal cell death by the time the first observable 
symptoms of neurodegeneration appear (74, 129), a relatively small degree of repair or trophic 
compensation is likely to lead to a dramatic clinical improvement. 
Cells of non-neural derivation, such as MSCs have been used for experimental 
transplantation. The precise mechanism of recovery afforded by the transplantation of MSCs 
from bone marrow and umbilical cord blood is unclear, although there is widespread 
acceptance that humoural factors secreted by the grafted cells play a significant role (149, 224). 
For example, hBMSCs release factors capable of supporting the prolonged expansion of human 
embryonic stem cells in vitro (50). These diffusible factors may enhance endogenous repair 
systems by providing trophic support (153, 155, 172, 173, 232). 
There is little direct evidence to suggest that implanted stem cells participate in the 
structural reconstruction of neural circuitries damaged or lost as a result of injury or disease. 
Indeed, there is a growing number of transplantation studies where functional improvements 
have been observed in lesioned animals after stem cell therapy even though the graft does not 
appear to have integrated. This is supported by the finding that intravenous injection of MSCs 
into rats following middle cerebral artery occlusion-induced cerebral ischaemia reduces cell 
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death and enhances endogenous vascular endothelial growth factor (VEGF) synthesis, VEGF 
receptor 2 (VEGFR2) expression, host cell proliferation and angiogenesis in the ischaemic 
boundary zone promoting functional recovery (44). Similarly, it was recently shown that MSCs 
expressing the pro-survival gene Akt improved outcome in a model of myocardial ischaemia by 
producing trophic factors for endogenous repair (92, 175). 
 
1.5.1 Parkinson’s Disease 
Parkinson’s disease (PD) is attributed to a selective loss of A9 dopaminergic neurones in 
the substantia nigra pars compacta (SNpc) typically resulting in motor symptoms including 
tremor, rigidity and bradykinesia (slowness of gait). Symptomatic relief is provided by 
pharmacological dopamine stimulation in the form of levodopa which, despite being highly 
effective for the first few years of treatment, causes disabling side-effects including 
tachykinesia (fast involuntary movements), dyskinesias (abnormal movements) and tremors 
(221). To date, there is no cure for PD. 
From a cell therapy perspective, experience already exists of foetal neural cell transfer in 
humans suffering neurodegenerative disorders. Over 300 patients with Parkinson’s disease have 
now received grafts of foetal mesencephalic cells into the striatum. These grafts are 
spontaneously active and can restore dopamine release to near-normal levels with symptomatic 
improvement. There is a downside however; in a recent clinical trial of 40 patients aged 34 to 
75 from Denver and New York, 15% of grafted patients developed unacceptable dyskinesias 
(76). Furthermore, the supply of foetal neural tissue is limited and only small numbers of 
neurones are available. This could be partially overcome by in vitro expansion however, foetal 
tissue contains a heterogenous population of cells, many of which are inappropriate for use in 
clinical transplantation. The limitation of tissue supply might be overcome by generating 
dopaminergic neurones from NSCs, MSCs or ES cells. 
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In the past 2 to 3 years, rodent and human MSCs have been implanted in the rodent 
Parkinsonian brain either undifferentiated or after neural induction. Dezawa et al (2004) (65) 
successfully implanted rat and human MSCs transfected with the Notch intracellular domain 
(NICD) and subsequently treated with FGF2, forskolin, ciliary neurotrophic factor (CNTF) 
followed by glial-derived neurotrophic factor (GDNF) into the striata of apomorphine-treated 6-
hydroxy dopamine-lesioned rats, an experimental model of PD. Behavioural improvement was 
observed. In culture, the modified MSCs expressed tyrosine hydroxylase (a recognised marker 
of dopaminergic neurones) and synthesised dopamine as well as exhibiting the 
electrophysiological features of such cells. Using a protocol similar to that described for ES 
cells by Steve Goldman’s group (219), Guo et al (2005) (100) obtained 30% TH-positive rat 
bone marrow-derived MSCs after treatment with IBMX for 2 days followed by GDNF, IL1, 
mesencephalic glial-cell-conditioned medium and flash-frozen mesencephalic membrane 
fragments. More recently, Fu et al. in 2004 and 2005 (85, 86) obtained dopaminergic-like cells 
from Wharton’s Jelly cells, using a stepwise exposure to neurone-conditioned medium, sonic 
hedgehog (Shh) and FGF8. These cells were also found to partially correct amphetamine-
induced rotational behaviour in 6-hydroxy dopamine-lesioned rats. 
 
1.5.2 Huntington’s Disease 
Huntington’s Disease (HD) result from a similar type of cell loss to PD except that the 
inhibitory GABAergic striatal neurones are damaged and degenerate. This has a direct 
consequence on motor and cognitive functions (60-62). In contrast to the availability of 
pharmacological agents for treatment of PD, there is currently no effective therapy for HD. 
Clinical trials of foetal human and porcine striatal cell implantation into the striata of patients 
with HD have yielded encouraging but limited success (114, 206). More dramatic improvements 
in motor and cognitive function have been observed by several groups at the experimental level 
using whole bone marrow cells (149) and NSCs (11, 13). Approximately 1% of the cells from 
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whole bone marrow injected autologously into the striata of quinolinic acid-treated rats 
expressed nestin and III-tubulin 14 days post-grafting. They had also migrated extensively from 
the implantation sites (149). However, due to the very low percentage of cells expressing neural 
antigenic markers, the investigators concluded that the benefits observed were likely to be a 
result of humoural factors released from the bone marrow cells (149). 
 
1.5.3 Multiple Sclerosis 
Multiple sclerosis (MS) is an acute autoimmune inflammatory demyelinating disease 
which leads to axonal loss and the formation of chronic multifocal sclerotic plaques in the CNS. 
With a lifetime risk of one in 400, it is one of the major causes of neurological disability in 
young adults (57). Current treatment is pharmacological, involving the administration of -
interferons for the functional antagonism of proinflammatory cytokines and down-regulation of 
major histocompatibility class II (MHC II) antigen expression (103). A major drawback of -
interferons is their limited ability to suppress relapses and the ensuing neural damage, in 
addition to the fact that not all patients respond to this treatment. Furthermore, they are of 
limited effectiveness once axonal degeneration has reached a critical threshold and clinical 
progression is under way (57). Endogenous remyelination can partially restore axonal 
conduction and motor function, but is limited to acute inflammatory lesions within which 
oligodendrocytic progenitors are found (43, 228, 229, 275, 276). 
Cell restoration for MS is still at the experimental stage, using cells from a range of sources, 
including peripheral nerve Schwann cells (131), olfactory bulb ensheathing cells (19) as well as NSCs 
and MSCs. The additional demands placed on the implanted cells compared to focal 
neurodegenerative conditions include the need to migrate extensively through the adult brain and 
spinal cord towards lesion sites, survive, proliferate and then remyelinate bare axons. 
Nevertheless, rodent ES cell-derived oligodendrocytes transplanted into an adult rat model of 
MS have shown efficient remyelination (31). Similarly, the implantation of an immortalised cerebellar 
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stem cell line into newborn shiverer mice brains (which produce oligodendrocytes but not myelin) 
lead to the replacement of dysfunctional oligodendrocytes and myelination (280). Rodent NSCs can 
generate large numbers of oligodendrocytes at all passages, which can remyelinate experimental MS-
like spinal cord lesions (105). Canine and rodent ‘oligospheres’ can be generated from NSCs by 
supplementing the culture medium with neuroblastoma B104-conditioned medium (B104CM) (16, 
283, 284). Similarly, neonatal rat NSCs exposed in vitro to EGF and B104CM to induce their 
differentiation into oligodendrocytes have been shown to produce myelin when transplanted into the 
myelin-deficient rat (284). 
Recently, CD117+ HSCs from adult bone marrow have been shown to differentiate into 
oligodendrocytes after intracerebral transplantation into experimental mice (26). This represents an 
important development in the search for more effective cell types for cell replacement in MS. 
However, further analysis is required in order to confirm the neurogenic potential of this abundant 
source of stem cells and establish the safety of the procedure. MSCs have also been used successfully 
in experimental models of CNS demyelination. For example, MSCs implanted into an ethidium 
bromide-mediated lesion of the adult rat spinal cord extensively remyelinated damaged axons (23). 
 
1.5.4 Ischaemic Stroke 
 Ischaemic stroke is an acute onset cerebral deficit caused by a vascular event such as a 
thromboembolism. Current pharmacological interventions include the administration of aspirin 
and other anti-coagulants that are designed primarily to disperse blood clots and minimise the 
risks of a recurrence (266). Despite the established knowledge that widespread cell death 
follows such cerebrovascular incidents, pharmacological interventions to minimise this (using 
anti-apoptotic agents) are not common practice. Anti-apoptotic agents cannot address the 
necrotic cell death that occurs immediately after an ischaemic stroke although they can decrease 
the amount of delayed cell death in the subsequent hours, days and weeks. In severe cases, 
however, the amount of damage caused by the ischaemic event can be so extensive that a lasting 
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motor and/or cognitive deficit is sustained. In such cases, cell replacement would be an ideal 
way to restore lost cells and function. 
Foetal neural cell transplantation has been successfully applied to several experimental 
models of adult ischaemic brain injury. Foetal cortical grafts survive in the infarct area 
following focal forebrain ischaemic injury in adult rats and appear to receive connections from 
the surrounding brain with a resulting improvement in motor function (236), spatial learning and 
memory (110). Furthermore, transformed NSCs have been used to replace cortical neurones 
undergoing photolytic injury-induced apoptosis. Significantly, these cells demonstrated 
appropriate differentiation in situ into region-specific neuronal and glial subtypes determined by 
the site of injection (235). Similarly encouraging observations have been made with MSCs from 
bone marrow and umbilical cord blood (44-49, 51, 52, 151-154, 156) (Figure 1-5). Human 
MSCs injected intracerebrally or intravenously into non-immunosuppressed rodent models of 
stroke one day after injury demonstrated functional benefit on a range of outcome measures 
without immune rejection but also without a reduction in lesion size (149). This indicates that 
the functional benefit is likely to have been a consequence of a humoural effect of the implanted 
MSCs. 
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Figure  1-5 : Illustration of experimental work supporting the potential application of 
MSC to the treatment of stroke. Bone marrow is extracted from the animal or human being and the 
MSCs are separated and cultured for three to five passages. They are then injected intravenously into 
the animal with neural injury and migrate selectively to injured tissue and localise to the boundary zone 
of the lesion. The MSC activate an array of restorative events, mediated by MSC and possibly by 
parenchymal-cell secretion of cytokines, growth and trophic factors. These factors remodel the brain 
and activate mechanisms to improve neurological function (149). 
 
1.5.5 Traumatic Brain and Spinal Cord Injury 
Traumatic brain injury (TBI) and spinal cord injury (SCI) are multi-factorial conditions in 
which several mechanisms of injury and cellular damage contribute to cell death following the 
initial insult. These include inflammation, excitotoxicity, demyelination and ischaemia. In this 
respect, when considering cases of TBI or SCI for restorative cellular therapy, several factors 
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need to be taken into account in order to address the various levels and modes of damage, and to 
set realistic targets of clinical improvement (198). Early results obtained with embryonic murine 
NSCs implanted into the striata of adult mice following cortical impact injury are encouraging, 
with behavioural (motor and cognitive) recovery was sustained for at least a year post-
implantation. Surprisingly, most of the grafted cells expressed the NG2 antigen, a marker of 
oligodendrocytic progenitors but not neuronal, astrocytic or microglial markers. The implanted 
cells also migrated extensively towards the injury site (233). MSCs implanted intravenously into 
the experimentally injured rodent CNS have been found to behave in a similar way to NSCs (53, 
166, 167). Motor and neurological deficits were significantly reduced, and implanted cells were 
found to preferentially migrate towards and into the injured parenchymal tissue. A small 
proportion also expressed the neuronal antigenic marker NeuN and astrocytic marker GFAP 
(53, 166). 
 
1.5.6 Brain Tumours 
Gliomas are a highly invasive form of CNS neoplasms with a very low patient survival 
rate. Due to the highly motile phenotype of glioma cells, tumour margins tend to be diffuse and 
complete resection is almost impossible. In this context, NSCs are also highly motile and can 
migrate through the brain parenchyma towards the area of pathology before integrating into the 
host cytoarchitecture (234). They also exhibit a striking degree of tropism for glioma cells (1, 
21), and when genetically engineered to secrete the proinflammatory cytokine interleukin-12 
(IL-12), have been shown to prolong the survival of tumour-bearing mice by promoting a 
targeted T cell-mediated immune response against the glioma cells (68-70). A recent study 
found that MSCs also have the same effect on glioma cells in vitro and in vivo after 
transplantation into experimentally-induced tumours (196).  
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1.6 Future Perspectives 
There are many issues that remain to be clarified about stem cell transplantation into 
injured or diseased brains, including the fundamental one as to which cell sources are best suited 
for therapy (244). The pathogenesis of many CNS disorders is not fully understood and this 
precludes the directed use of stem cells for restorative therapy in many cases. In an ideal world, 
one would be able to stimulate the proliferation and appropriate differentiation of endogenous 
stem cells. Indeed, a number of gene delivery growth factor-based therapies may work, at least 
in part, through this mechanism. 
Early experiments in stem cell transplantation suggested that embryonic tissue is 
significantly more plastic than that derived from the adult. Although subsequent research has 
indicated that adult NSCs possess a broader developmental potential than was first thought, they 
have a more limited lifespan compared to ES or foetal-derived cells. Any research that relies on 
foetal tissues, particularly when derived by therapeutic cloning, will be ethically controversial. 
Consequently, efforts should also focus on adult sources of stem cells for neural cell 
replacement.  
Whether the starting material is embryonic, foetal or adult-derived, cell replacement 
strategies must also contend with the influence of environmental signals. In several models of 
adult brain repair, transplants are prone to apoptosis for prolonged periods after transfer and so 
clinical improvement may only be temporary (246). Considerable work is therefore needed to 
identify the triggers for specific neural cell survival and integration, and to further determine 
how the environment of the injured brain can be manipulated to become more permissive for 
effective repair. 
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1.7 Summary 
The ethical hurdles presented by the prospective use of embryonic, mesenchymal and 
neural stem cells obtained from elective abortions have highlighted the urgent need for an 
alternative source of easily expandable (and yet non-teratogenic) cells with neurogenic 
potential. 
Wharton’s Jelly cells represent a potential ethical source of highly proliferative stem cells 
from every single birth. Whilst two previous reports have characterised these cells (189), this 
project aims to further explore their phenotype in culture as well as their mesodermal and 
neurogenic differentiation potentials. 
A criticism of many studies on the neurogenic differentiation potential of mesenchymal 
stem cells is the use of toxic (non-physiological) agents that would preclude the use of treated 
cells in the clinic, even if one could be sure of their ability to induce neural specification or 
differentiation. Therefore, a feature of the current approach will be the use of non-toxic 
physiological (epigenetic) neurogenic inducers. 
 
1.8 Aims 
This project aims to : 
1. Characterise cells isolated from the human umbilical cord matrix (Wharton’s Jelly cells). 
2. Compare them to foetal human mesenchymal stem cells (fhMSCs). 
3. Investigate the neurogenic potential of Wharton’s Jelly cells and fhMSCs. 
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2 MATERIALS & METHODS 
2.1 List of Reagents 
Reagent Concentration 
Catalogue 
number 
Source 
-Glycerophosphate 10mM G9891 Sigma-Aldrich 
2-Mercaptoethanol  F8775 Sigma-Aldrich 
Acrylamide 30% 161-0158 BioRad, UK 
Agarose MP    
Alizarin Red S (ARS) 2% A5533 Sigma-Aldrich, UK 
Ammonium Persulphate (APS)  A9164 Sigma-Aldrich 
Anti-DIG-AP solution    
Ascorbate-2-phosphate 0.2mM  Sigma-Aldrich 
Ascorbic acid 0.2mM A8960 Sigma-Aldrich 
B27 with retinoic acid (B27/RA or 
B27+RA) 
1:50 dilution 12587-010 Invitrogen 
B27 without retinoic acid (B27-RA) 1:50 dilution 17504-044 Invitrogen 
Bovine Serum Albumin (BSA) 
10µg/ml for 
coating 
substrates 
A8806 Sigma-Aldrich 
Ca2+ and Mg2+-free PBS   Sigma-Aldrich 
Cetylpyridinium chloride (CPC)  1% (w/v) C0732 Sigma-Aldrich, UK 
Chloroform - C2432 Sigma-Aldrich 
Colcemid 0.01g/ml D7385 Sigma-Aldrich 
Collagenase I and II 1mg/ml 
17101-015, 
C9891 
GibcoBRL/ 
Invitrogen or  Sigma-
Aldrich 
CyQUANT® Cell Proliferation 
Assay Kit 
- C7026 Molecular probes 
Deoxyribonuclease from bovine 
pancreas Type II-S, Lyophilized 
powder 
 D4513 Sigma-Aldrich 
Dexamethasone 0.01-1M D4902 Sigma-Aldrich 
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DIG Easy Hyb solution   Roche 
DIG molecular weight marker    
DMEM:F12 mix - 
31330-38, 
D6421 
GibcoBRL/ 
Invitrogen,  Sigma-
Aldrich 
DMSO, Spectrosol 10%  BDH 
DPX (distyryne, tricresol phosphate 
and xylene) 
-  BDH, Dorset, UK 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
- D5796 Sigma-Aldrich 
EDTA 2mM ED2SS Sigma-Aldrich 
Epidermal Growth Factor (rhEGF), 
Recombinant Human 
20ng/ml E9644 Sigma-Aldrich 
FBS, heat-inactivated 10%  Sigma-Aldrich 
Fibroblast Growth Factor-2 (FGF2), 
Human 
20ng/ml GF003 Chemicon 
Fibroblast Growth Factor-8 (FGF8) 100ng/ml 100-25 Peprotech 
Fibronectin (FN) 10µg/ml F1141 Sigma-Aldrich 
Foetal Bovine Serum (FBS), heat-
inactivated and batch-tested 
10%  Sigma-Aldrich 
Formaldehyde  M6250 Sigma-Aldrich 
Gentamicin solution,50mg/ml  G1397 Sigma-Aldrich 
Glacial acetic acid   BDH 
Glucose - G7021 Sigma-Aldrich 
Glycine - G8898 Sigma-Aldrich 
GlycoBlue co-precipitant  AM9515 Ambion Inc., UK 
Hank’s Buffered Saline (HBSS) - H9394 Sigma-Aldrich 
HEPES - H3375 Sigma-Aldrich 
IBMX 0.5mM I5879 Sigma-Aldrich 
Indomethacin 0.2mM  Sigma-Aldrich 
Insulin 10g/ml  Sigma-Aldrich 
Insulin - I2767 Sigma-Aldrich 
Isoamyl alcohol   BDH 
Isopropanol - I9030 Sigma-Aldrich 
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ITS+ Pre-Mix 1:100 dilution 354352 BD 
Laminin-1 (Lam-1), from human 
placenta 
10µg/ml L6274 Sigma-Aldrich 
L-glutamine 1% G7513 Sigma-Aldrich 
Low-Fat milk   BioRad 
MEM-HEPES, containing Earle's 
salts and 25 mM HEPES buffer, but 
no L-glutamine. 
- 32360-026 Invitrogen 
N1 supplement 1% N6530 Sigma-Aldrich 
N2 supplement 1% 17502-048 Invitrogen 
Neurobasal medium   GibcoBRL/Invitrogen 
Noggin 100ng/ml 120-10 Peprotech 
Oil Red O 
0.6% in 60% 
isopropanol 
O 0625 Sigma-Aldrich 
Penicillin/Streptomycin 0.1% P0781 Sigma-Aldrich 
Penicillin/streptomycin solution 0.1%  Sigma-Aldrich, UK 
Phenol   BDH 
Platelet-Derived Growth Factor 
(PDGF-AB) 
10ng/ml 100-00AB Peprotech 
Poly-D-lysine (PDL) 100g/ml P7886 Sigma-Aldrich 
Potassium chloride solution (KCl) 0.075M  Sigma-Aldrich 
Proline 0.35mM P5607 Sigma-Aldrich 
Proteinase K 20mg/ml  Sigma-Aldrich 
Safranin O - S 2255 Sigma-Aldrich 
SDS 10%  Sigma-Aldrich 
Sodium azide 0.01-0.1% S8032 Sigma-Aldrich 
Sodium phosphate, pH 7.0 10mM  Sigma-Aldrich 
Sodium pyruvate 1mM S8636 Sigma-Aldrich 
Sonic Hedgehog (Shh),  human 
recombinant 
500ng/ml 1314-SH Peprotech 
SSC solution   Sigma-Aldrich 
TEMED - T7024 Sigma-Aldrich, UK 
Transforming Growth Factor beta3 
(TGF3) 
10ng/ml T5425 Sigma-Aldrich 
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Tris-HCL, for Western blotting 1.5M pH 8.8 161-0798 BioRad, UK 
Tris-HCL, for Western blotting 0.5M pH 6.8 161-0799 BioRad, UK 
Trypsin/EDTA (TE) - T3924 Sigma-Aldrich 
Trypsin/EDTA solution 1% T3924 Sigma-Aldrich 
Tween - T1379 Sigma-Aldrich 
Vascular Endothelial Growth Factor-
C (VEGF-C) 
100ng/ml 2179-VC R&D 
 
Table 1 : List of Reagents used – concentrations and sources. 
 
Tissue culture dishes and flasks were purchased from Greiner. 96-well plates for 
immunocytochemistry (Special Optics) and 8-Stripwells for CyQuant were purchased from 
Corning. 
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2.2 Isolation & Culture of Human Wharton’s Jelly (hWJ) Cells from 
the Umbilical Cord 
10cm of umbilical cord was collected from consenting mothers post-partum (ethics code 
RREC 2758; R&D reference 02TE002), and placed in a sterile 150ml container containing 40ml 
PBS and penicillin/streptomycin (1:1000). 
Using aseptic technique, the tissue was dissected in fresh HBSS during which the vein 
and arteries carefully removed. The pieces of Wharton’s jelly were then transferred to 
collagenase and diced into small pieces using a scalpel blade. Initial training in dissection 
techniques was kindly provided by Dr Reza Ghazanfar (Imperial College, London, UK). 
The Wharton’s jelly was then incubated for 2 hours at 37oC in collagenase I and II 
solution on an orbital shaker before adding Ca2+ and Mg2+-free PBS to the viscous cell 
suspension, triturating, centrifuging at 2000 rpm for 10 minutes at room temperature and 
seeding into an uncoated tissue culture dish in DMEM + 10% FBS (complete medium). This 
culture was referred to as passage number (p#) 1A. 
The arteries and vein were digested and using the same protocol, and the dissociated cells 
obtained were cryogenically frozen. 
After 2 to 5 days, the non-adherent human Wharton’s Jelly (hWJ) cells were either 
discarded or reseeded into a fresh dish (p#1B). Fresh complete medium was added to the 
original dish (p#1A) and the cells were grown to 80% confluence before passaging (p#2A), 
plating out for immunocytochemistry and/or freezing. The medium was completely replaced 
twice a week. 
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2.3 Isolation & Culture of Foetal Human Mesenchymal Stem Cells 
2.3.1 Research Ethics Committee Approval (Performed by Professor 
Nick Fisk, Imperial College) 
Foetal blood collection for research purposes was approved by the Research Ethics 
Committee of Hammersmith and Queen Charlotte’s National Health Service (NHS) Trust 
(99/5575; 2001/6194; 2001/6234). National guidelines (1988 Polkinghorne Guidelines on 
Foetal Tissues) were complied with in relation to the use of foetal tissues for research purposes. 
All pregnant women gave written informed consent for the surgical procedure, foetal tissue 
sampling and percutaneous needling for foetal blood sampling. 
 
2.3.2 First Trimester Foetal Blood (Performed by Professor Nick 
Fisk, Imperial College) 
First trimester foetal blood samples (50-500μl) were obtained by ultrasound guided 
cardiac aspiration between 7-14 weeks gestation (n=30, median gestation 10+5 weeks, range 
7+6-13+5) before clinically-indicated surgical termination of pregnancy. Cardiocentesis was 
carried out under general anaesthesia using a disposable siliconised 20 gauge (G) 15 cm needle 
(Cook Ltd., Hertfordshire, UK) and a 1 ml syringe. Both the syringe and the needle were 
heparinised before use by flushing them repeatedly with heparin sodium (1000 units/ml, CP 
Pharmaceuticals Ltd., Wrexham, UK). Foetal gestational age was determined by crown-rump 
length (CRL) measurement. 
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2.3.3 Isolation of Foetal MSCs (Performed by Dr Nigel Kennea, 
Imperial College) 
Foetal MSCs were isolated as previously described (38). Nucleated cell concentrations 
were first calculated using a haemocytometer. Then, unselected nucleated cells from foetal 
blood were suspended at a density of 1.0 x 105/ml in ‘complete medium’ and plated into a well 
of a 6-well-plate and incubated at 37°C with 5% CO2 in air. Foetal MSC were selected by their 
spontaneous adherence to tissue culture plastic. At 72 hours, non-adherent cells were removed 
and the medium replaced. Foetal blood MSC lines were named by the Crown-Rump length of 
the original foetal blood sample and the sex (XX or XY) of the cells, and stored with this code. 
 
2.4 Cryogenic Storage & Thawing of Cells 
Cells were frozen in freezing mix (30ml heat-inactivated FBS, 4ml DMSO, 6ml DMEM 
and 1.2g glucose) at a density of 1 to 2 million cells per 0.5ml of freezing mix. Freezing was 
carried out by placing cryovials (Greiner, UK) in a container of isopropanol (Nalgene, UK), and 
storing at -80oC overnight before transferring to liquid nitrogen for long-term storage. Cells 
were thawed by placing the cryovial in a waterbath set to 37oC, and adding 10ml of 
DMEM/10% FBS slowly so as to minimise osmotic shock. They were then centrifuged at 
1110rpm for 6 minutes at room temperature and resuspended in DMEM/10% FBS for culture. 
 
2.5 Poly-D-Lysine & Fibronectin or Laminin-1 Coating of Culture 
Substrates 
Tissue culture substrates were coated by incubating with poly-D-lysine dissolved in 
distilled water containing antibiotics for 1 hour at 37oC or overnight at room temperature, 
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washing 3 times with distilled water, at which point culture vessels could be dried and stored at 
4oC until use no later than a month later. 
For coating with either fibronectin or laminin-1, vessels were incubated with the ECM 
diluted in DMEM or DMEM/F12 for at least 2 hours at 37oC, then washed with PBS, HBSS or 
DMEM 3 times, without allowing the substrate to dry. At this point, coated substrates could be 
stored in PBS or DMEM containing antibiotics at 4oC for up to one month. 
 
2.6 Characterisation of Human Mesenchymal Stem Cells 
2.6.1 Doubling Time 
Doubling time was determined using 2 methods – serial passaging and the CyQuant 
fluorescent cell proliferation assay (Molecular Probes, UK). 
2.6.1.1 Serial Passaging 
Cultures were tryptically passaged twice a week. Cells were washed once in warm PEB 
solution (Ca2+ and Mg2+-free PBS or HBSS + 2mM EDTA + 0.5% BSA  15mM HEPES, adjusted to 
pH 7.4) and incubated for 5 minutes at 37oC in fresh PEB. The flask was gently but firmly tapped to 
release the adherent cells, which were then transferred to a 20ml centrifuge tube. Trypsin/EDTA 
solution was then added to dissociate the cells, followed by an equal volume of FBS to inhibit the 
enzymatic digestion. Fresh medium was added to the flask to collect any remaining cells, which were 
added to the tube. The cells were centrifuged at 1110rpm for 6 minutes at room temperature, the 
supernatant was aspirated and discarded, and the cells were resuspended in 1000l fresh medium and 
dissociated by gentle trituration. 
Total cell counts and viabilities were determined haemocytometrically using the trypan 
blue dye exclusion assay. Cells were reseeded into fresh 100mm dishes at 2.5 x 105 cells per 
10ml. At every passage, a portion of the MSCs was used for antigenic profiling, experiments or 
cryogenically frozen. 
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In order to test the accuracy and reliability of serial passaging as a means of 
determining doubling time, that of immortalised human neural stem cells derived from the 
ventral mesencephalon (R197VM hNSCs, ReNeuron) was confirmed. 
The proliferative undifferentiated hNSCs were cultured as a monolayer on a poly-D-lysine 
(PDL)- and fibronectin (FN)-coated substrate in DMEM:F12 medium supplemented with B27/RA, 
EGF and FGF2 (serum-free expansion medium, SFEM). Cell numbers and viabilities were 
determined at every passage using a trypan blue dye exclusion assay. 
Growth population doubling times were determined at each passage by counting the 
number of adherent cells at the start and end of each passage, along with the time elapsed. 
Doubling times were calculated using the equation below. 
A = A02n 
A = final cell number 
A0 = Initial cell number 
n = number of cell divisions 
n = T/Tc 
T = time elapsed 
Tc = doubling time 
 
Therefore: 
A = A02T/Tc 
ln(A/A0) = T/Tc ln2 => 2.3log(A/A0) = T/Tc x 0.69 
Tc =  0.3 T 
       log (A/A0) 
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2.6.1.2 CyQuant Proliferation Assay 
Cells were plated out into a 96 well-plate (8-Stripwell, Corning, UK) at a cell density of 500 
cells per well in 200l medium. Medium without cells was added to control wells (2 wells per strip). 
The first strip in each condition was removed after the cells had been left to attach overnight (day 0.5). 
Every subsequent 1, 2 or 4 days, another strip was removed, the medium was aspirated and the strip 
was frozen at -80oC.  
When all the strips had been collected, they were left to thaw out for a few minutes before 
200l of a mixture of CyQuant reagent and lysis buffer were added to each well. After incubating at 
RT for 10 minutes, the well-plate was read in a SpectraMAX GeminiXS microplate fluorometer 
(Molecular Devices, UK) (operated using SoftmaxPro version 4.0 software) at an excitation of 480nm 
and emission of 520nm (Figure 2-1). 
In order to determine the number of cells corresponding to the fluorescence values, a 
standard curve was constructed by plating out known numbers of hWJ cells into a 96 well-plate 
by serial dilution. The cells were left to attach overnight before the medium was aspirated and 
the well-plate was frozen at -80oC. 
The standard curve and test curve were plotted using GraphPad Prism 3.0 (GraphPad 
Software Inc.). The doubling time of hWJ cells was calculated directly from the fluorescence 
readings, since they fell within the linear portion of the standard curve. Three separate 
calculations of doubling time were made per curve. 
Figure  2-1 : CyQuant fluorescent cell proliferation assay protocol. 
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2.6.2 Antigenic Profile 
2.6.2.1 Immunocytochemistry 
A range of antibodies was used to characterise fhMSCs and WJ cells (Tables 2 & 3). 
Labelling was carried out in 96-well plates specially designed for immunocytochemistry or on 
poly-L-lysine/fibronectin-coated 13mm-diameter glass coverslips (VWR). MEM-HEPES 
containing 2% FBS was used as the antibody diluent. Incubations times for primary and 
secondary antibodies were overnight at 4oC or 1 hour at room temperature (RT). 
Controls included embryonic mouse neural stem cells (mNSCs) and foetal human 
neural stem cells (epigenetic R202VM and immortalised R197VM hNSCs), which were plated 
out in mitogen-supplemented medium with or without 10% FBS to induce differentiation. CG4 
oligodendrocytic progenitor cells were used as additional labelling controls. All cells were fixed 
in 4% paraformaldehyde 1 day after plating 10 000 cells per well (except hNSCs differentiated 
in FBS, which were fixed 2-3 days after plating). 
Samples were analysed using a Nikon Eclipse TE2000U inverted fluorescence 
microscope. Images were captured with a QImaging MicroPublisher 5.0 RTV digital camera, 
and processed using QCapture Pro 5.1.1.14) 
 
Antibody Target cell type Dilution Catalogue 
number 
Company 
Nestin Neural stem cells (NSCs) 1:100 mAB5326 Chemicon 
A2B5 Oligodendrocytic pre-progenitors Neat - DSHB 
III-tubulin Neurons and their progenitors 1:400 T8660 Sigma-Aldrich 
GFAP Astrocytes 1:400 Z0334 DakoCytomation 
O4 
Oligodendrocytes and their 
progenitors 
Neat - DSHB 
GalC Mature oligodendrocytes 1:50 AB142 Chemicon 
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PSA-NCAM 
Neural stem cells and later 
progenitors 
1:100 MAB5324 Chemicon 
     
SH2 
Mesenchymal stem cells (MSCs) - 
CD105; endothelial cell progenitors 
Neat HB-10743 ATCC hybridoma 
SH3 
Mesenchymal stem cells (MSCs) - 
CD73 
Neat HB-10744 ATCC hybridoma 
5B5 
MSCs, Fibroblasts, prolyl-4 
hydroxylase 
1:100 M0877 DakoCytomation 
Ki67 Proliferation marker 1:100 
NCL-Ki67-
MM1 
Novcocastra 
Vimentin Mesenchymal stem cells, radial glia 1:100 CBL46 Chemicon 
Table 2 : Antibodies used & their target cell types. 
 
For use in differentiation experiments, all antibodies were tested using Western blotting to 
confirm their suitability and specificity. Cells from one T175 flask (Greiner) were harvested 
(using trypsin/EDTA) and split into two portions for Western blotting and PCR. Samples for 
Western blotting were treated with hot 1% SDS and passed through a syringe needle to break up 
DNA and reduce the viscosity. They were then stored until use at -20oC. The concentration of 
protein in each sample was measured using the Pierce BCA Protein Assay Kit (Perbio, 23225) 
50g of protein was loaded per lane for each sample. Western blotting was carried out under 
reducing conditions. Blots of 5 cell types (hWJ, fhMSCs, hNSCs and hFibs) were probed with 
HRP-linked secondary antibodies only (anti-mouse polyclonal goat IgG, Dako P0447; anti-
rabbit IgG, Cell Signalling 7074), but were all negative (no bands, data not shown). Primary 
human fibroblasts (hFibs) HS27 were obtained from ATCC/LGC Promochem (Cat. CRL-1634). 
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Sample 
number 
Marker Expected size Dilution Company % Gel Cell Type 
Catalogue 
Number 
1 Nestinms 200kDa 1:1000 Chemicon 5 hNSCs mAB5326
3 CD133ms IgG1 117kDa 1:200 Miltenyi Biotec 5 hNSCs 130-090-422
5 NG2rb 250kDa 1:600-1:1500 Chemicon 5 
Undifferentiated 
MOG3.13 
AB5320 
2 MAP2gt 220kDa 1:1000 Sigma-Aldrich 5 SHSY5Y M4403 
11 MBP 18.5kDa  (Pre-diluted) Biogenesis 10 
Differentiated 
MOG3.13 
- 
13 CNPase 46-48kDa 1:500 Chemicon 10 
Differentiated 
MOG3.13 
MAB326 
6 βIII-tubulinms 46kDa 1:1000 Sigma-Aldrich 10 hNSCs T8660 
12 NSE 45-47kDa 1:500 Chemicon 10 
Differentiated 
SHSY5 
MAB324 
 Musashi 39.121kDa 200-1:1000 Chemicon 10 hNSCs AB59771 
9 SH2ms 71-75kDa Neat 
ATCC/LGC 
Promochem 
10 fhMSCs HB-10743
4 SH3ms 97.2-103.8 Neat 
ATCC/LGC 
Promochem 
5 fhMSCs HB-10744
 Vimentin (V9) 57kDa 1:1000 DakoCytomation 10 fhMSCs M0725 
10 5B5ms 
Non-reduced 
240kDa, 
Reduced 60kDa 
1:1000 DakoCytomation 10 hFibs M0877 
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7 Oct4ms 44-45kDa 1:100-1:1000 Chemicon 10 NTera 
MAB4305-
20 
8 Nanoggt 34-39kDa 0.1 - 0.2 g/ml Chemicon 10 NTera AB9220 
14/ NeuN/GFAP 
Recognizes 2-3 
bands in the 46-
48kDa range and 
possibly another 
band at 
approximately 66 
kDa/46-50kDa 
1:500/1:1000 
Chemicon/Dako
Cytomation 
10/10 
Differentiated 
SHSY5Y/hNSCs 
MAB377/ 
Z0334 
15 Sox1rb  1:200 Chemicon  hNSCs AB5768 
16 βIII-tubulinms 46kDa 1:1000 Sigma-Aldrich 10 fhMSCs T8660 
17 OSP 22kDa 1:1000 Abcam 10 
Undifferentiated 
MOG3.13 
AB7474 
18 Nkx2.2gt  1:500 Chemicon 10 
Undifferentiated 
MOG3.13 
AB5740 
19 Olig2 32kDa 1:500 Chemicon 10 
Undifferentiated 
MOG3.13 
AB9610 
 
Table 3 : Antibodies used to characterise cells. Cell types used as positive controls to test 
the specificity of antibodies are listed, along with concentrations of antibodies. Sample numbers refer 
to the Western blot (Appendix Figures A1-3). 
 
2.6.2.2 Fluorescence-Activated Cell Sorting (FACS) 
Cells were examined for cell surface and intracellular markers using FACS analysis to 
determine the proportion of cells expressing (positive labelling) the antigen of interest.  
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Cells were trypsinised from flasks or thawed and following a single wash in flow 
cytometry buffer (2% bovine serum albumin (BSA) containing 0.01% (w/v) sodium azide in 
PBS), were resuspended in flow cytometry buffer at a density of 0.5 x 106 cells/ml and placed in 
FACS tubes (BD Biosciences, UK). For intracellular markers, cells were permeabilised using 
0.1% Triton for 10 minutes at room temperature, followed by incubation with specific primary 
antibodies either conjugated to a fluorochrome (negating the use of a secondary antibody) or 
non-conjugated  for 30 minutes at 4°C in the dark (see Table 4 for antibody specifications and 
dilutions). After 30 minutes’ incubation with non-conjugated primary antibodies, cells were 
washed three times with flow cytometry buffer and the fluorochrome-conjugated secondary 
antibody was added and incubated for a further 30 min at 4°C.  All cells were washed three 
times in flow cytometry buffer and placed on ice in the dark until analysed on a flow cytometer. 
Data were analysed by collecting 10,000 events on a 4 colour Becton Dickinson 
FACSCalibur flow cytometer using Cell Quest™ software. 
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Table 4 : Antibodies used for FACS analysis of fhMSCs and hWJ cells. 
 
 
 
Target Antigen Primary antibody Host 
Working 
dilution 
Secondary 
antibody 
Host 
Working 
dilution 
IgG1 
Isotype Control 
FITC-conjugated (BD, 
Pharmingen) 
mouse 20 µl/106cells 
IgG1 
Isotype Control 
Phycoerythrin R (PE)-
conjugated 
(BD, Pharmingen) 
mouse 20 µl/106cells 
CD34 
CD34-PE conjugated 
(BD, Pharmingen) 
mouse 20 µl/106cells 
CD45 
CD45-FITC conjugated (BD, 
Pharmingen) 
mouse 20 µl/106cells 
CD105 
CD105-PE conjugated 
(Ancell) 
mouse 1:50 
CD166 
CD166-FITC conjugated 
(Ancell, UK) 
mouse 1:50 
Alkaline 
phosphatase 
ALP-Allophycocyanin 
(APC) conjugated (R&D 
Systems) 
mouse 1:50 
Ki67 
Ki67-FITC conjugated  
(Dako) 
mouse 10 µl/106cells 
Not applicable 
5B5 
5B5 
(Dako) 
mouse 10 µl/106cells anti-mouse PE sheep 1:50 
OB Cadherin 
(Cadherin 11) 
OB Cadherin 
(Biocompare) 
mouse 20 µl/106cells anti-mouse PE sheep 1:50 
Collagen Type I (Chemicon) mouse 20 µl/106cells anti-mouse PE sheep 1:50 
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The following negative controls were used to detect non-specific fluorescence: 
i) Only cells in flow cytometry buffer (no antibodies). 
ii) Cells treated with anti-mouse non-specific monoclonal antibodies with matching isotype to 
the other primaries. 
iii) Cells were incubated only with anti-mouse secondary antibody labelled with FITC, PE or 
APC fluorochromes. 
 
2.6.3 Telomere Length Assay  
For the determination of telomere length, the DNA of cell samples was extracted using 
the following protocol. Cells were centrifuged after tryptic harvest from a 100mm culture dish, 
the supernatant was removed and discarded, and after counting, 4 x 105 cells were finally snap-
frozen and stored at -80oC. 
A volume of 1ml of lysis buffer (0.5M EDTA, 10% SDS and 20mg/ml Proteinase K) 
was added to each sample, and incubated overnight at 50oC. A volume of 1ml phenol was then 
added, and the mixture was vortexed and centrifuged at 14 000 rpm for 10 minutes at room 
temperature. The supernatant (aqueous top layer) was collected and transferred into a fresh 
Eppendorf tube, and the phenol extraction process was repeated once more. 
After collecting the supernatant, 1ml chloroform:isoamyl alcohol (24:1) was added, and 
the mixture was vortexed and centrifuged at 14 000 rpm for 10 minutes at room temperature. 
The supernatant (aqueous top layer) was collected and transferred into a fresh Eppendorf tube, 
and the chloroform extraction process was repeated once more. 
After collecting the supernatant, the DNA was precipitated by the addition of twice the 
volume of propan-2-ol (isopropanol), inverting the Eppendorf tube twice, and immediately 
centrifuging the mixture at 14 000 rpm at 4oC for 30 minutes. 
Given that the pellets of DNA were quite small, sodium acetate solution containing a 
dyed glycogen carrier (GlycoBlue, Ambion Inc., UK) was added to the samples in order to 
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enhance DNA precipitation. They were then incubated at -80oC for 1 hour before centrifuging at 
14 000 rpm at 4oC for 45 minutes. 
Telomere length was assessed using Southern blotting by Dr Faisal Al-Allaf. 
 
2.6.3.1 Genomic DNA Digestion 
Genomic DNA digestion was carried out using a Hinf l/Rsa I enzyme mixture (20 U/l 
for each enzyme) incubated at 37oC for 6 hours. The reaction was stopped by adding cold gel 
electrophoresis loading buffer and vacuum spinning samples for 30 minutes at medium heat. 
 
2.6.3.2 Gel Electrophoresis  
For gel electrophoresis, 1-4l of digested DNA samples (containing the same amount of 
DNA in order to obtain a valid quantitative analysis of telomere length) was loaded onto a 0.8% 
agarose gel. In order to measure telomere length accurately, DIG molecular weight marker was 
loaded on either side of the respective samples. The gel was run at 5V/cm for 2-4 hours. 
 
2.6.3.3 Southern transfer  
In order to improve the efficiency of Southern transfer of larger fragments, a 
depurination step was carried out by submerging the gel in 0.125M HCl for 5-10 minutes and 
rinsing in distilled water for 1-2 minutes. The gel was then submerged in denaturation solution 
twice for 15-30 minutes at 15-25oC, and again rinsed in water. The gel was finally submerged in 
neutralizing solution twice for 15-30 minutes at 15-25oC, and again rinsed in water. The 
digested DNA was blotted from the gel onto nylon membrane by capillary transfer (using 
Hybond-N+ blotting paper, Amersham Biosciences, UK RPN203B) at 15-25°C using 20x SSC 
solution as a transfer buffer for overnight. 
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 Small fragments (0.5 - 1.5 Kb) are rapidly transferred upwards in a few hours larger 
fragments (>10 Kb) require at least overnight transfer. After transfer and without any 
intervening rinse, the DNA was fixed by baking the membrane at 80°C for 2 hours, followed by 
two rinses in 2x SSC solution. 
 
2.6.3.4 Hybridization and Chemiluminescence Detection  
The blot was pre-hybridised by incubating in pre-warmed DIG Easy Hyb solution for 
30-60 minutes with gentle agitation. The blot was then exposed to hybridization solution and 
incubated for 3 hours at 42°C with gentle agitation. After washing twice in stringent wash 
buffer I for 5 minutes at 15-25°C and then stringent wash buffer II for 15-20 minutes at 50°C 
with gentle agitation, the membrane was rinsed in washing buffer for 1-5 minutes at 15-25°C, 
and finally incubated in blocking solution for 30 minutes at 15-25°C. The membrane was then 
incubated in anti-DIG-AP solution for 30 minutes at 15-25°C. After washing in washing buffer, 
the membrane was incubated in detection buffer for 2-5 minutes at 15-25°C. After adding 
substrate solution to the membrane and incubating for 5 minutes at 15-25°C, it was exposed to 
Kodak X-ray film for 5-20 minutes in a light-proof autoradiography cassette (Amersham 
Biosciences, UK RPN1642). 
 
2.6.4 Karyotyping 
Cells were cultured in 100mm dishes. When cells were ready for karyotyping at 70 to 
80% confluence, 100µl Colcemid was then added and the cells were incubated for 4 hours at 
37oC, after which 2ml of PEB + 1ml of trypsin/EDTA was added for 1-5 minutes to detach the 
cells. 
A volume of 4ml of hypotonic KCl solution (0.075M) was added to the cell suspension, 
transferred to a 15ml centrifuge tube, and incubated for 20 minutes at 37oC. After centrifuging 
the cells at 1500rpm for 5 minutes and discarding the KCl solution, 5ml of fix solution 
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(methanol plus glacial acetic acid in a 3:1 ratio kept at 4oC) was then added dropwise with 
gentle mixing, and centrifuged at 1500rpm for 5 minutes. The supernatant was removed and the 
tube was flicked twice to agitate the cells. A volume of 5ml of fix solution was then added to 
resuspend the pellet. It was recentrifuged at 1500rpm for 5 minutes, the supernatant was 
removed and 2ml of fix solution was added to resuspend the cells one final time before storing 
at -20oC until karyotype analysis. 
Slides were prepared by sonicating for 30 minutes in deionised water, rinsing in 
deionised water and kept at 4oC until use. After the final fix, the supernatant was removed and 
the cells were resuspended in a minimal volume of fresh fixative. Two drops of cell suspension 
were dropped onto each slide which was then incubated at 30oC for 2-3 hours. Slides were 
stored at room temperature until G-banding and analysis. 
G-banding was performed by Dr Alistair Reid (Imperial College) based on the method 
described by Yunis in 1976 (282). Slides were immersed in a 0.025% solution of trypsin in 
distilled water for 1-2 minutes before being placed in Geimsa/Leishman solution for 4-5 
minutes containing 5-6ml of Leishman, 0.3-0.5ml of Giemsa and 50ml of pH 7.2 phosphate 
buffered saline (PBS). After rinsing in tap water slides were left to dry and mounted using 2 
drops of DPX and a glass coverslip. G-band images were analysed using a Zeiss Axioplan 2 
microscope (Carl Zeiss Ltd., Herts, UK). Where necessary, software-aided karyotyping was 
performed using the SmartCapture 2 and SmartType imaging programs (Digital Scientific Ltd., 
Cambridge, UK). 
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2.7 Mesodermal Differentiation of Human Mesenchymal Stem Cells 
Mesodermal differentiation protocols were modified from two publications (22, 96). 
Three different lines of passage 6 human Wharton’s Jelly (hWJ) cells (hWJ-25-10-04, hWJ-27-
10-04 and hWJ-18-02-05) were compared with respect to mesodermal differentiation potential. 
In order to obtain sufficient numbers of cells, passage 4 cells were thawed and expanded 
(passage 5) to 80% confluence. These were trypsinised and used in the differentiation 
experiments (Table 5). 
HS27 primary human fibroblasts (hFibs, LGC Promochem) of the same passage and 
immortalised human foetal neural stem cells (R197VM, ReNeuron) were used as negative 
controls, whilst foetal human mesenchymal stem cells (fhMSCs, 40mm) were used a positive 
control. 
All differentiation treatments and conditions were carried out in triplicate wells. For 
Western blotting and PCR, cells were lysed and pooled from triplicate wells. 
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Ingredient 
BONE 
(BDM1) 
BONE 
(BDM2) 
FAT 
(FDM) 
FAT 
(FMM) 
CARTILAGE 
DMEM + 10% FBS 
+ 1% L-glutamine + 
0.1% Pen/Strep  
(= D10) 
     
Ascorbic acid 0.2mM - - - - 
Ascorbate-2-
phosphate 
- 0.2mM - - 0.2mM 
Dexamethasone 0.01M 1M 1M - 1M 
-Glycerophosphate 10mM 10mM - - - 
      
Insulin - - 10g/ml 10g/ml - 
IBMX - - 0.5mM - - 
Indomethacin - - 0.2mM - - 
      
TGF3 - - - - 10ng/ml 
Proline - - - - 0.35mM 
Sodium pyruvate - - - - 1mM 
ITS+ - - - - 1:100 
Table 5 : Mesodermal Differentiation Media. 
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2.7.1 Bone Differentiation 
Cells were seeded in D10 medium into uncoated 24-well tissue culture plates at a 
density of 1 x 105 cells per 12 wells (1ml per well) or 6-well plates at a density of 2.5 x 105 cells 
per plate (2ml per well). These were left overnight to attach before changing the medium to 
differentiation medium (BDM1 or 2, Table 5). The medium was replaced twice a week. 
Triplicate wells were used per condition. All controls except for untreated cells were treated 
identically to test wells. 
One, two, three and four weeks after changing into differentiation medium, the cells 
were fixed in 10% buffered formalin (10 minutes at room temperature), and stained with 
Alizarin Red S (ARS) to detect mineralised extracellular deposits (22). 
ARS dye was eluted with 1% (w/v) cetylpyridinium chloride (CPC, Sigma, UK) in 
10mM sodium phosphate, pH 7.0, for 15 min at room temperature. Samples from each well 
were further divided into triplicates and their absorbances measured on an OptiMAX (tunable) 
microplate reader (Molecular Devices, UK) at 562nm using SoftMaxPro version 4.0 software. A 
standard curve was constructed using serial dilutions of ARS in 1% CPC solution. 
Untreated cells (negative control) were cultured in D10 medium. 
2.7.2 Fat Differentiation 
Cells were seeded as for bone differentiation. After cell attachment, the medium was 
replaced with fat differentiation medium (FDM, Table 5). Treated cells were either kept 
throughout the duration of the experiment in FDM, or alternated between FDM and fat 
maintenance medium (FMM). One, two, three and four weeks after changing into differentiation 
medium, the cells were fixed in 10% buffered formalin (10 minutes, room temperature), and 
stained with Oil Red O (ORO) to detect intracellular fat globules. 
ORO stain was eluted in 100% isopropanol. Samples from each well were further 
divided into triplicates and their absorbances measured on an OptiMAX (tunable) microplate 
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reader (Molecular Devices, UK) at 500nm using SoftMaxPro version 4.0 software. A standard 
curve was constructed using serial dilutions of ORO in 100% isopropanol. 
Untreated cells (negative control) were cultured in D10 medium. 
2.7.3 Cartilage Differentiation 
Cells were counted and 0.25 x 106 were seeded into a 15ml centrifuge tube (Corning) 
and centrifuged at 1110rpm for minutes at room temperature. The supernatant was aspirated and 
the cells were resuspended in 1ml differentiation medium (CDM, Table 5) without TGF3 and 
recentrifuged. After discarding the supernatant, the cells were resuspended in 1ml 
differentiation medium containing TGF3 before recentrifuging. 
The lid of the tube was loosened and the cells were cultured for 4 weeks, replacing the 
medium twice a week. After 4 weeks, the cells were fixed in 4% paraformaldehyde for 20 
minutes at room temperature, embedded in paraffin, sectioned and stained with Alcian Blue. 
Embedding, sectioning and labelling was carried out by Ms Lorraine Lawrence at the Imperial 
College Histology Service. 
Untreated cells (negative controls) were cultured in CDM without TGF3. 
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2.8 Neural Differentiation of Human Mesenchymal Stem Cells - 
Summary of Protocols 
Pr
ot
oc
ol
 
Target Lineage 
Reagents/ 
Growth Factors 
D
ur
at
io
n 
(D
ay
s)
 
R
ef
er
en
ce
s 
1 NSC 
DF/SFEM (DMEM/F12 + EGF + FGF2 
+ B27 + RA) 
14 
(33, 120, 197, 214, 
247) 
2 
DMEM/F12 + Neurobasal + B27 
containing retinoic acid + N2 + noggin 
21 (90) 
3 
Neuronal DMEM/F12 + Neurobasal + B27 
containing retinoic acid + N2 + FGF2 + 
FGF8 + Shh 
21 (128) 
4 
35% B104-Conditioned Medium + 1% 
N1 supplement 
28 (283, 284) 
5 
Oligodendrocytic DMEM/F12 & Neurobasal medium 
containing N2 + B27+RA + PDGF-AB + 
FGF2 + VEGF-C 
21 (144) 
Table 6 : Summary of Neural Differentiation Protocols. 
The following cell types were used in neural differentiation experiments : 
- 24XY foetal human MSCs, passage 10 
- Human Wharton’s Jelly cells, 3 different isolates (hWJ-25-10-04, hWJ-27-10-04 and hWJ-18-
2-05), passage 10 
- Human fibroblasts (ATCC/LGC Promochem, negative control), passage 10 
- Immortalised R197VM foetal human neural stem cells from the ventral mesencephalon 
(obtained from ReNeuron, positive control) 
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The following antigenic markers were used to probe for neural differentiation (Table 6) 
and mesenchymal phenotype : 
1. Nestin/Olig2 (Olig2 : Chemicon AB9610, 1:500) 
2. A2B5/NG2 (NG2 : Chemicon AB5320, 1:100) 
3. III-tubulin/GFAP 
4. O4/GalC (GalC : Chemicon AB142, 1:100) 
5. PSA-NCAM 
6. SH2 
7. SH3 
8. Secondary antibodies only (negative labelling controls) 
 
2.9 Protocol 1 – Neural Differentiation of Human Mesenchymal Stem 
Cells 
R197VM foetal human NSCs were thawed and seeded in DMEM:F12 containing B27 
supplement (1:50), without retinoic acid, EGF and FGF2 at a density of 2.5 x 105 cells per 
100mm dish coated with poly-D-lysine and fibronectin. The medium was replaced twice a week 
and the culture was tryptically passaged at 80% confluence. Trypsin was inhibited by dilution 
with DMEM/F12 followed by immediate centrifugation of the cell suspension. 
Neural differentiation of foetal human MSCs and Wharton’s Jelly cells was carried out 
by culturing in serum-free neurogenic medium used to maintain the proliferative and 
undifferentiated state of neural stem cells. The medium DF/SFEM consisted of DMEM/F12 + 
1:50 B27 with retinoic acid + 20ng/ml EGF + 20ng/ml FGF2 + 1% L-glutamine + 0.1% 
penicillin/streptomycin . 
Cells which had been cultured in DMEM/10% FBS (except hNSCs, which were grown 
in DF/SFEM) were thawed by resuspending in DMEM/F12 without any serum or supplements. 
They were counted by trypan blue dye exclusion and seeded onto poly-D-lysine and fibronectin-
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coated 96-well plates specially designed for immunocytochemistry at 5000 cells per 200l per 
well. 
Three different conditions were tested : 
1. DMEM/10% FBS 
2. DMEM/F12 only 
3. DF/SFEM 
16 wells were used per condition. The medium was changed twice a week. Cells were 
fixed for immunocytochemistry in 4% paraformaldehyde for 10 minutes at room temperature 
after the cells had attached overnight (timepoint 0 day) and 2 weeks later (timepoint 14 days). 
 
2.10 Protocols 2 & 3 – Neuronal Differentiation of Human 
Mesenchymal Stem Cells 
Cells were seeded at a density of 1250 per poly-D-lysine/laminin-1-coated well (150l 
per well) in D10 medium (DMEM + 10% FBS) into a 96-well plate specially designed for 
immunocytochemistry. After 4 days in culture, the cells were washed three times in DMEM/F12 
medium and the medium was replaced with differentiation medium. This was changed twice a 
week. 
The following conditions were tested : 
1. DMEM/10% FBS (D10 medium) (0 day only; negative control); for neural stem cells, this 
was DMEM/F12+B27+EGF+FGF2. 
2. DMEM/F12 + Neurobasal (1:1) + B27 containing retinoic acid + N2 + noggin (100ng/ml) 
3. DMEM/F12 + Neurobasal (1:1) + B27 containing retinoic acid + N2 + FGF2 (20ng/ml) + 
FGF8 (100ng/ml) + Shh (500ng/ml) 
4. (2) - noggin (negative control); only for hWJ cells. 
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Cells in the first condition (D10 medium) were fixed 4 days after seeding (when 
differentiation was initiated) in 4% paraformaldehyde for 10 minutes at room temperature, 
washed 3 times and stored in MEM/HEPES/10% FBS/2% gelatine/0.02% sodium azide. Cells 
in the other conditions were fixed in the same way 21 days after induction. 
Positive and negative control cell types (R197VM hNSCs and fibroblasts, respectively) 
were not exposed to condition number 4. 
For immunocytochemistry, labelling was performed on duplicate wells. 
 
2.11 Protocol 4 – Oligodendrocytic Differentiation of Human 
Mesenchymal Stem Cells 
2.11.1 Culture of B104 Neuroblastoma Cells & Collection of 
Conditioned Medium 
After harvesting cells from a confluent T75 flask tryptically, B104 cells were 
transferred to three 500cm2 tissue culture trays (DW Spillguard, Corning, UK) in DMEM/10% 
FBS/0.1% penicillin/streptomycin. The cells were grown to confluence before they were 
washed 5 times in Ca2+ and Mg2+-free Hank’s (HBSS). The medium was then replaced with N1 
medium (DMEM/1% N1 supplement/0.1% penicillin/streptomycin). After 4 days’ incubation at 
37oC and 10% CO2, the medium was collected, filtered through a 0.2m pore low-protein 
binding filter unit (Millipore, UK), and stored at -80oC until use. 
 
2.11.2 Determination of the Optimal Concentration of B104-
Conditioned medium (CM) 
In order to determine the optimal dilution of B104-CM, different cell types were 
cultured in a range of B104-concentrations (0% (N1-supplemented medium), 5, 10, 15, 20, 25, 
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30, 35, 40, 45 and 50%). Proliferation and survival was measured using the CyQuant assay. 
Cells were plated out into two 96-Stripwell plates and 2 rows of a 96-well plate specially 
designed for immunocytochemistry at a density of 5 000 per 100µl per well, at 10% CO2. The 
different conditions employed are listed in the table below. 
 
Cell type Growth Medium Substrate 
CG4 oligodendrocytic progenitors B104-CM/N1 Poly-D-lysine 
24XY foetal human MSCs (fhMSCs) DMEM/10% FBS Uncoated 
Human Wharton’s Jelly cells (hWJ-18-2-05) DMEM/10% FBS Uncoated 
Human fibroblasts (hFibs) DMEM/10% FBS Uncoated 
R197VM foetal human neural stem cells 
(hNSCs) 
DMEM/F12/B27 without 
Retinoic Acid/EGF/FGF2 
Poly-D-lysine 
 
The cells were left overnight to adhere, after which they were washed 3 times in 
DMEM and the medium was replaced with different proportions of B104-CM. Each condition 
was tested by CyQuant in triplicate wells. 
CG4 medium (B104-CM/N1) in each well was removed by careful pipetting so as not to 
lose cells and 100µl of each B104-conditioned medium dilution was transferred into each well. 
A standard calibration curve for CG4 cells was generated by plotting measured 
fluorescence values versus cell number. Serial CG4 dilution ranging from 2 to 250 000 cells was 
set up on 96 well microplate; cells were grown overnight in CG4 medium, frozen, and mixed 
with CyQuant dye according to the protocol described above. The linear range of the standard 
curve fell between 0 and 32000 cells. 
As controls, CG4 were cultured throughout the duration of the experiment in N1 
medium, fhMSCs and hWJ cells were cultured in DMEM/10% FBS, and hNSCs were kept in 
DMEM/F12 + supplements. 
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The proliferation, survival and antigenic profile of the above cell types were also tested 
in B104-conditioned DMEM/F12 (rather than DMEM), in order to determine whether 
DMEM/F12 promotes survival better than DMEM under oligodendrocytic differentiation 
conditions. 
Strips for each condition from each 96-well plate were removed every 24hours starting 
from 0 day (first medium change) until 6 days, the medium aspirated and the strips stored at -
80oC until the CyQuant assay was performed. 
For immunocytochemistry, at 6 days, cells were fixed in 4% paraformaldehyde for 10 
minutes at room temperature, and stained for A2B5/NG2 and O4/GalC. Nuclei were 
counterstained with Hoechst dye to facilitate cell counting. A single well was used for each 
antibody combination per condition. 3 fields were counted at x400 magnification, and the 
proportion of positive cells was calculated as a percentage of the total numbers of cells in a 
field. 
 
2.11.3 Comparison of the Oligodendrocytic Differentiation Potential 
of 3 Different Wharton’s Jelly Cell Lines 
In order to determine the Wharton’s Jelly cell line with the best oligodendrocytic 
differentiation potential, cells from 3 different lines were plated onto poly-D-lysine-coated glass 
coverslips in a 24-well plate at a density of 10 000 per 1ml per well and 0.25 x 106 cells were 
seeded into uncoated 100mm dishes. 24XY fhMSCs, R197VM hNSCs, human fibroblasts and 
CG4 cells were used as controls. All cells were cultured at 10% CO2. Cells in the well plate 
were left overnight to attach before washing 3 times in DMEM only and replacing the medium 
with 35% B104-CM for 6 days. Cells in dishes were grown to 70% confluence before initiating 
differentiation. The medium was changed every 3 days. For fhMSCs only, an additional 
condition was tested whereby the dish was coated with poly-D-lysine/fibronectin. The 
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appearance of bipolar and multipolar cells was closely monitored and recorded by phase-
contrast photomicrography. 
At 6 days, cells in the well plate were fixed in 4% paraformaldehyde for 10 minutes at 
room temperature, and stained for A2B5/NG2 and O4/GalC. Nuclei were counterstained with 
Hoechst 33342 for determination of cell number. 5 fields per coverslip were counted at x400 
magnification, and the proportion of positive cells was calculated as a percentage of the total 
numbers of cells in a field. 
Cells in dishes were incubated for 4 weeks, with medium changes twice a week. At the 
end of this period, cells were harvested. Samples were processed and stored at -80oC for 
subsequent western blotting and PCR. 
 
2.11.4 B104-CM-Induced Oligodendrocytic Differentiation 
The following  two questions were addressed : 
a) Do fhMSCs differentiate into oligodendrocytes ? 
b) Do they express and/or upregulate embryonic genes upon differentiation towards the 
oligodendrocytic lineage ? 
Oligodendrocytic differentiation was induced by exposure to B104 neuroblastoma-
conditioned medium (DMEM containing 1% N1 supplement).  
Each cell type was seeded onto poly-D-lysine and fibronectin-coated tissue culture 
substrate at a density of 750 000 cells per 30ml of medium into two T175 Greiner flasks and 
5000 cells per 200µl into 4 horizontal rows of 96-well plates specially designed for 
immunocytochemistry. This maintained a constant cell: volume ratio between flasks and 
wellplates of 0.04µl per cell. However, in T175 flasks, there were 4286 cells/cm2, whilst in 96-
well plates there were 15625 cells/cm2. In order to equalise both the cell:volume ratio and the 
cell density, 2.734 million cells would have been required per T175 flask in 109.4ml of 
medium. This was impractical, since this volume of medium does not fit into a T175 flask.  
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Alternatively, 1371 cells could be plated into each well of the 96-well plates in 55µl of 
medium. However, previous experience in the laboratory has shown that using such low 
volumes in 96-well plates is detrimental to the cells being cultured due to evaporation, even 
when the well plate is incubated in a highly humidified environment (more than 95% humidity). 
The only way to offset this is to use larger volumes.  
All cells were seeded in their respective expansion medium (either DMEM/10% FBS 
for all cells except neural stem cells or DMEM/F12/B27-retinoic acid/EGF/FGF2 for neural 
stem cells). After being left to attach overnight, the cells were washed 3 times in DMEM before 
initiating treatment by replacing the medium with oligodendrocytic differentiation medium 
(35% B104-conditioned medium + 1% N1 supplement). The medium was replaced every 3 
days. 
As negative controls, foetal human MSCs and Wharton’s Jelly cells were cultured in 
N1-supplemented medium without B104-conditioned medium. Untreated (N1 supplement 
without B104-conditioned medium) hFibs and hNSCs were omitted from the experiment. 
At various timepoints (0, 1, 2, 4, 7, 14, 21 and 28 days), cells in appropriate flasks were 
processed for RNA extraction for PCR and protein extraction for Western blotting, and cells in 
96-wellplates were fixed in 4% paraformaldehyde for immunocytochemistry. A range of 
markers were probed for, as listed in Table 2. Samples processed at 0 day served as additional 
negative controls. Cells harvested from each flask for either Western blotting or PCR were 
divided into three equal portions before freezing. 
 
2.11.5 Proliferation profile of fhMSCs & hWJ cells in response to 
B104-CM 
The proliferation of fhMSCs (24XY line, passage 9) and hWJ (18-2-05 cells, passage 9) 
in response to B104-CM was determined using CyQuant. Three different conditions were tested 
: 
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(1) 35% B104-CM 
(2) DMEM only for 6 days, then 35% B104-CM 
(3) DMEM only for 12 days, then 35% B104-CM. 
All media were supplement with 1% fresh L-glutamine. In addition, B104-CM was 
supplemented with fresh N1 (1%). 
 
For the first condition, 1000 cells were seeded in D10 medium into 72 wells of an 
uncoated Stripwell (96 wells, Corning). The remaining wells were used as cell-free negative 
controls (blanks). For conditions 2 and 3, 2000 cells were seeded in D10 medium into a 
Stripwell each. Triplicate wells were used for each cell type for each timepoint. Duplicate wells 
were used for blanks. In order to monitor any changes in cell morphology, phase-contrast 
photomicrographs were taken of cells in all conditions. 
 
Cells were left to attach overnight, before removing the first strip of 8 wells (Day 0). 
Thereafter, one strip was removed, the medium aspirated and the cells stored at -80oC every 
other day. The medium in all wells was replaced twice a week. Cell numbers, and proliferation, 
was measured using CyQuant. 
In the next repeat of this experiment, four additional conditions were tested on 
fhMSCs and hWJ cells : 
1. B104-CM for 14 days, then D10 medium 
2. DMEM only for 7 days, then D10 medium 
3. DMEM only for 7 days, then B104-CM 
4. DMEM only throughout 
Cell proliferation was measured as previously described using CyQuant. 
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2.11.6 Effect of Cell Stress on the Morphology of fhMSCs & 
Implications for Oligodendrocytic Differentiation in B104-CM 
The aim of this experiment was to determine the role of L-glutamine supplementation and 
its degradation into glumatate and ammonia to cell retraction during B104-CM-induced 
oligodendrocytic differentiation of fhMSCs. Passage 10 24XY fhMSCs were counted and 20 
000 were plated in D10 medium onto uncoated 13mm glass coverslips of a 24-well plate. The 
following conditions were tested in triplicate wells after 24 hours in D10 medium : 
1. D10 - 1% L-glutamine (made up in DMEM already containing L-glutamine) 
2. DMEM (already containing L-glutamine) – 1% L-glutamine + N1 
3. B104-CM freshly thawed + 1% L-glutamine + N1, made up fresh 
4. B104-CM freshly thawed - 1% L-glutamine + N1, made up fresh 
5. 35% B104-CM + 1% L-glutamine (added before incubation) incubated for 3 
weeks at 37oC 
6. 35% B104-CM + 1% L-glutamine (added before incubation) incubated at 4oC for 
3 weeks 
7. DMEM (already containing L-glutamine)  + 5M glutamate (28) + N1 – 1% L-
glutamine 
8. B104-CM freshly thawed + 5 M glutamate (28) + N1 – 1% L-glutamine 
9. SSP, 100nM for 210 mins on 25k/24WP well, in DMEM already containing L-
glutamine (No FBS) 
10. SSP, 100nM for 210 mins on 25k/24WP well, in DMEM already containing L-
glutamine (10% FBS) 
The morphology of the cells was constantly monitored over a period of 5 to 14 days. At 
the endpoint, cells were fixed for 10 minutes in 4% paraformaldehyde at room temperature and 
probed immunocytochemically for the oligodendrocytic markers A2B5, GalC and O4. 
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2.12 Protocol 5 – VEGF-C/PDGF/FGF2-Induced Oligodendrocytic 
Differentiation 
Cells were plated onto poly-D-lysine/laminin-1-coated 96-well plates specially designed 
for immunocytochemistry (Special Optics, Corning) at a density of 1000 cells per 150l per 
well and 100mm culture dishes (2.5 x 105 cells per 10ml). Cells were cultured overnight in D10 
medium (except hNSCs, DF/SFEM without retinoic acid) before washing 3 times in 
DMEM/F12 and the initiation of treatment. The medium was replaced every 3 days, and the 
cells were fixed for immunocytochemistry or prepared for Western blotting and PCR at 21 days. 
Two conditions were tested : 
1. D10 medium / Untreated 
2. Differentiation medium : DMEM/F12 and Neurobasal medium 1:1 containing N2 
+ B27+RA + PDGF-AB + FGF2 + VEGF-C 
Duplicate wells were used for each antibody combination. 
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2.13 Western Blotting 
Gels were made up according to the Table 7 below : 
 
2 gels of 10% Running/Resolving gel (10%) Stacking gel (4%) 
Distilled water (DW) 8.2ml 6.1ml 
30% acrylamide 6.6ml 1.3ml 
Tris-HCl 1.5M Tris HCl pH 8.8 – 5ml 0.5M Tris HCl pH 6.8 – 2.5ml 
10% SDS 0.2ml 0.1ml 
 Leave for 20mins at room temperature 
 For 20ml : For 10ml : 
10% APS (fresh) 100l 50l 
TEMED 20l (10ul if TEMED is fresh) 20l (10ul if TEMED is fresh) 
2 gels of 7% Running/Resolving gel (7%) Stacking gel (4%) 
Distilled water (DW) 10.2ml 6.1ml 
30% acrylamide 4.6ml 1.3ml 
Tris-HCl 1.5M Tris-HCl pH 8.8 – 5ml 0.5M Tris-HCl pH 6.8 – 2.5ml 
10% SDS 0.2ml 0.1ml 
 Leave for 20mins at room temperature 
 For 20ml : For 10ml : 
10% APS (fresh) 100l 50l 
TEMED 20l (10ul if TEMED is fresh) 20l (10ul if TEMED is fresh) 
Table 7 : Western blotting reagents and concentrations used. 
 
Samples (25g or 50g, maximum 35l) and sample buffer containing full-range 
Rainbow Marker (SB, 1:5 ratio with sample volume, Amersham Biosciences, UK RPN800V) 
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were mixed and heated to 70oC for 3 to 4 minutes prior to loading onto gels. The gels were then 
pre-run on a BioRad Mini-Protean II using the BioRad PowerPAC 300 to remove contaminants 
for 5 minutes at 200V.10% gels were run for 50 minutes at 200V (or for 1 hour at 100V) until 
the dye front ran off the gels. 
Gels were soaked in freshly made transfer buffer (TB) for 15 minutes at room 
temperature. Transfer buffer consisted of 5.82g Tris-Base, 2.93g glycine, 800ml DW, 200ml 
methanol, and 3.7ml 10% SDS. Pieces of PVDF Millipore membrane (Immobilon P, Millipore 
IPVH00010 pore size 0.45m) were cut out of the same size as gels. One corner was cut out for 
orientation and labelled with a pencil. They were then placed in 100% methanol for 30 seconds 
to 1 minute, and then washed in distilled water (DW) for 2 to 3 minutes. 
Proteins of up to 120kD were transferred for up to 1 hour at 20V (up to 3 hours for 
larger proteins such as nestin) on an ESA model 80-0022. After transfer, the PVDF membrane 
was blotted on tissue paper to remove excess TB but not allowed to dry. It was then placed in 
100% methanol for up to 1 minute and washed in DW before incubating in blocking buffer (BB; 
5% milk + TBS/T) for 1 hour at room temperature or overnight at 4oC on an orbital shaker. 
Without any intervening washes and after discarding the BB, the blot was incubated in 
primary antibody (diluted in 5% low-fat milk, BioRad, + TBS) for 1 hour at room temperature 
or overnight at 4oC on an orbital shaker. The blot was washed 3 times in TBS/T for 10 minutes 
at room temperature before incubating in secondary antibody for 1 hour at room temperature or 
overnight at 4oC on an orbital shaker. This was followed by 3 washes in TBS/T for 10 minutes 
at room temperature. 
The blot was then placed on Saran wrap before exposing to LumiGlo ECL reagents A 
and B (1:1 ratio) for 1 minute at room temperature. The blots were finally wrapped in Saran 
before aligning and securing with autoclave tape in an autoradiography cassette (RPN1642, 
Amersham Biosciences, UK). 
The blots were then exposed to Hyperfilm ECL film (Amersham Biosciences, UK) for a 
variety of durations (1-60 seconds), depending on the signal strength. After developing and 
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fixing, the films were digitally scanned and analysed. In order to quantify expression levels, 
densitometry was performed using Kodak Digital Science 1D version 1.6 software. Protein 
loading was verified by reprobing blots with anti-actin antibody. Expression levels (signal 
strengths) were standardised against protein loading (actin band intensity). 
In order to store the PVDF blots, they were dipped in 100% methanol (BDH, 15250) for 
1 minute and washed in distilled water. They were then allowed to dry, wrapped in Saran and 
foil and kept at room temperature. 
In order to re-probe the blots at a later date, they were unwrapped, dipped in 100% 
methanol for 1 minute and washed in distilled water. Afterwards, the blots were incubated in 
primary antibody. All antibodies used were tested for specificity by Western blotting. 
 
2.14 Polymerase Chain Reaction (PCR) (Performed by Maria 
Georgiou, Dr Faisal Al-Allaf & Dr Sophia Apostolidou) 
2.14.1 RNA extraction (Performed mostly by Reaz Vawda) 
Because of the chemical instability of RNA and the ubiquitous presence of RNAses, 
several precautions were taken when handling RNA, including treating bench surfaces with 
RNAse inactivating agents (RNA Zap, Ambion Ltd., Huntingdon, UK), making use of 
disposable gloves, RNAse-free pipette tips and plasticware. 
Treated fhMSCs, negative control (untreated) fhMSCs, human fibroblasts and R197VM 
hNSCs were harvested at time points 0, 1, 4, 7 and 14 days from the initiation of differentiation. 
For RNA extraction, the cell suspensions were first centrifuged at 12,000rpm for 15 minutes. 
The resulting pellets from each of these cell lines and time points were lysed with 1ml of TRIzol 
reagent (Invitrogen Ltd., Paisley, UK) by repetitive pipetting. TRIzol is a monophasic solution 
of phenol and guanidine isothiocyanate and acts to maintain the integrity of the RNA whilst 
disrupting cells and dissolving cell components. The lysed samples were then incubated for 5 
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minutes at room temperature in order to permit the complete dissociation of nucleoprotein 
complexes.  This was followed by the addition of 200μl of chloroform (Sigma-Aldrich Ltd., 
UK, UK) to each sample and vortexed thoroughly. The tubes were then incubated at room 
temperature for 5 minutes, and centrifuged at 4ºC at 12 000 rpm for 15 minutes. 
Following centrifugation, the sample had separated into a lower red, phenol-chloroform 
phase, an interphase and a colourless upper aqueous phase, containing RNA exclusively. The 
aqueous phase of each sample was transferred to fresh tubes and precipitated using isopropanol 
(Sigma-Aldrich Ltd., UK). Tubes were inverted 10-12 times and left to incubate at room 
temperature for 10 minutes. The samples were then centrifuged at 12,000rpm for 30 minutes at 
4ºC. The supernatant was removed and the remaining RNA pellet was washed with 1ml of 70% 
ethanol. The ethanol was then tipped off and pulse centrifuged and all remaining ethanol was 
taken off carefully with pipette. The RNA pellet was allowed to air dry for approximately 5-10 
minutes and then re-suspended in 25μl of 1mM filtered ethylenediaminetetraacetic acid (EDTA) 
and stored at -80ºC until use. 
 
2.14.2 DNAse treatment of extracted RNA 
Traces of DNA contamination in the isolated RNA were removed by treating with 1μl 
of DNase I, Amplification Grade (Invitrogen Ltd., UK). 2μl of each sample was removed and 
stored at -80ºC, to be used to check for ribosomal bands (See Section 2.14.3). The remaining 
23μl was diluted with 77μl diethylpyrocarbonate (DEPC; Sigma-Aldrich Ltd., UK, UK)-treated 
water to make up 100μl. 1μl of DNAse I was added and placed in a water bath at 37ºC for 10 
minutes. 350μl of TRIzol reagent was then added to each sample to inactivate the DNAse, 
followed by 100μl of chloroform. The RNA extraction protocol described earlier was then 
repeated. The treated RNA (25μl) was again re-suspended in EDTA and stored at -80ºC. 
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2.14.3 Determining RNA concentration and quality 
Spectrophotometric measurement of ultraviolet (UV) light absorbance was used to 
determine the RNA concentrations in samples. The concentration of RNA was determined by 
measuring the absorbance at 260nm in a spectrophotometer. An absorbance of 1 unit at 260nm 
corresponds to 40μg of single-stranded RNA per ml. The spectrophotometer was initially 
calibrated using a quartz cuvette filled with 100μl of water. 2μl was taken from each RNA 
sample to be analysed, and was diluted using 98μl RNase-free DEPC-treated water. The 
absorbance for each sample was measured 3 times to obtain an average. Finally, the RNA 
concentration was calculated using the equation below.  The concentration result was then used 
to dilute each RNA sample appropriately to 1g/l. 
Single-stranded RNA concentration in g/ml = Measured OD260 x 1 OD260 x Dilution factor 
where, measured OD260 is the absorbance reading at 260nm 
 1 OD260 corresponds to 40g/ml of single-stranded RNA 
 The dilution factor was 50. 
The ratio of the readings at 260nm and 280 nm (260/280) provided an estimate of the 
purity of the RNA with respect to contaminants that absorb UV, such as protein and phenol. 
Pure RNA has a 260/280 ratio of 1.9-2.1. This value was noted whilst measuring the 
concentration to ascertain the quality of the RNA. 
RNA samples were also subjected to electrophoresis in an Ethidium Bromide (Sigma-
Aldrich Ltd., UK, UK) pre-stained 1% (w/v) agarose (Agarose MP, Roche Applied Science, 
Penzberg, Germany) gel matrix in order to check the RNA quality.  This agarose concentration 
was achieved by weighing 1.5 grams of powdered agarose in a conical flask followed by the 
addition of 150ml 1x TAE buffer (Tris-acetate/EDTA; 40mM Tris, 20mM acetate, 2mM EDTA; 
pH 8.1).  After heating to melt, addition of 15l Ethidium Bromide (10mg/ml), and transfer to a 
gel mould fixed with the desired comb templates, the gel solution was allowed to solidify.  
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Following this, 2l of each RNA sample were pre-mixed with 2l of a 6x gel-loading dye 
(0.03% bromophenol blue, 0.03% xylene cyanole FF, 0.4% orange G, 15% Ficoll, 10mM Tris-
HCl (pH 7.5) and 50mM EDTA (pH 8.0); Promega Corp., Southampton, UK) before loading in 
the gel wells.  Electrophoresis was then carried out in 1x TAE running buffer at a constant 
current of 150mA and a variable voltage (100-150V) for approximately 45 minutes.  Following 
electrophoresis, the gel was removed from the electrophoretic tank, viewed on a UV 
transilluminator and then photographed.  RNA isolated from fhMSCs showed two predominant 
ribosomal RNA (rRNA) bands at ≈2.5kb (28S) and at approximately 0.8kb (18S), and low 
molecular weight transfer RNA (tRNA) at  approximately 0.2kb (5S). 
 
2.14.4 Primer selection and design 
The RNA transcript sequence of the selected markers (Tables 2 and 3) was obtained 
from the Ensembl Genome Browser (http://www.ensembl.org/).  Primers were then designed 
using the freely available Primer3 software, http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi/. 
The primers selected for this study (Table 8) were designed using 
www.genome.ucsc.edu and www.ncbi/nih.gov. The following guidelines were taken into 
consideration when designing the primers: primer length between 20 and 24 nucleotides long, 
even distribution of all nucleotides without many repetitions, no more than a 5ºC plus difference 
between the melting temperature of the pair of primers (forward and reverse), and a lack of 
cross- or self-homologies.  Furthermore, when the genes had more than one exon, the primers 
were designed across an exon-intron boundary. Furthermore, there should be approximately 50-
60 % of GC nucleotides. With these primers, any product amplified from contaminating 
genomic DNA would be much longer than a product amplified from intronless mRNA.   
Once designed, the primers were obtained from Thermo Electron GmbH, Germany. The 
desalted primers were re-suspended in diethylpyrocarbonate (DEPC) treated water, following 
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the guidelines of the manufacturer to attain a concentration of 100μM. The primers were further 
diluted with the DEPC treated water to achieve a concentration of 10μM and then stored at -
20ºC until needed. 
A (One-Step PCR) 
Marker 5’ to 3’ sequence Length % GC Tm (oC) Product size 
PLURIPOTENCY MARKERS     
Left: CGA AAG AGA AAG CGA ACC AG 20 50.00 60.12 
OCT3/4 
Right: CTG AGA AAG GAG ACC CAG CA 20 55.00 60.52 
232bp 
      
Left: GCA GAG AAG AGT GTC GCA AA 20 50.00 59.32 
NANOG 
Right: CCC TGG TGG TAG GAA GAG TAA A 22 50.00 59.52 
277bp 
      
Left: CTG AAG AAA CGG GCA AAG AC 20 50.0 59.58 
REX1 
Right: GAA CAT TCA AGG GAG CTT GC 20 50.0 59.82 
344bp 
HOUSEKEEPING GENE     
      
GAPDH Left: ATG TTC GTC ATG GGT GTG AA 20 59.81 45.00 242bp 
 Right: GAG GCA GGG ATG ATG TTC TG 20 60.62 45.00  
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B (Two-Step PCR) 
 
Table 8 : Properties of the selected oligonucleotide primers specific for pluripotency, 
neural and glial markers (Thermo Electron GmbH, Ulm, Germany) used for one- and two-
step PCR. 
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2.14.5 Temperature & Cycle Number Optimisation 
The Tm value of each primer is the temperature where half the primer has annealed to 
the specific target region, and therefore can be used as an indication of annealing temperature. 
The Tm value of the primer can be calculated using the following equation: 
Tm = [(C+G) x 4] + [(A+T) x 2] - 5ºC 
A manufacturer’s guide of the Tm came with the primers; however, the above 
equation was used to ascertain the Tm to form a temperature gradient for the optimisation of 
each primer. The annealing temperature sets the specificity of the reaction, assuring that the 
primary primer binding events are the ones specific for the target in question.  Using RNA 
extracted from cells known to express the respective markers, the initial annealing 
temperature of the marker-specific primers was taken as 5oC below the lowest Tm of the 
primer pair. The annealing temperature was then optimised (usually by using higher annealing 
temperatures) to reduce spurious PCR products arising from mispriming or non-specific 
binding.  
Cycle number optimisation was also carried out with regards to all the primers. An 
aliquot was removed from the thermal cycler after 24, 26, 28, 30, 32, 34, 35, 36, 38 & 40 
cycles. 
 
2.14.6 Reverse Transcription (RT) & Polymerase Chain Reaction 
(PCR) 
 RT-PCR detects and quantifies a starting strand of mRNA that has been reverse 
transcribed to produce complementary DNA (cDNA).  There are two ways how one can 
approach an RT-PCR, namely a ‘two-step’ or a ‘one-step’ procedure.  In the former, cDNA 
synthesis is initially performed in a tube followed by a second experimental setup of the PCR 
reaction using a cDNA aliquot as a template. On the other hand, in the ‘one-step’ procedure, 
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both cDNA synthesis and PCR amplification are performed with the same buffer and site-
specific primer, eliminating the need to open the reaction tube between the RT and PCR steps. 
 Both methods were evaluated, with the one-step procedure giving fewer problems than 
the two-step procedure possibly because it is less susceptible to contamination and has 
improved sensitivity and specificity. GAPDH housekeeping gene was used as the loading 
control for one-step PCR during characterisation of cells and the ribosomal protein L19 
housekeeping gene (4) as that for two-step PCR during oligodendrocytic differentiation. This 
is because of the possibility that GAPDH expression levels might shift during treatment as it 
does during development (291). 
 
2.14.6.1 One-Step PCR (Qiagen Ltd., West Sussex, UK) 
 In a sterile 1.5ml microcentrifuge tube, a master mix was prepared by adding 5l of 5x 
RT-PCR Buffer (Tris-Cl, KCl, (NH4)2SO4, 12.5 mM MgCl2, dithiothreitol [DTT]; pH 8.7), 
1μl dNTPs (200M each of dATP, dCTP, dGTP and dTTP), 1μl of both forward and reverse 
primers (20μM each), 15μl RNase-free water and 1μl RT-PCR Enzyme Mix (optimised 
combination of Omniscript Reverse Transcriptase, Sensiscript Reverse Transcriptase, and 
HotStarTaq DNA Polymerase). 
 Following a gentle spin in a microcentrifuge, 24μl of the master mix was pipetted into 
separate labelled 0.2μl polypropylene microcentrifuge tubes. 1l of RNA (1g/μl) was then 
added to the tubes in ice. 
 A negative control, containing either water or culture medium instead of RNA, was 
included with every run. Furthermore, for amplification of markers whose primers were 
designed on a single exon, an RT-negative control was also included. In the case of the latter, 
the RNA sample was pipetted after the 50oC reverse transcription step (Figure 2-2).  40l of 
mineral oil were then added to prevent evaporation. NTera2 embryonal carcinoma cells were 
used as a positive control cell line. 
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2.14.6.2 Two-Step PCR 
Two-step PCR requires the initial synthesis of complementary DNA (cDNA) known 
as the RT step. 1μg of each sample of RNA is required for this step; therefore, 1 is divided by 
the RNA concentrations (μg/μl), deduced from the spectrophotometric measurement to 
achieve this value (1μg ÷ RNA conc. = x (μl)). Once the values of 1μg of RNA were 
calculated for each sample, this value was then taken away from 14μl, as this was the total of 
RNase-free water including 1μg of RNA to be used in this step. Therefore, in a sterile 0.2ml 
microcentrifuge tube, a total of 14μl of RNase-free water (Qiagen) including 1μg of the 
respective RNA was added and vortexed. This was repeated for each sample of RNA. 
In a sterile 1.5ml microcentrifuge tube the master mix was prepared using Omniscript 
RT reagents provided by Qiagen and Promega. For a x 1 reaction for each sample of RNA, 
2μl of 10 x buffer (Qiagen) was added, followed by 2μl of 5mM dNTP mix, (Qiagen), 1μl of 
random primers (Promega) and 1μl of the Omniscript Reverse Transcriptase enzyme. 
(Qiagen). This was not added to the negative control master mix and replaced with 1μl of 
RNase-free water. 
Negative controls were prepared for fhMSCs and R197VM hNSCs, whereby cDNA 
should not be synthesised, and PCR amplification is unsuccessful. This would demonstrate 
negative expression during analysis. Negative controls were not included for untreated 
fhMSCs and human fibroblasts as the RNA concentrations for these samples were too low, 
and therefore, inadequate amounts were available to include such a control. 
The master mix was then vortexed only briefly, to avoid degradation of the 
Omniscript Reverse Transcriptase and then was added to the 0.2ml microcentrifuge tube 
containing the 14μl of water and RNA (above), totalling 20μl. The master mix and RNA were 
then briefly vortexed and incubated in the thermal cycler (MWG AG Biotech PrimusHT, 
Ebersberg, Germany) at 37ºC for 60 minutes. On completion, the samples were stored at -
20ºC. It should be stated that the above volumes were multiplied by the respective number of 
samples of RNA to be reverse transcribed, plus an extra 2 reactions were added to make up 
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for pipetting errors. There were 5 samples of RNA for fhMCSs, R197VM hNSCs, human 
fibroblasts and 4 samples for the control fhMSCs. Therefore, the above volumes were 
multiplied respectively. An extra master mix was prepared for both fhMSCs and R197VM 
hNSCs that did not contain the Omniscript Reverse Transcriptase enzyme but replaced by 
RNase-free water. This was used as a negative control. 
Care was taken so that the buffer, dNTPs and primer solutions were thoroughly 
thawed out on ice before use in order to avoid adding incorrect concentrations of reactants 
when these were partially thawed. 
Similarly to the RT step, a master mix was again prepared for the PCR reaction. The 
cDNA and master mix reagents were thawed on ice while preparations were made for this 
next step. The master mix (x 1 reaction) was prepared by adding to a 1.5ml microcentrifuge 
tube, 2.5μl of 10 x NH4 buffer (Bioline), 0.75μl of MgCl2 (Bioline), 0.5 of 10mM dNTPs, 
7.5μl 5M Betaine (Sigma) which aids in denaturation and prevents non-specific binding of the 
primers, 10.55μl of RNase-free water (Qiagen), 1μl of 10mM forward and reverse primers 
(Thermo Electron GmbH, Germany) and 0.2μl of BIOTAQ DNA Polymerase (Bioline). The 
master mix was then vortexed and aliquoted into 0.2ml microcentrifuge tubes (24μl per 
reaction) for each cDNA sample. 1μl of cDNA and/or –cDNA respectively (negative controls) 
was added last to the aliquot and then vortexed ensuring that none of the mix remained on the 
lid of the 0.2μl tube. Similarly to the RT step, the volumes of the master mix reagents were 
multiplied by the number of samples to be amplified, plus an extra reaction was added for 
pipetting errors. The aliquots were then placed in the thermal cycler, which was programmed 
according to the optimal conditions of each primer (Figure 2-2). Due to the variable 
conditions required by each primer, samples could not be amplified together. Once 
amplification was complete, PCR products were kept at 4ºC until needed further analysis. 
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A 
 Reverse transcription 50oC 30 minutes 
 
 Reverse transcriptase inactivation 
 HotStarTaq DNA polymerase activation 95oC 15 minutes 
 cDNA template denaturation 
 
 Denaturation 94oC 30 seconds   
 Annealing Primer specific 30 seconds    30-35 cycles 
 Extension 72oC 1 minute   
 Final extension 72oC 10 minutes  
 
B 
 
 Figure  2-2 : Thermal Profiles for One-(A) and Two-Step PCR (B). The thermal cycler 
(MWG AG Biotech PrimusHT, Ebersberg, Germany) was programmed according to the thermal 
profile shown.  The RT-PCR program was then commenced while the PCR tubes were still in ice.  
The latter were inserted into the heating block of the thermal cycler only when it reached a 
temperature of 50oC. Following completion, the samples were removed from the machine and stored 
at –20oC until analysed. 
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2.14.7 Analysis of PCR products 
The PCR products were analysed using an Ethidium Bromide stained 2% (w/v) 
agarose gel [4g of agarose powder + 200ml of 1 x TAE buffer (Tris-acetate/ EDTA)]. This 
enabled DNA fragments to be resolved on the basis of their molecular weight. The agarose 
and TAE mixture was then heated until a clear solution was obtained, and left to cool for 
approximately 5-10 minutes, ensuring that agarose fibres did not begin to form. 6μl of 
Ethidium Bromide was then added, which fluoresces under UV light. 
This solution was then transferred to a gel rack fixed with the desired sized combs 
and allowed to solidify. Once the gel had solidified it was transferred along with the rack to 
the chamber that had been filled with 1 x TAE buffer to ensure complete coverage of the gel. 
The combs were then carefully removed to avoid damage to the individual wells and 5μl of 
each PCR product that had been pre-mixed with 3μl of loading dye was loaded into the gel 
wells alongside a 100bp DNA ladder (Promega Corp., Southampton, UK). Electrophoresis 
was then carried out at a voltage of 100-120V for approximately 45 minutes. Once 
electrophoresis was complete gels were viewed on a UV transilluminator and photographed. 
The photographs of the gels were then scanned to be used for semi-quantitative analysis, 
using the ID Kodak programme, to determine density of the individual bands on the gels. 
These values were then normalised to the loading control L19 (housekeeping gene). A 
different program was used for earlier experiments - Quantity One densitometric software 
(Bio-Rad Laboratories Inc., Hercules, California, USA). Values obtained were then 
normalised to the loading control GAPDH (glyseraldehyde-3-phosphate dehydrogenase), a 
housekeeping gene. 
 Unexpected products sometimes accumulated from enzymatic extension of primers 
that annealed to non-specific target sites. This problem was resolved by raising the annealing 
temperature in 2oC increments until the spurious PCR products were totally eliminated.   
 Furthermore, a positive ‘RT-negative control’ indicated the presence of genomic DNA 
contamination. This problem was solved by treating the RNA (1g) with 10x DNase I 
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reaction buffer, 1l DNase I Amplification Grade (1U/l) and 7l DEPC-treated water, for 15 
minutes at room temperature. DNase I was then inactivated by adding 1l of 25mM EDTA 
and then heated for 10 minutes at 65oC.  Following this, the treated RNA sample was re-run 
again alongside an RT-negative control.   
 PCR has the potential sensitivity to amplify single molecules, so contamination of the 
template DNA with only a tiny amount of material can result in misleading results.  
Contamination can result due to the presence of inappropriate template from natural sources 
or due to products of previous reactions and is usually detected by the presence of a product 
band in the PCR negative control.  In general, contamination was avoided by designing 
dedicated pipette devices and separate work areas for pre- and post-PCR work.  Using a fresh 
pair of gloves when beginning work in the pre-PCR area was another potential precaution 
undertaken. 
 
2.14.8 Verification of the specificity of amplified products 
 In order to confirm the specificity of the amplified PCR products, automated DNA 
sequencing was performed on the majority of the PCR-amplified samples.  By using the 
dideoxy (dye termination) sequencing method, single stranded DNA acts as a template for 
making a new complementary DNA strand in vitro using a suitable DNA polymerase.  The 
reaction involves the use of four dNTPs each carrying a different fluorophore plus a small 
proportion of one of the four analogous dideoxynucleotides, which will serve as base-specific 
chain terminators.  During electrophoresis, a monitor detects and records the fluorescence 
signal as the DNA passes through a fixed point in the gel, thereby allowing an output in the 
form of intensity profiles for each of the differently coloured fluorophores.   
 Prior to DNA sequencing, the double-stranded PCR products were purified from 
primers, nucleotides, enzyme and salts using the QIAquick PCR purification kit (Qiagen Ltd., 
West Sussex, UK) according to the manufacture’s instructions.  Nine microlitres of the 
purified DNA were then added to three microlitres forward primer (14M), and the 
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subsequent automated DNA sequencing steps were performed by the MRC Genomics Core 
Facility (Faculty of Medicine, Imperial College London, Hammersmith Hospital).  The NCBI 
Blast 2 sequences tool was then used to compare the reference and the obtained sequencing 
(www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi). 
When the DNA sequencing result was anomalous, restriction digestion of the PCR product 
was performed. Type II restriction endonucleases are molecular scissors that bind to specific 
sequences in the DNA and cut within or adjacent to these sites.  These enzymes isolated from 
bacteria, received their name because they restrict or prevent viral infection by degrading the 
invading viral DNA.  In our case, the restriction endonuclease BstXI (New England BioLabs, 
Beverly, Massachusetts, USA) was used to confirm the specificity of the amplified OCT3/4 
transcript.  One unit of BstXI is defined as the amount of enzyme required to digest 1g of PhiX174 
DNA in 1 hour at an optimal incubation temperature of 55oC in a total reaction volume of 50l. 
 BstXI was supplied in a buffer consisting of 50 mM KCl, 10 mM Tris-HCl (pH 7.4), 
0.1 mM EDTA, 1mM DTT, 200 g/ml BSA and 50% glycerol.  It was stored at –20oC and 
when used it was removed from such storage conditions for as short a time as possible.  
Following complete thawing of all solutions in ice (except enzyme), the reaction mixture was 
prepared in a sterile 0.5ml microcentrifuge tube by adding 3l 10x NEBuffer 3, 10l PCR 
product, 16.5l sterile deionised water and 0.5l BstXI restriction enzyme (5U). An 
undigested control reaction was also prepared as above with the addition of 0.5l water 
instead of the restriction enzyme.  After a brief spin, the tubes were inserted into a heating 
plate for 1 hour at 55oC.  After digestion, the samples were analysed electrophoretically using 
the conditions described above (page 99). 
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2.15 Statistical Analysis 
For the antigenic profiles and other multiple comparisons, a one-way ANOVA was 
used with a Bonferroni multiple comparison post-test to compare all data between passages 
for each marker. For single comparisons, an unpaired T-test was used. The following chart 
was used to determine the most suitable statistical tests (Figure 2-3). 
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Figure   2-3 :  Statistical chart used to select appropriate tests. 
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3 RESULTS 
3.1 Characterisation of Human Mesenchymal Stem Cells 
3.1.1 Morphology 
In ‘complete’ culture medium (DMEM + 10% FBS) on uncoated tissue culture plastic, 
undifferentiated or naïve Wharton’s jelly cells were fibroblastic (Figure 3-1A & B) and 
morphologically similar to circulating first trimester foetal human MSCs (Figure 3-1C) (38), 
adult human bone marrow stromal cells (hBMSCs) (Figure 3-1D) and resembled those cells 
obtained by Mitchell et al., 2003 (189). As previously recorded for fhMSCs, the morphology 
of hWJ cells changed with serial passaging from slender spindle-shaped to broadened with 
irregular shapes (Figure 3-1E & F), often with a visible cytoskeleton and intracellular lipid 
accumulations. All cell lines tested were karyotypically normal at all passages. The positive 
controls (Hela cells) were abnormal (data not shown). 
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Figure  3-1 : Phase-contrast photomicrograph of undifferentiated human Wharton’s 
jelly cells (hWJ-25-10-04, A & B), foetal mesenchymal stem cells (fhMSCs 40mm, C) and adult 
bone marrow stromal cells (hBMSCs, D). E, hWJ-18-2-05 cells at passage 6 in DMEM/10% 
FBS. F, hWJ-18-2-05 cells at passage 20 in DMEM/1-% FBS. All cells except E and F were at 
Naïve hWJ cells 
hBMSCs fhMSCs 
A 
C D 
B 
E F 
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passage three and were cultured in DMEM + 10% FBS + 0.1% penicillin/streptomycin + 1% L-
glutamine. All cells had a typical fibroblastic morphology under these conditions. Bar is 100µm. 
 
3.1.2 Antigenic Profile 
The antigenic profiles of hWJ cells and fhMSCs were determined using 
immunocytochemistry and Fluorescence-Activated Cell Sorting (FACS). 
 
3.1.2.1 Immunocytochemistry 
A high proportion (90-100%) of all 3 lines of undifferentiated hWJ cells used expressed 
the mesenchymal cell markers CD73 (SH3 antibody), CD105 (SH2 antibody), prolyl-4 
hydroxylase (5B5 antibody) and vimentin (V9 antibody) at all passages tested (Figure 3-2A-
C). The proportion of these cells increased with passage number, as did that of Ki67+ cells 
immunopositive for the proliferative marker Ki67 (Figure 3-2D-F). 49% of vimentin-positive 
cells in one of the hWJ cell lines (hWJ-18-02-05) at passage 6 co-expressed Ki67 (Figure 3-
2E, data not shown). 
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Figure  3-2 : hWJ-25-10-04 cells (A-C) stained for various mesenchymal cell markers. 
Nuclei are counterstained blue with Hoechst. A – SH3 antibody (HB-10744, LGC Promochem, 
ATCC) against CD73 (FITC, green). B – 5B5 antibody (1:100, Dako) against fibroblastic prolyl-4-
hydroxylase (FITC, green). C – SH2 antibody (HB-10743, LGC Promochem, ATCC) against 
endothelial marker CD105 (FITC, green). D (hWJ-25-10-04 cells) – Intra-nuclear proliferative 
marker Ki67 (1:100, NCL-Ki67-MM1, Novocastra; FITC, green). E (hWJ-18-2-05 cells, passage 
6) - Intra-nuclear proliferative marker Ki67 (1:100, Novocastra; TRITC, red) co-expressing vimentin 
(V9 antibody, 1:100, Dako) (FITC, green).  F - Proportion of undifferentiated hWJ cells 
expressing mesenchymal markers. Data pooled from three different hWJ cell lines (n=3). * 
represents significant differences of levels of expression between passages. Anti-rabbit TRITC-
conjugated IgG (T6778, Sigma-Aldrich, UK) and anti-mouse FITC-conjugated IgG (F4018, Sigma-
Aldrich, UK) secondary antibodies were both used at 1:100 dilution. One-way ANOVA non-
parametric tests with Bonferonni post-test : SH3 & 5B5 – p2 vs p6, p>0.05; p2 & 6 vs p10, p<0.001. 
SH2 & Ki67 – all passages significantly different from each other, p<0.001-0.01). 
 
Characterisation of Oligodendrocyte Maturation & Oligodendrocyte Lineage 
Antibody Testing 
In order to characterise the morphological changes that occur during oligodendrocytic 
maturation, CG4 rat oligodendrocytic precursor cells were used (14, 165). CG4 cells were 
differentiated into mature oligodendrocytes using CG4 differentiation medium (50µg/ml 
transferrin, 5µg/ml putrescine, 3ng/ml progesterone, 23.4nM selenium, 12.5µg/ml insulin, 
0.4µg/ml thyroxine, 0.3% glucose, 2mM L-glutamine, 10ng/ml biotin in DMEM:F12) for 5 
days. Morphological changes were observed after 1 day in CG4 differentiation medium. CG4 
cells were initially bipolar with an oval cell body, a morphology typical of OPCs (Figure 3-
3A). Cells lost their bipolar morphology as multiple processes formed and the cell bodies 
became more round (Figure 3-3B). As differentiation progressed, more processes formed 
networks while the cell bodies enlarged (Figure 3-3C, D). By the end of the differentiation 
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protocol, cells tended to cluster, which is indicative of terminal differentiation into mature 
oligodendrocytes (Figure 3-3 E, F). 
 
 
 
Figure  3-3 : Differentiation of CG4 cells into oligodendrocytes. Cells were 
grown in CG4 differentiation medium for 5 days and phase-contrast photomicrographs were 
taken. A to F : time points at which observations were made during CG4 cell differentiation. 
Arrow shows a bipolar cell in A; a multipolar cell in B and a multipolar cell cluster in F. 
Bipolar oligodendrocyte precursors became multipolar and formed cell clusters after 5 days in 
differentiation medium. Scale bar is 100m. 
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The CG4 cells expressed various OPCs cell surface markers such as A2B5, O4 and 
GalC (Figure 3-4). Upon differentiation, differences in fluorescence intensities suggested that 
A2B5 expression decreased, O4 expression was maintained, and GalC expression increased 
(Figure 3-4). No MBP labelling was observed in neither CG4 cells nor differentiated CG4 
cells (not shown). 
 
 
Figure  3-4 : Differential expression of oligodendrocytic markers in CG4 cells 
and differentiated CG4 cells (dCG4 cells).  CG4 cells seeded at 20 000 cells per well in 
chamber slides and grown overnight in CG4 medium and dCG4 cells further obtained after 5 
days incubation in CG4 differentiation medium. All cells were fixed, immunoprobed without 
permeabilisation for the indicated primary antibody and appropriate secondary antibody. A: 
CG4 cells                  dCG4 cells  
A2B5/TRITC 
O4/TRITC 
GalC/FITC 
A2B5/TRITC 
O4/TRITC 
GalC/FITC 
A 
B 
C
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CG4 and dCG4 cells stained for early oligodendrocyte marker A2B5; B: CG4 and dCG4 cells 
stained for later oligodendrocyte marker O4; C: CG4 and dCG4 cells stained for late 
oligodendrocyte marker GalC. No labelling was observed in negative controls consisting in 
secondary antibody incubation only (not shown). Scale bar is 100m. 
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3.1.2.2 Fluorescence-Activated Cell Sorting (FACS) 
FACS was used to probe for haematopoietic, mesenchymal and osteogenic markers in 
order to compare previously published data on foetal human MSCs. Like fhMSCs and foetal 
osteoblasts, hWJ cells expressed low levels of haematopoietic marker (Table 9). Although 
both fhMSCs and hWJ cells expressed similar levels of collagen type I, hWJ expressed much 
higher levels of alkaline phosphatase, but lower levels of cadherin than fhMSCs. hWJ cells 
and fhMSCs both expressed much higher levels of CD166 than foetal osteoblasts. 
 
 
Table 9 : FACS - Proportions of cells expressing antigenic markers. 24XY fhMSCs and 
hWJ-25-10-04 cells of passage 10 and primary human foetal osteoblasts were used. Vim, 
vimentin; Col I, collagen I; ALP, alkaline phosphatase; OB Cad, osteoblast cadherin. 
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SH2 
(CD105)
SH3 
(CD73)
5B5 Vim Ki67 Col I ALP OB Cad 
fhMSCs 0.72 2.38 30.54 16.80 84.87 14.24 20.88 55.55 13.59 2.17 6.9 
hWJs 1.03 0.9 78.56 11.65 72.75 11.68 53.51 65.08 12.54 50.68 0.17 
Human foetal 
osteoblasts 
1.3 1.56 0.62 20.86 92.25 4.65 35.77 1.16 5.23 15.26 9.25 
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3.1.3 Doubling Time 
The doubling times of hWJ cells and fhMSCs were determined using serial passaging 
and the CyQuant fluorescent cell quantitation assay. 
 
3.1.3.1 Serial Passaging 
The doubling time of undifferentiated hWJ cells cultured in DMEM/10% FBS was 
39.43  18.6 hours from passages 2 to 12, as determined by serial passaging. The doubling 
time remained stable until passage 12, after which it started increasing (Figure 3-5). 
 
Figure  3-5 : Doubling time of hWJ cells from 8 different lines obtained by serial 
passaging up to passage 9. The doubling time of one representative line remained constant 
until passage 12, after which the proliferation rate decreased gradually. There was no 
statistically significant difference (one-way ANOVA with a Bonferonni post-test) between the 
doubling times of hWJ cells between passages 2 to 9. No values for doubling time were 
obtained at passage one since cell numbers were not counted at the initial seeding of primary 
cells from isolates. 
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3.1.3.2 CyQuant Proliferation Assay 
Doubling times were determined directly from fluorescence curves, since 
fluorescence values corresponding to the exponential portion of the curves fell within the 
linear portion of the standard curve (Figure 3-6B, inset). The doubling time of a single 
undifferentiated hWJ cell line (hWJ-25-10-04) cultured in DMEM/10% FBS was 36.72 to 
66.00 hours, as determined by CyQuant (Figure 3-6A). The doubling time increased with 
passage number. Similarly, the doubling time of a single line of fhMSCs (40mm) at passage 
number 8 was 64.08 hours. Other hWJ cell lines had similar proliferation curves and showed 
the same changes in doubling times with passaging. 
There was some variation in the doubling times of hWJ cell cultures from different 
isolates at the same passage. For instance, at passage 10, the doubling time in DMEM/10% 
FBS ranged from 46.32 hours (1.93 days) to 66.00 hours (2.75 days) (Figure 3-6B). 
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Figure  3-6 : A - Doubling times of hWJ-25-10-04 cell line at different passages 
and fhMSCs at passage 8 obtained by CyQuant fluorescent proliferation assay. Doubling 
times were estimated by triplicate measurements of the gradient of the linear portion of each 
curve. Mean values are shown. B – Doubling times of 3 different hWJ cell lines (hWJ-25-
10-04, 27-10-04 and 18-2-05) at passage 10, showing the variation in proliferation 
profiles between different isolates under the same culture conditions. B, Inset – standard 
curve obtained using serial dilutions of hWJ-25-10-04 cells. Fluorescence values in the linear 
portions of the curves in Figure 6A & B obtained during doubling time analysis corresponded 
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to cell numbers within the linear portion of the standard curve. Therefore, those values were 
used as a direct estimate of cell number. 
 
Summary : 
Human Wharton’s jelly cells resemble foetal mesenchymal stem cells, with regard to 
their morphology, antigenic profile and doubling time. 
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3.2 Expression of Embryonic Genes in Mesenchymal Stem Cells 
All lines of Wharton’s jelly cells and fhMSCs used expressed the embryonic markers 
Oct4, Nanog and Rex-1 (Figure 3-7). Oct4 and Nanog were expressed strongly in all cell 
lines, whilst Rex-1 was expressed strongly in all but one cell line (hWJ-19-11-04*). This was 
not due to differences in sample loading, since GAPDH loading controls were comparable in 
all samples. 
 
Figure  3-7 : RNA level expression of embryonic markers by fhMSCs and hWJ cells. 
fhMSCs 1, 48XY; 2, 50XX; 3, 40XY; 4, 24XY ; hWJ cells 1, hWJ-25-10-04; 2, hWJ-27-10-04; 3, 
hWJ-18-2-05; 4, hWJ-19-11-04. All cells were cultured in D10 medium and processed at passage 
10. +, RT Positive (NTera2 embryonal carcinoma cells); , RT Negative. Fainter bands in Oct4 blot 
represent incomplete genomic DNA digestion. 
1 2 3 4 - +
hfMSCs hfWJCs
1 2 3 4
312 bp
Rex-1*
Nanog
GAPDH
Oct-4
232 bp
344 bp
~600 bp
Incomplete Genomic 
DNA digestion 
Reaz Vawda  IC PhD Thesis 2008 
 115
3.3 Telomere Length 
From Figure 3-8, it is apparent that the telomere lengths of all three hWJ cell lines tested fell 
dramatically from passage 4 to 14, but then in the two lines (hWJ-25-10-04 and hWJ-27-10-04) rose 
again at passage 17/18. 
The telomere lengths of both fhMSC lines tested (40mm and 24XY) decreased slightly 
from passage 4 to 14 (40mm cells) or 4 to 11 (24XY cells). Beyond passage 11, the telomere 
length of 24XY cells stabilised at a level slightly greater than at passage 11, but lower than at 
passages 4 and 9. 
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Figure  3-8 : Telomere lengths of different cell lines and types at different passages. 
Low control (L), High control (H). The red squares indicate the telomere length for each cell type.  
Telomere lengths decreased with passage number up to a point, after which they rose again at the 
latest passages tested. 
Cell Line               hWJ-25-10-04   hWJ-27-10-04     40mm fhMSCs   24XY fhMSCs 
Passage Number   4          14           4         14           4           14         9          14         25 
       9         17          9          18          11           4         11         20           L      H 
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3.4 Mesodermal Differentiation of Human Mesenchymal Stem Cells 
3.4.1 Osteogenic Differentiation 
Osteogenic differentiation was determined by Alizarin Red S labelling and quantified by 
the extraction using 1% CPC solution and measurement of the absorbance of this dye. A 
standard curve (not shown) was obtained by serial dilution of known concentrations of 
Alizarin Red S (ARS) dye (Sigma-Aldrich, UK). It was linear throughout the range of dye 
concentrations used. Therefore, absorbance values were used as a direct measure of ARS 
concentration. 
BDM1 medium (containing ascorbic acid) was toxic to cells, and therefore results from 
these were not taken into account. For cells treated with BDM2 bone differentiation medium, 
the formation of bone nodules is clearly apparent in the fhMSC line 40mm. No such nodules 
were seen in 24XY fhMSCs (not shown) or hNSC negative controls (Figure 3-9). 
Both hWJ cell lines (25-10-04 and 27-10-04) responded to BDM2 treatment (Figure 3-
10A & B), with maximal Alizarin Red labelling at 2-3 weeks of differentiation culture. 
Amounts of stain extracted from untreated hWJ cells remained constant throughout. hWJ cells 
treated with BDM1 were much lower than untreated ones at all timepoints except at 1 week. 
At this first timepoint, hWJ cells in BDM1 (containing ascorbic acid) were higher than either 
untreated ones or those in BDM2 (containing ascorbate-2-phosphate, a more stable form of 
ascorbic acid). The latter were also lower than untreated controls. 
In order to determine the effects of culturing hWJ cells in mitogen-supplemented 
medium on their osteogenic differentiation potential, hWJ-18-2-05 cells were cultured in 
D10/SFEM (D10 medium + EGF + FGF2 + B27 without retinoic acid) before inducing bone 
differentiation in BDM1 and 2. Untreated cells (also cultured in D10/SFEM) were used as 
negative controls. The amount of ARS extracted from stained cells was compared to hWJ-18-
2-05 cells grown in D10 medium and induced to differentiate in bone cells (Figure 3-10C). 
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Culturing in D10/SFEM compared to D10 medium reduced the amount of calcium-rich 
extracellular matrix deposited by the cells. Although BDM2-induced osteogenic 
differentiation (as determined by dye extraction) did take place in hWJ cells previously 
cultured in the mitogen-supplemented medium, this was significantly different from those 
grown in D10 (Figure 3-10C). 
A line of fhMSCs (40mm) was used as a positive control for bone differentiation (Figure 
3-10D). There was an increase over time in both untreated (control, DMEM/10% FBS) cells 
and those treated with BDM2. fhMSCs treated with BDM1 remained much lower than 
untreated ones at all timepoints, due to the toxicity of this medium and consequent cell death. 
Whilst the amount of stain extracted from untreated cells fell after 3 weeks, it continued to 
rise for those in BDM2.  
hNSCs were used as a negative control for bone differentiation (Figure 3-10E). Although 
there was a small increase in the amount of Alizarin Red dye extracted from cells treated with 
BDM2 and untreated cells (control, DMEM/10% FBS), this was much lower than the 
response of fhMSCs and hWJ cells treated in the same way – there was no statistically 
significant difference in the amount of dye extracted from treated and untreated hNSCs at 
week 3 (Figure 3-10E). The amount of Alizarin Red dye extracted from hNSCs treated with 
BDM2 were lower or equal to untreated hNSCs at all timepoints except at 4 weeks, when 
BDM2-treated hNSCs were more heavily stained than control (untreated, in D10 medium) 
hNSCs. The amount of Alizarin Red dye extracted from hNSCs treated with BDM1 remained 
much lower than untreated hNSCs at all timepoints. 
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Figure  3-9 : Phase-contrast photomicrographs of fhMSCs (40mm), hWJ cells (hWJ-
25-10-04) and hNSCs exposed to osteogenic differentiation medium BDM2. Bone nodules 
(dark rim and paler centre) were only seen in BDM2 and only in fhMSCs. Bar is 100µm. 
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Figure  3-10 A-E : Alizarin Red S (ARS) stain extracted from cells treated for up to 
4 weeks in bone differentiation medium (BDM2). Readings were obtained from triplicate 
wells which were further divided into triplicates for absorbance measurement at 562nm. 
Osteogenic differentiation of hWJ-25-10-04 (A), hWJ-27-10-04 (B), hWJ-18-2-05 cells (C, 3 
weeks only), 40mm fhMSCs (D) and hNSCs (E) in BDM1 and BDM2 for 4 weeks, as 
determined by Alizarin Red S (ARS) absorbance measurements after extraction from stained 
cells. A One-Way ANOVA was carried out followed by a Bonferroni Multiple Comparison 
Post-Test to compare untreated (control) cells at different timepoints. No significant 
difference between untreated hWJ-25-10-04 cells at different timepoints (p>0.05). There was 
a significant difference only between untreated hWJ-27-10-04 cells at 1 and 4 weeks 
(p<0.01), and 2 and 4 weeks (p<0.001). Except at 1 and 2 weeks, amounts of due extracted 
from untreated fhMSCs were significantly different from each other between timepoints 
(p<0.01). BDM2-treated and untreated cells were compared with untreated controls at 3 
weeks using an unpaired two-tailed T-test. S, Significant; NS, Non-Significant. n=3. 
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Summary : 
 hWJ cells and fhMSCs have osteogenic differentiation potential. 
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3.4.2 Fat Differentiation 
Adipogenic differentiation was determined by Oil Red O (ORO) labelling and quantified 
by the extraction using 100% isopropanol and measurement of the absorbance of this dye. A 
standard curve (not shown) was obtained by serial dilution of known concentrations of Oil 
Red O (ORO) dye (Sigma). It was linear throughout the range of dye concentrations extracted 
from stained cell samples (corresponding to absorbance values of up to 0.75 units). Therefore, 
absorbance values were used as a direct measure of ORO concentration. 
Similarly to 40mm fhMSCs, intracellular lipid globules were only seen in hWJ cells 
treated with FDM only (Figure 3-11). In terms of ORO accumulation, hWJ-27-10-04 
responded best to the FDM/FMM fat differentiation protocol (Figure 3-12B). Although there 
was a gradual increase in the amount of ORO extracted from hWJ-25-10-04 cells treated 
using the same protocol, the control levels were unusually high compared to treated 
conditions (Figure 3-12A).  
Using the same measure of adipogenic differentiation, 40mm fhMSCs responded only to 
the FDM/FMM protocol (Figure 3-12D), although there were no typical adipogenic cell 
morphologies using this protocol. These intracellular fat globules were only seen in the FDM 
protocol (Figure 3-11), even though the amount of ORO stain extracted from cells treated 
with FDM only was lower than untreated fhMSCs at all timepoints (Figure 3-12D). 
As measured by the amount of ORO extracted, hNSCs responded to both fat 
differentiation protocols, even though their morphological characteristics were not the same 
as fhMSCs treated in the same way (Figure 3-11). hNSCs treated with FDM with no 
alternation with FMM medium accumulated more total lipid at all timepoints than those that 
were alternated between the two media (Figure 3-12E). Untreated hNSCs accumulated some 
lipid over 4 weeks. 
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Figure  3-11 : Phase-contrast photomicrographs of fhMSCs (40mm), hWJ cells (hWJ-
25-10-04) and hNSCs exposed to adipogenic differentiation media. Intracellular lipid globules 
were only seen in FDM. Bar is 100µm. 
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Figure  3-12 : Adipogenic differentiation of hWJ-25-10-04 (A), hWJ-27-10-04 (B), 
hWJ-18-2-05 cells (C), 40mm fhMSCs (D) and hNSCs (E) in fat differentiation medium 
(FDM) only and FDM alternated with fat maintenance medium (FMM) for 4 weeks, as 
determined by Oil Red O (ORO) absorbance measurements at 500nm after extraction from 
cells. Readings were obtained from triplicate wells which were further divided into triplicates for 
absorbance measurement at 500nm. 
 
For cells treated using the FDM/FMM fat differentiation protocol, there were no 
typical adipogenic cell morphologies (intracellular fat globules), unlike those treated using the 
FDM protocol (Figure 3-11). No such morphologies were seen in 24XY fhMSCs (not shown) 
or hNSC negative controls (Figure 3-11). This is the reason why no statistical comparisons 
were made, since regardless of the total amount of accumulated lipid, it is the specific 
globules which are indicative of adipogenic differentiation (220). 
 
Summary : 
 hWJ cells and fhMSCs have adipogenic differentiation potential. 
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3.4.3  Cartilage Differentiation 
Not all fhMSC or hWJ lines responded positively to chondrogenic stimulation. Only one 
fhMSC and one hWJ line did (Figure 3-13). Safranin labelling, in this case, could not be used 
to determine chondrogenic differentiation, since the cells used as positive controls (fhMSCs, 
40mm line) showed no increase in labelling with treatment (data not shown). Therefore, 
Alcian Blue (pH 1.0) was used as the indicator of chondrogenic differentiation. 
Figure  3-13 : Chondrogenic differentiation of fhMSCs and hWJ cells, as determined 
by Alcian Blue (pH 1.0) labelling. Only one fhMSC and one hWJ cell line (hWJ-19-11-04) showed 
chondrogenic differentiation. Untreated cells were cultured in CDM without TGF3. Scale bar is 
100m. 
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3.5 Differentiation of MSCs into Neural Stem Cells - Protocol 1 
The aim of these experiments was to investigate the potential of mesenchymal stem 
cells from foetal blood and Wharton’s Jelly to differentiate into neural stem cells (as defined 
by the expression or upregulation of selected neural antigenic markers). Cells were seeded at a 
density of 5000 cells per well in DMEM/10% FBS (D10) in poly-D-lysine and fibronectin-
coated 96-well plates. After attaching overnight, differentiation was initiated. Cultures were 
exposed to culture conditions (DMEM/F12 + B27 containing retinoic acid + EGF + FGF2) 
which support the proliferation of undifferentiated human NSCs (33, 120, 197, 214, 247). 
Negative controls were cultured in D10 or DMEM/F12 (DF) without supplements. 
Cells were fixed in 4% paraformaldehyde for immunocytochemistry at days 0 (negative 
control in D10 medium) and 14. Duplicate wells were used for each antibody combination to 
probe each cell type in each condition. Triplicate counts of different fields were made for 
quantification of each well. 
Nestin is a marker of stem and precursor cells. Although positive and negative control 
cell types (R197VM NSCs and fibroblasts, respectively) were not quantified, the majority of 
NSCs were strongly positive for nestin. It was difficult to ascertain whether a few fibroblasts 
were very weakly positive in D10 medium, since although labelling intensity was slightly 
higher than secondary antibody only negative controls, it was still too faint (Figure 3-14). In 
D10 medium (untreated), a greater proportion of fhMSCs expressed nestin (10%) than hWJ 
cells (0-5%) (Figure 3-15). The proportion of nestin-positive fhMSCs and hWJ cells 
decreased slightly in DMEM/F12 medium lacking supplements (DF). The proportion of 
treated cells expressing nestin (35-45%) was greatly increased compared to controls, except 
one particular line of hWJ cells (hWJ-18-2-05), which showed almost no change in the 
proportion of nestin+ cells (Figure 3-15). Olig2 is a marker of oligodendrocytic progenitors. 
All cells were immunonegative for Olig2. 
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Figure  3-14 : Fluorescence photomicrographs of untreated and treated cells stained 
for nestin (FITC, green) expression. Scale bar is 100m. Untreated for hWJ cells, fhMSCs and 
hFibs were cultured in D10 medium (DMEM + 10% FBS), and untreated hNSCs in DF/SFEM 
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(DMEM/F12 + B27 + EGF + FGF2). All cells were immunonegative for Olig2 (not shown). Treated 
hWJ-25-10-04 cells at 14 days were representative of other hWJ cell lines. 
 
 
Figure  3-15 : Proportion of nestin+ cells in different conditions. D10 is DMEM/10% 
FBS, DF is DMEM/F12 only, DF/SFEM is DMEM/F12 + B27/Retinoic acid + EGF + FGF2. 
Duplicate wells were used for each antibody combination to probe each cell type in each condition. 
Triplicate counts of different fields were made for quantification of each well (n=3). There was no 
statistically significant different between the proportions of nestin+ hWJ cell lines in D10 medium at 
day 0 (p>0.05). 
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Although not quantified, R197VM NSCs (positive controls) were strongly A2B5+, 
whilst fibroblasts (negative controls) were A2B5- (Figure 3-16). No cells in D10 medium 
expressed A2B5, a marker of oligodendrocytic pre-progenitors and progenitors (but not 
mature oligodendrocytes). This proportion rose in hWJ-18-2-05 and fhMSCs to 15%, only 
slightly in hWJ-25-10-05 to 3-4% and not at all in the remaining hWJ line. There was a 
noticeable but slight increase in the proportions of A2B5+ cells with treatment compared to 
D10 medium, but surprisingly these were lower than in DMEM/F12 alone (Figure 3-17). 
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Figure  3-16 : Fluorescence photomicrographs of untreated cells stained for A2B5 
(FITC, green) expression. Scale bar is 100m. Untreated for hFibs were cultured in D10 medium 
(DMEM + 10% FBS), and untreated hNSCs in DF/SFEM (DMEM/F12 + B27 + EGF + FGF2). 
24XY fhMSCs shown were cultured for the duration of the experiment in DMEM/F12 alone. All 
cells were immunonegative for NG2. 
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Figure  3-17 : Proportion of A2B5+ cells in different conditions. D10 is DMEM/10% 
FBS, DF is DMEM/F12 only, DF/SFEM is DMEM/F12 + B27/Retinoic acid + EGF + FGF2. 
Duplicate wells were used for each antibody combination to probe each cell type in each condition. 
Triplicate counts of different fields were made for quantification of each well (n=3). 
 
Although not quantified, R197VM hNSCs (positive controls) were strongly III-tubulin+, 
whilst fibroblasts (negative controls) were III-tubulin- (Figure 3-18). In contrast, 50-70% of all cell 
types in D10 medium (untreated) expressed III-tubulin, a classical marker of neurones (Figure 3-19). 
These proportions increased in DMEM/F12 alone (DF), and even further in neural induction 
medium (to 73-85%). Compared to DMEM/F12 alone, the increase in positive fhMSCs with 
treatment was slight. The largest increases were observed for 2 hWJ lines (hWJ-18-2-05 and hWJ-
27-10-05) (Figure 3-19). No GFAP labelling was seen in fhMSCs or hWJ cells. 
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Figure  3-18 : Fluorescence photomicrographs of treated and untreated cells stained for III-
tubulin (FITC) and GFAP (TRITC) expression. Scale bar is 100m. Untreated for hWJ cells, 
fhMSCs and hFibs were cultured in D10 medium (DMEM + 10% FBS), and untreated hNSCs in 
DF/SFEM (DMEM/F12 + B27 + EGF + FGF2). All cells, except hNSCs, were immunonegative for 
GFAP.  
 
 
Figure  3-19 : Proportion of III-tubulin+ cells in different conditions. D10 is 
DMEM/10% FBS, DF is DMEM/F12 only, DF/SFEM is DMEM/F12 + B27/Retinoic acid + 
EGF + FGF2. Duplicate wells were used for each antibody combination to probe each cell 
type in each condition. Triplicate counts of different fields were made for quantification of 
each well (n=3). All hWJ-25-10-04 values are non-significantly different from each other. 
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A large proportion of cells in D10 medium (untreated) were GalC+ (40-55%), but the 
labelling pattern in the vast majority of cells was cytoplasmic rather than cell surface (Figure 3-20). 
The proportion of positive cells decreased in DMEM/F12 and in neural induction medium 
(compared to D10) in all but one cell line (hWJ-18-2-05). In the latter, the proportion of GalC+ cells 
increased from 40% in D10 medium to 82% in neural induction medium. Unlike hWJ-27-10-05 and 
fhMSCs, in hWJ-25-10-05 cells, there was a slightly greater proportion of positive cells in neural 
induction medium compared to DMEM/F12 alone (Figure 3-21). No O4 labelling was seen in any 
condition for any cell type, although CG4 cells used as positive labelling controls were positive. 
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Figure  3-20 : Fluorescence photomicrographs of treated and untreated cells stained 
for O4 (FITC) and GalC (TRITC) expression. Note the atypical intracellular labelling pattern of 
GalC. No O4 labelling was seen in any cells in any condition. Scale bar is 100m. Untreated hWJ 
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cells and hFibs were cultured in D10 medium (DMEM + 10% FBS), and untreated hNSCs in 
DF/SFEM (DMEM/F12 + B27 + EGF + FGF2). 
 
 
Figure  3-21 : Proportion of GalC+ cells in different conditions. D10 is DMEM/10% 
FBS, DF is DMEM/F12 only, DF/SFEM is DMEM/F12 + B27/Retinoic acid + EGF + FGF2. 
Duplicate wells were used for each antibody combination to probe each cell type in each condition. 
Triplicate counts of different fields were made for quantification of each well (n=3). Cells counted 
showed a cytoplasmic labelling pattern. 
 
Although not quantified, positive control R197VM NSCs were strongly PSA-
NCAM+, whilst fibroblasts were negative for this neural progenitor cells marker. No cells in 
D10 medium expressed detectable PSA-NCAM (Figure 3-22). However, in DMEM/F12 
alone, this increased dramatically in the hWJ cells (to 15-84%). There was only a slight 
increase in the proportion of immunopositive fhMSCs in DMEM/F12 alone or in neural 
induction medium compared to D10 medium. In the latter condition, hWJ-18-2-05 cells were 
not found to express detectable levels of PSA-NCAM.  The other two lines of hWJ cells 
expressed the marker at higher levels than in D10 (16% and 43%), but at lower levels than 
DMEM/F12 alone (Figure 3-23). 
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      Figure  3-22 : Fluorescence photomicrographs of treated and untreated cells stained 
for PSA-NCAM (FITC) expression. Scale bar is 100m. Untreated hWJ cells and hFibs 
were cultured in D10 medium (DMEM + 10% FBS), and untreated hNSCs in DF/SFEM 
(DMEM/F12 + B27 + EGF + FGF2). 
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Figure  3-23 : Proportion of PSA-NCAM+ cells in different conditions. D10 is 
DMEM/10% FBS, DF is DMEM/F12 only, DF/SFEM is DMEM/F12 + B27/Retinoic acid + EGF + 
FGF2. Duplicate wells were used for each antibody combination to probe each cell type in each 
condition. Triplicate counts of different fields were made for quantification of each well (n=3). 
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As found during initial characterisation studies, a high proportion of all cell types 
expressed CD105 (SH2) and CD73 (SH3) in D10 medium. This fell modestly by 5-10% in 
DMEM/F12 alone and neural induction medium (Figures 3-24 & 3-25). 
 
Figure  3-24 : Proportion of SH2+ cells in different conditions. D10 is DMEM/10% FBS, 
DF is DMEM/F12 only, DF/SFEM is DMEM/F12 + B27/Retinoic acid + EGF + FGF2. Duplicate 
wells were used for each antibody combination to probe each cell type in each condition. Triplicate 
counts of different fields were made for quantification of each well (n=3). There was no significant 
difference between the proportions of SH2+ 24XY fhMSCs in all three conditions. 
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Figure  3-25 : Proportion of SH3+ cells in different conditions. D10 is DMEM/10% FBS, 
DF is DMEM/F12 only, DF/SFEM is DMEM/F12 + B27/Retinoic acid + EGF + FGF2. Duplicate 
wells were used for each antibody combination to probe each cell type in each condition. Triplicate 
counts of different fields were made for quantification of each well (n=3). There was no statistically 
significant difference between the cell types in D10 at Day 0. 
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In order to determine the mitogenic effect of neural induction medium on the cells 
tested, the average number of cells per field was plotted against each cell type in each 
condition (Figure 3-26). As expected, cell numbers fell in DMEM/F12 alone. In neural 
induction medium, cell numbers remained constant for hWJ-25-10-04 and fhMSCs, increased 
slightly for hWJ-27-10-04, and rose dramatically for hWJ-18-2-05. 
 
Figure  3-26 : Average number of each cell type per field under different conditions.  
D10 is DMEM/10% FBS, DF is DMEM/F12 only, DF/SFEM is DMEM/F12 + B27/Retinoic acid + 
EGF + FGF2. Triplicate counts of different fields were made for quantification of each well (n=3). 
Cell numbers (for all cell types except hWJ-18-2-05) in D10 and DF/SFEM were both statistically 
significantly different from those in DF (p<0.05). 
 
In all experiments, cell monolayers were stained with secondary antibodies only as 
negative controls (Figure 3-27). No non-specific labelling was observed. 
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Figure  3-27 : Negative labelling controls, using only secondary antibodies on untreated 
cells at day 0. Scale bar is 100m. FITC, Green; TRITC, red/orange; Hoechst nuclear stain, blue. 
Untreated hWJ cells and fhMSCs were cultured in D10 medium (DMEM + 10% FBS). Secondary 
antibody only negative labelling controls were performed on all cell types in all conditions. 
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Summary : 
1. A proportion of untreated hWJ cells and fhMSCs expressed neural antigenic markers, 
including nestin and III-tubulin. 
2. Although a few neural antigenic markers were upregulated in DF/SFEM, no 
morphological changes occurred to indicate neural differentiation. 
3. DF/SFEM sustained the survival of hWJ cells and fhMSCs in the absence of serum 
for at least 14 days. 
4. As for osteogenic and adipogenic differentiation potentials, different hWJ cell lines 
had varying responses to culture in DMEM/F12 alone and DF/SFEM. 
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3.6 Neuronal Differentiation of MSCs - Protocols 2 & 3 
The aim of these experiments was to induce the neuronal differentiation of 
mesenchymal stem cells from foetal blood and Wharton’s Jelly using a modification of two 
published protocols used for embryonic stem cells (90) and bone-marrow-derived stem cells 
(85, 86, 90, 127, 128, 133). 
The following conditions were tested : 
1. DMEM/10% FBS (D10 medium) (0 day only; negative control); for neural stem cells, this 
was DMEM/F12+B27+EGF+FGF2 
2. DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + noggin 
3. DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + FGF2 + FGF8 + Shh 
4. Condition 2 without noggin (negative control); only for WJ cells (DF) 
 
The medium was changed completely twice a week. Cells in D10 medium were fixed 
for immunocytochemistry at day 0. Cells in other conditions were fixed at day 21 after the 
initiation of treatment. Duplicate wells were used for each antibody combination to probe 
each cell type in each condition. Triplicate counts of different fields were made for 
quantification of each well. 
Nestin is a marker of stem and precursor cells. Positive and negative control cell types 
(R197VM NSCs and fibroblasts, respectively) were not quantified. However, most NSCs 
were strongly positive for nestin (not shown). It was difficult to assess the labelling of a few 
fibroblasts, which stained slightly more intensely then secondary only negative controls, but 
which were considerably fainter than either hNSCs, fhMSCs or hWJ cells. 
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Figure  3-28 : Fluorescence photomicrographs of hWJ cells following treatment with a 
combination of Shh, FGF2 and FGF8 stained for nestin (FITC, green) expression. No cells 
were immunopositive for Olig2 (not shown). Scale bar is 100m. R197VM NSCs and fibroblasts 
were used as positive and negative labelling controls, respectively. 
 
In D10 medium (untreated), the proportion of nestin+ fhMSCs and hWJ cells (Figure 
3-29) was low (4-8%) and similar to results obtained in previous independent experiments 
(using DMEM/F12 + B27 + FGF2 + FGF2) (Figure 3-15). There was no statistically 
significant difference between the proportions of nestin+ corresponding hWJ cell lines and 
24XY fhMSCs in D10 medium at day 0, except for hWJ-27-10-04 (p=0.004) in the two 
experiments (protocols 1 and 2/3). 
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The proportion of nestin+ cells decreased in DFN/B27/N2 (to 1% or less), as seen in 
previous independent experiments (using DMEM/F12 + B27 + FGF2 + FGF2). 
Treatment with noggin for 21 days had different effects on different cell lines, even of 
the same cell type. The proportion of nestin+ cells increased in hWJ-18-2-05 and hWJ-25-10-
04 (to 11%), but decreased in hWJ-27-10-04 and fhMSCs to near undetectable levels (Figure 
3-29). 
In Shh + FGF2 + FGF8 for 21 days, the proportion of nestin+ cells increased 
dramatically in all cell lines, except hWJ-18-2-05 (Figures 3-28, 29). Once more, this is 
similar to results obtained using DF/SFEM for 14 days. The increase in the proportion of 
nestin+ cells under these conditions, however, was more pronounced than with DF/SFEM. 
Since no dramatic increase in the proportion of nestin+ cells was seen in noggin-treated cells, 
this might be related to the presence of FGF2 or a mitogen under serum-free conditions. 
 
Figure  3-29 : Proportion of nestin+ cells in different conditions. D10 is 
DMEM/10% FBS, Noggin is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 
+ noggin, Shh/FGF2&8 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + 
Shh + FGF2 + FGF8, DFN/B27/N2 is DMEM/F12 + Neurobasal + B27 containing retinoic 
acid + N2 only. Duplicate wells were used for each antibody combination to probe each cell 
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type in each condition. Triplicate counts of different fields were made for quantification of 
each well (n=3). There was statistically significant difference in the proportions of nestin+ 
cells in D10 medium at day 0 (p>0.05). 
 
Although not quantified, R197VM NSCs (positive controls) were strongly A2B5+ 
(Figure 3-30), whilst fibroblasts (negative controls) were A2B5-. As seen with DF/SFEM, no 
cells in D10 medium expressed A2B5 (Figure 3-31), a marker of oligodendrocytic pre-
progenitors and progenitors but not mature oligodendrocytes. 
Unlike in DF/SFEM, there was no change in the proportion of A2B5+ cells in 
DFN/B27/N2 compared to D10 in any cell line (Figure 3-31).  
In noggin, there was no change from undetectable levels of A2B5 expression. In Shh 
+ FGF2 + FGF8, there was a slight increase in only two lines (hWJ-27-10-04 and fhMSCs) to 
4-5% (Figure 3-31). NG2 expression was not seen in any of the cells or conditions tested (not 
shown). 
Figure  3-30 : Fluorescence photomicrographs of 24XY fhMSCs and hNSCs following 
treatment with a combination of Shh, FGF2 and FGF8 stained for A2B5 (FITC)  expression. Scale 
bar is 100m. 
A2B5, FITC (Green) 
24
X
Y
 fh
M
SC
s 
Sh
h/
FG
F2
&
8,
 D
ay
 2
1 
R
19
7V
M
 h
N
SC
s 
Sh
h/
FG
F2
&
8,
 D
ay
 2
1 
Hoechst (Blue) 
Reaz Vawda  IC PhD Thesis 2008 
 152
Figure  3-31 : Proportion of A2B5+ cells in different conditions. D10 is DMEM/10% 
FBS, Noggin is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + noggin, 
Shh/FGF2&8 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + Shh + FGF2 + 
FGF8, DFN/B27/N2 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 only. 
Duplicate wells were used for each antibody combination to probe each cell type in each condition. 
Triplicate counts of different fields were made for quantification of each well (n=3). 
 
Although not quantified, untreated R197VM NSCs (positive controls) were strongly 
III-tubulin+ and GFAP+, whilst fibroblasts (negative controls) were III-tubulin- and GFAP-. 
55-95% of all cell types in D10 medium (untreated) expressed III-tubulin, a classical marker 
of immature and mature neurones (Figure 3-32). This was even higher than under the same 
conditions during DF/SFEM experiments (50-70%). Also in contrast to DF/SFEM 
experiments, these proportions decreased sharply in DFN/B27/N2, especially in hWJ-27-10-
04 cells from 89% to 10%. 
Noggin treatment for 21 days had contrasting effects on different cell lines. Although 
it lead to a slight increase in hWJ-25-10-04 III-tubulin+ cells (from 57% to 64%), the 
proportion of positive cells fell sharply in other cell lines, especially fhMSCs (from 95% to 
32%) (Figure 3-32). 
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Shh + FGF2 + FGF8 treatment also lead to a dramatic fall in the proportion of III-
tubulin+ cells, which varied with the cell line or type (Figure 3-32). 
 
Figure  3-32 : Proportion of III-tubulin+ cells in different conditions. D10 is 
DMEM/10% FBS, Noggin is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 
+ noggin, Shh/FGF2&8 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + 
Shh + FGF2 + FGF8, DFN/B27/N2 is DMEM/F12 + Neurobasal + B27 containing retinoic 
acid + N2 only. Duplicate wells were used for each antibody combination to probe each cell 
type in each condition. Triplicate counts of different fields were made for quantification of 
each well (n=3). 
 
For GalC expression, only cells with cell surface labelling were counted. Neural stem 
cells and fibroblasts under all conditions tested were negative for GalC (Figure 3-33), 
although CG4 cells used as positive labelling controls were immunopositive for this mature 
oligodendrocytic marker. A very low percentage of hWJ cells and fhMSCs were GalC+ in 
D10 medium. This decreased in DFN/B27/N2 to near undetectable levels (Figure 3-34). 
Following noggin treatment for 21 days, there was a decrease in the proportion of 
GalC+ cells, except for hWJ-27-10-04, which rose from less than 1% to 7% (Figure 3-34). 
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In Shh + FGF2 + FGF8 for the same duration, there was a general decrease in the 
proportion of positive cells. No O4 labelling was seen in any condition for any fhMSCs or 
hWJ cells (Figure 3-34). 
 
 
Figure  3-33 : Fluorescence photomicrographs of hWJ-18-2-05 cells and hNSCs following 
treatment with a combination of Shh, FGF2 and FGF8 stained for O4 (FITC, green) expression. 
Scale bar is 100m. 
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Figure  3-34 : Proportion of GalC+ cells in different conditions. D10 is DMEM/10% 
FBS, Noggin is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + noggin, 
Shh/FGF2&8 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + Shh + FGF2 + 
FGF8, DFN/B27/N2 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 only. 
Duplicate wells were used for each antibody combination to probe each cell type in each condition. 
Triplicate counts of different fields were made for quantification of each well (n=3). There was no 
statistically significant difference (p>0.05) between the cell types in D10 medium at Day 0. 
 
 
Although not quantified, positive control R197VM NSCs were strongly PSA-
NCAM+, whilst fibroblasts were negative for this neural progenitor cells marker.  Few cells of 
any type expressed PSA-NCAM in D10 medium, although hWJ-27-10-04 expressed the 
highest proportion (4%) (Figures 3-35 & 3-36). 
In DFN/B27/N2, the percentage of PSA-NCAM+ hWJ-27-10-04 cells rose 
dramatically to 74%. In previous experiment, this increase was from 0% to only 44%. The 
increase in the proportion of PSA-NCAM+ hWJ-25-10-04 cells was modest in comparison, 
from 1% to 5%. There was no increase in the proportion of other cell types in DMEM/F12 
alone (Figure 3-36). 
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In noggin-containing medium for 21 days, the percentage of positive hWJ-27-10-04 
was unchanged compared to DMEM/F12 alone. That of positive hWJ-25-10-04 cells, 
however, increased from 5% to 16% (Figure 3-36). 
In Shh + FGF2 + FGF8, the proportion of positive hWJ-27-10-04 cells increased 
further compared to DMEM/F12 alone to 80%, whilst in contrast that of hWJ-25-10-04 cells 
fell to levels similar to those in D10 medium. The proportion of immunopositive cells in other 
cell lines remained at undetectable levels (Figure 3-36). 
These results were similar to previous experiments in DF/SFEM, whereby hWJ-25-
10-04 and hWJ-27-10-04 cells contained the highest proportion of PSA-NCAM+ cells in 
DMEM/F12 alone and following treatment in DF/SFEM for 14 days (Figure 3-23). 
Figure  3-35 : Fluorescence photomicrographs of hWJ-27-10-04 cells and hNSCs 
following treatment with a combination of Shh, FGF2 and FGF8 stained for PSA-
NCAM expression. Scale bar is 100m. 
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Figure  3-36 : Proportion of PSA-NCAM+ cells in different conditions. D10 is 
DMEM/10% FBS, Noggin is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + 
noggin, Shh/FGF2&8 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + Shh + 
FGF2 + FGF8, DFN/B27/N2 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 
only. Duplicate wells were used for each antibody combination to probe each cell type in each 
condition. Triplicate counts of different fields were made for quantification of each well (n=3). 
 
As seen in previous characterisation experiments and neural differentiation in 
DF/SFEM, most fhMSCs and hWJ cells expressed CD105, an endothelial marker recognised 
by the SH2 antibody. Unlike in DF/SFEM, DFN/B27/N2, Shh/FGF2/FGF8 or 
DMEM/F12/Neurobasal + B27/RA, where a modest decrease in the proportion of CD105+ 
cells was seen, noggin treatment of hWJ cells and fhMSCs lead to a dramatic decrease, 
especially in hWJ-18-2-05 cells and fhMSCs (Figure 3-37). 
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Figure  3-37 : Proportion of SH2+ cells in different conditions. D10 is DMEM/10% FBS, 
Noggin is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + noggin, Shh/FGF2&8 is 
DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + Shh + FGF2 + FGF8, 
DFN/B27/N2 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 only. Duplicate 
wells were used for each antibody combination to probe each cell type in each condition. Triplicate 
counts of different fields were made for quantification of each well (n=3). The proportions of SH2+ 
24XY fhMSCs and hWJ-18-2-05 cells in different conditions were statistically significant from each 
other (p<0.001). 
 
As seen in previous characterisation and neural differentiation experiments, most hWJ 
cells and fhMSCs expressed CD73 (Figure 3-38, 39), a mesenchymal cell lineage marker 
recognised by the antibody SH3. Noggin treatment for 21 days lead to a decrease in the 
proportion of CD73+ hWJ cells, especially hWJ-25-10-04 (Figure 3-39). In contrast, the 
percentage of CD73+ fhMSCs was only slightly decreased in response to Shh/FGF2/FGF8 
treatment (Figures 3-38 & 3-39). A smaller proportion of untreated cells 
(DMEM/F12/Neurobasal + B27/RA only) at day 21 expressed CD73 to those at day 0 in D10 
medium, similar to observations made in DMEM/F12 alone at 14 days. 
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Figure  3-38 : Fluorescence photomicrographs of Shh/FGF2/FGF8-treated 
cells stained for CD73 expression (FITC, green) using SH3 antibody at day 21. Scale bar 
is 100m. 
 
Figure  3-39 : Proportion of SH3+ cells in different conditions. D10 is DMEM/10% FBS, 
Noggin is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + noggin, Shh/FGF2&8 is 
D10, Day 0 Noggin, Day 21 Shh/FGF2&8, Day 21 DFN/B27/N2, Day 21
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DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + Shh + FGF2 + FGF8, 
DFN/B27/N2 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 only. Duplicate 
wells were used for each antibody combination to probe each cell type in each condition. Triplicate 
counts of different fields were made for quantification of each well (n=3). 
 
Figure 3-40 shows that only cells in Shh, FGF2 and FGF8 were mitogenically 
stimulated. In Protocol 1 (using DMEM/F12 + B27 + FGF2 + EGF) at 14 days in DMEM/F12 
alone, the numbers of all cell types per field had fallen below those at Day 0 in D10 medium. 
However, in this protocol after 21days in DMEM/F12 + ‘non-neural’ supplements (B27 and 
N2), the numbers of all cell types were virtually the same as those at day 0 in D10 medium. 
 
Figure  3-40 : Average number of each cell type per field under different conditions. 
D10 is DMEM/10% FBS, Noggin is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 
+ noggin, Shh/FGF2&8 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 + Shh + 
FGF2 + FGF8, DFN/B27/N2 is DMEM/F12 + Neurobasal + B27 containing retinoic acid + N2 
only. Duplicate wells were used for each antibody combination to probe each cell type in each 
condition. Triplicate counts of different fields were made for quantification of each well (n=3). 
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Summary : 
1. As seen previously, a proportion of untreated hWJ cells and fhMSCs expressed neural 
antigenic markers, including nestin and III-tubulin. 
2. Although a few neural antigenic markers were upregulated in treated cells, no 
morphological changes occurred to indicate neural differentiation. 
3. Noggin and the combination of Shh, FGF2 and FGF8 sustained the survival of hWJ 
cells and fhMSCs in the absence of serum for at least 14 days. 
4. As for osteogenic and adipogenic differentiation potentials, different hWJ cell lines 
had varying responses to treatment. 
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3.7 Oligodendrocytic Differentiation - Protocols 4 & 5 
3.7.1 B104-CM-Induced Oligodendrocytic Differentiation of MSCs 
- Protocol 4 
The aim of these experiments was to induce the oligodendrocytic differentiation of 
mesenchymal stem cells from foetal blood and Wharton’s Jelly using modified published 
protocols used for neural stem cells (283, 284). 
 
3.7.1.1 Determination of the Optimal Concentration of B104-Conditioned Medium 
& Optimisation of Substrate 
Previous experiments in the laboratory showed that the optimal concentration of 
B104-conditioned medium (CM) for the appearance of oligodendrocytic morphologies in 
fhMSC cultures is 35% (Nigel Kennea, data not shown). 
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Figure  3-41 : Mitogenic effect of fresh B104-CM on CG4 cells. Fluorescence values 
(Arbitrary Units, AU) are directly proportional to cell numbers. 0% B104-CM is N1-supplemented 
DMEM only. Fluorescence was measured at 485nm excitation, 538nm emission; cells seeded at 
5000 cells per well in 96-Stripwell plates. Bars represent standard error, n=3. 
 
The quality of each batch of B104-CM was assessed by its mitogenic effect on CG4 
rat oligodendrocytic progenitor cells (Figure 3-41), which are routinely cultured in this 
medium. No normalisation of the fluorescence values obtained with respect to the standard 
curve (Figure 3-42) was carried out, since the former fell within the linear portion of the 
standard curve. This was obtained using serial dilutions of known numbers of CG4 cells. This 
means that fluorescence values smaller or equivalent to 75 AU are directly proportional to the 
cell number. 
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Figure  3-42 : CyQuant standard curve for cell proliferation assay in CG4 cells. 
Fluorescence in arbitrary units (au) was measured at 485nm excitation and 538nm emission. Linear 
part of standard curve was between 0 and 32000 cells (Inset). Bars represent standard error, n=3. 
 
After changes of medium and during fixing, it was observed that many hNSCs and 
CG4 cells were lost through detachment. Therefore, poly-D-lysine only was not sufficient to 
provide strong enough cell attachment. Thus, in subsequent experiments, unless otherwise 
stated, all tissue culture substrates were coated with poly-D-lysine and fibronectin in order to 
minimise cell loss. 
No oligodendrocytic (bipolar or multipolar) morphologies were seen in fhMSCs and 
hWJ cells treated with B104-conditioned medium. No positive labelling for the antigenic 
markers was obtained on these cell types. 
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3.7.1.2 Comparison of the Oligodendrocytic Differentiation Potential of Three 
Different Wharton’s Jelly Cell Lines 
The aim of these experiments was to compare the B104CM-induced oligodendrocytic 
differentiation of hWJ cells and 24XY fhMSCs. Orange Scientific dishes were used to 
replicate previous work in the laboratory as closely as possible. 
Cells were seeded into 100mm dishes at a density of 2.5 x 105 cells per 10ml of D10 
medium and grown to 70% confluence. At this point, the cells were washed three times in 
DMEM and the medium was changed to 35% B104-CM. Cells cultured in N1-supplemented 
medium were used as negative controls (Table 10). All media were supplemented with 1% 
fresh L-glutamine. The medium was replaced twice a week for 4 weeks, during which time 
the appearance of bipolar and multi-polar cells was closely monitored and phase-contrast 
photographs were taken. 
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Dish Cells Condition 
1 N1 
2 
hWJ-18-2-05 
35% B104CM 
3 N1 
4 
hWJ-25-10-04 
35% B104CM 
5 N1 
6 
hWJ-27-10-04 
35% B104CM 
7 N1 
7 PDL/Fn PDL/Fn, 35% B104CM 
8 
24XY fhMSCs 
35% B104CM 
9 N1 
10 
hFibs (negative control) 
35% B104CM 
11 N1 
12 
R197VM hNSCs (positive 
control) 35% B104CM 
 
Table 10 : Cell types tested during B104-conditioned medium-induced 
oligodendrocytic differentiation. 
 
At the end of 4 weeks, cells were harvested, centrifuged at 4000rpm for 4 minutes at 
room temperature, and snap-frozen for subsequent Western blotting and PCR. 
No morphological change indicative of oligodendrocytic differentiation was observed 
in any cell type at any point (Figure 3-43). Although the survival of cells appeared to be better 
supported in B104-CM compared to N1 only, no bipolar or multipolar cells were seen. 
On a poly-D-lysine/fibronectin-coated substrate, fhMSCs were slightly more spread 
out compared to an uncoated substrate, possibly due to better adherence (Figure 3-43). 
Neural stem cells continued to proliferate in B104-CM, as observed previously, to the 
point that they formed a confluent monolayer that lifted off.  
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Given the absence of oligodendrocytic morphologies in response to treatment, the 
effect of B104-CM not supplemented with fresh L-glutamine and B104-CM pre-incubated at 
37oC on the morphology of fhMSCs was tested on uncoated 6-well plates (Orange Scientific) 
– Refer to Results section 3.7.1.5. 
No morphological change indicative of neural (particularly oligodendrocytic) 
differentiation was observed at any timepoint during this experiment. All cells continued to 
proliferate in B104-CM (but not in N1 medium) and attained confluence after about 7 days 
treatment – Refer to Results section 3.7.1.4. 
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Figure  3-43 : Phase-contrast photomicrographs of cells treated with B104-conditioned 
medium (CM). Occasional bipolar cells were observed in untreated (N1) human fibroblasts (hFibs), 
treated hWJ-25-10-04, untreated and treated hWJ-27-10-04, and treated hWJ-18-2-05 cells 
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(indicated by arrows). hNSCs continued to proliferate in B104-CM, reached confluence and 
detached from the culture substrate. Scale bars are 100m. 
 
3.7.1.3 B104-CM-Induced Oligodendrocytic Differentiation of fhMSCs 
No difference had previously been found on fibronectin compared to uncoated tissue 
culture substrate with regard to the number of bi- and multipolar cells appearing, but the ECM 
substrate resulted in prolonged survival of fhMSCs (Nigel Kennea, data not shown). 
Therefore, in the present experiments, cells were seeded onto poly-D-lysine and fibronectin-
coated Greiner T175 dishes and 96-well plates. The poly-D-lysine was used to enhance the 
efficiency of ECM coating by providing a charged surface for the binding of the ECM 
molecules. Poly-D-lysine was not used in previous experiments in the laboratory. 
No morphological change indicative of oligodendrocytic differentiation was observed 
in any cell type at any point. Although the survival of cells appeared to be better supported in 
B104-CM compared to N1 only, no bipolar or multipolar cells were seen. 
  In order to identify the possible cause of the absence of bi- and multipolar fhMSCs 
and hWJ cells in B104-CM, several experiments were carried out. 
Firstly, the effect of cell seeding density and B104-CM concentration was assessed. 
24XY fhMSCs (originally used by Nigel Kennea for B104-CM differentiation) were seeded at 
1000, 2000, 5000 and 10 000 cells per well of uncoated 8-well tissue culture plastic chamber 
slides (Nunc). After 24 hours incubation in D10 medium, the cells were washed in DMEM, 
and the medium was switched to different concentrations of B104-CM : 0 (N1 supplement 
only), 20, 25, 30, 35, 40 and 45%. Cells left in D10 after washing served as negative controls. 
The latter were fixed after 24 hours. The medium was changed twice a week. After 3 weeks, 
all the cells were fixed in 4% paraformaldehyde for 10 minutes and stained for A2B5/NG2 
and O4/GalC. Triplicate wells were used for each condition and antibody combination. CG4 
cells served as positive labelling controls, whilst primary human fibroblasts (HS27 line) 
served as negative labelling controls. Additional labelling negative controls included the use 
of secondary antibodies only. 
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No morphological changes indicative of neural differentiation was observed (data not 
shown), and all cells were negative for the oligodendrocytic markers probed for (data not 
shown). 
Secondly, the effect of ECM substrate coating on B104-CM-induced differentiation of 
24XY fhMSCs and hWJ-25-10-04 cells was examined. Cells were seeded in D10 medium at a 
density of 1000 cells per well (except one set, which was 5000 cell per well on 
PDL/fibronectin in order to assess the effect of a higher cell density) into 96-well plates left 
uncoated or coated with one of the following substrates : 
1. Poly-D-lysine (PDL) and fibronectin 
2. PDL and laminin-1 
3. PDL and gelatin 
4. PDL and bovine serum albumin (BSA) 
5. PDL only 
6. Fibronectin only 
After 24 hours in D10 medium, the cells were washed in DMEM and the medium was 
switched to 35% B104-CM supplemented with N1. Thereafter, the medium was replaced 
twice a week. After 14 days, the cells were fixed and stained for A2B5/NG2 and O4/GalC as 
described earlier. The same controls were used as for previous experiments. In addition, 
primary human fibroblasts were exposed to the same conditions, as a negative control. 
No morphological changes indicative of neural differentiation was observed (data not 
shown), and all cells were negative for the oligodendrocytic markers probed for (data not 
shown). 
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3.7.1.4 Proliferation of MSCs & hWJ Cells in Serum-Free Culture 
Mesenchymal cells (fhMSCs & hWJ) exposed to 35% B104-CM serum-free mitogen-
supplemented medium (DF/SFEM) after initial culture in D10 medium continued to 
proliferate for at least 2-3 weeks. This means that they reached confluence during treatment, 
and this might have affected their differentiation. 
The aim of these experiments was to determine the duration and rate of proliferation 
in such conditions using the CyQuant proliferation assay, in order to control and optimise cell 
densities during neural differentiation of both cell types. 
Three conditions were tested : 
1. 35% B104-CM throughout 
2. DMEM only for 6 days, then 35% B104-CM 
3. DMEM only for 12 days, then 35% B104-CM 
Cells were seeded in D10 medium at a density of 1000 cells in a volume of 150l per 
well for condition 1. Cells in condition 2 and 3 were seeded at 2000 cell per well in the same 
volume. Cells were left to attach overnight (day 0) before washing three times in DMEM and 
switching into the appropriate medium. At this point, a strip was removed and snap-frozen at -
80oC from each 96-well plate. The medium in all conditions was replaced twice a week 
throughout the duration of the experiment. 
 fhMSCs and hWJ cells continued proliferating in B104-CM, although the latter did so at 
a lesser slower rate (Figure 3-44). Unlike hWJ cells, fhMSCs in DMEM only for 6 days 
before changing into B104-CM increased in numbers slightly. The numbers of hWJ cells in 
this condition did not increase. After 12 days in DMEM only, neither fhMSCs nor hWJ cells 
increased in numbers after changing into B104-CM. 
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Figure  3-44 : Proliferation profile of hWJ-18-2-05 cells and 24XY fhMSCs in DMEM 
only and B104-conditioned medium determined by CyQuant analysis. Arrows indicate medium 
changes from DMEM only into 35% B104-CM. 
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Figure  3-45 : Phase-contrast photomicrographs of cells exposed to DMEM only for 14 
and 28 days. Scale bars are 100m. 
 
After 14 days in DMEM only, both fhMSCs and hWJ cells were morphologically 
normal (Figure 3-45A, B). After 21 days, both cell types became large, typical of 
differentiated and non-proliferating cells (Figure 3-45C, D). Cell stress was evident from the 
accumulation of intra-cytoplasmic lipid droplets, especially in hWJ cells (Figure 3-45B, 
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Arrow). At 28 days, cell death (and a reduction in cell numbers) was evident. The remaining 
cells left were generally large and flattened. 
FhMSCs (24XY line) and hWJ (18-2-05 line) cells were tested for the ability to 
proliferate when re-exposed to serum after nutrient and serum deprivation. Cells were seeded 
in D10 medium, left to attach overnight, and washed three times in DMEM before switching 
to one of the following conditions : 
1. B104-CM throughout 
2. B104-CM for 14 days, then D10 medium 
3. DMEM only for 7 days, then D10 medium 
4. DMEM only for 7 days, then B104-CM 
5. DMEM only throughout (negative control) 
Cell-free wells were used as blanks. Media in all conditions was replaced twice a week. 
As seen previously, both cell types proliferated in B104-CM for 7 days before either 
declining in numbers (fhMSCs) or remaining constant (hWJ cells) (Figure 3-46). Changing 
into D10 medium at 14 days did not reverse the decline in fhMSC numbers, unlike hWJ cells, 
which reverted to a proliferative state. 
Reaz Vawda  IC PhD Thesis 2008 
 177
 
Figure  3-46 : Proliferation profile of hWJ-18-2-05 cells and 24XY fhMSCs exposed to 
various treatments.  
 
After 7 days in DMEM only and changing into D10 medium, both cell types 
proliferated, although hWJ at a lesser rate than fhMSCs. However, changing into B104-CM at 
7 days failed to revert either cell type to a proliferative state, as seen previously (Figure 3-44). 
Both cell types remained non-proliferative in DMEM only. 
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Conclusion : 
In order to keep the cell density constant during B104-CM-induced cell differentiation 
of fhMSCs and hWJ cells, it is possible to culture the cells in DMEM only (+ 1% L-
glutamine), so that upon exposure to B104-CM, they do not proliferate. 
 
 
3.7.1.4.1 Optimisation of PCR Conditions for Primers – Temperature & Cycle Number 
All of the primers used in this study were first optimised to find the optimal 
temperatures and optimal PCR cycle numbers (Table 11). Figures 3-47 and 3-48 show 
representative examples of temperature and cycle number optimisation. In Figure 3-47, the 
optimal annealing temperature for REX1 is approximately 50ºC. Figure 3-48 shows the 
optimal cycle number for OCT4 was 35, at which the strongest signal was obtained. These 
were determined by densitometry. 
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OCT4 59ºC 35 cycles 
REX1 50ºC 40 cycles 
NESTIN 58ºC 40 cycles 
CD133 55ºC 40 cycles 
OLIG2 59ºC 35 cycles 
SOX10 50ºC 40 cycles 
L19 59ºC 40 cycles 
Table 11 : Optimal conditions of primers to probe neural markers. L19 was used as a 
loading control. 
 
Figure  3-47 : Temperature optimisation of REX1 (50.3ºC optimum 
temperature) using a temperature gradient of 50-60ºC. DNA, DNA ladder; Neg, negative 
control 
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Figure  3-48 : Cycle number optimisation of OCT4 (optimal cycle number was 35). DNA, 
DNA ladder; Neg, negative control 
 
 
3.7.1.4.2 Gene Expression at Different Timepoints 
The mitochondrial ribosomal protein L19 (housekeeping gene) was used as a control 
in these experiments as it should be expressed in all cells (4). L19 was expressed at all time 
points as expected, however, at different intensities, therefore, the following graphs show 
expression of each genetic marker normalised with respect to the loading control L19 after 
densitometric analysis of the bands was performed. 
The changes in expression levels of Oct4, nestin and Sox10 were similar to each other 
in each cell type tested. The changes in expression levels of Rex1, nestin, Olig2 and Sox10 
were similar in untreated fhMSCs (Figure 3-49). At days 1 to 14, the expression pattern of 
CD133 was similar to Oct4, nestin and Sox10 in treated fhMSCs only (Figure 3-50).  
Olig2 expression appears in oligodendrocytic lineage cells earlier than Sox10 (136, 
242, 267, 289). Following B104-CM treatment, its expression level peaked in R197VM neural 
stem cells (at day 1) before Sox10 (at day 7) (Figure 3-51). R197VM human neural stem cells 
did not express Rex 1 or Oct4 (not shown). 
In fibroblasts, the changes in expression levels of Oct 4, Rex1 and Olig2 were similar; 
the opposite trend (a decline) was observed for nestin and Sox10 at days 7 and 14 in these 
cells (Figure 3-52). Human fibroblasts did not express CD133 (not shown). It was surprising 
to find the same markers in fibroblasts, especially Sox10 and nestin, which were both 
expressed at high levels (although still much lower than other cell types tested) and also 
DNA        24         26        28        30         32        34         35       36         38        40   
500 
400 300 
200 
100 
Cycle Number 
Reaz Vawda  IC PhD Thesis 2008 
 181
followed a similar pattern of expression during treatment (Figure 3-52). Interestingly, the 
changes observed in the levels of expression of Oct4, Olig2 and Rex1 were similar – all fell 
and then rose again towards 14 days.  
 
Figure  3-49 : Changes in levels of expression of CD133, L19, NESTIN, OLIG2, REX1, 
and SOX10 in untreated foetal mesenchymal stem cells at different time points. At Day 
0, cells in D10 medium were processed. Afterwards, cells were transferred into N1 medium 
(DMEM + N1). Oct4 expression in untreated fhMSCs was not analysed. Expression of each 
genetic marker was normalised with respect to the loading control L19 after densitometric 
analysis of the bands was performed. 
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Figure  3-50 : Changes in levels of expression of CD133, L19, NESTIN, OCT4, OLIG2, 
REX1, and SOX10 during induction of differentiation of foetal mesenchymal stem cells 
into oligodendrocytes, at different time points. fhMSCs at day 0 had been cultured in D10 
medium, and were thus untreated (same as Figure 3-46). +, RT-positive and -, RT-negative. 
Expression of each genetic marker was normalised with respect to the loading control L19 
after densitometric analysis of the bands was performed. 
CD133
L19
NESTIN
OCT4
OLIG2
SOX10
REX1
Days 0 Day 1                Days 4 Days 7 Days 14
+        - +       - +       - +       - +        -
hFibs
0 1.0 4.0 7.0 14.0
0.00
0.25
0.50
0.75
1.00
OLIG2
SOX10
CD133
NESTIN
REX1
OCT4
Days
N
or
m
al
is
ed
 B
an
d
In
te
ns
ity
Reaz Vawda  IC PhD Thesis 2008 
 183
 
 
 
Figure  3-51 : Changes in levels of expression of CD133, L19, NESTIN, OLIG2, and 
SOX10 during treatment of R197VM with B104-conditioned medium at different 
timepoints.  +: RT-positive, and -:  RT-negative. hNSCs at day 0 had been cultured in 
DMEM/F12 + EGF + FGF2 + B27 without retinoic acid, and were thus untreated. Expression 
of each genetic marker was normalised with respect to the loading control L19 after 
densitometric analysis of the bands was performed. 
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All the above markers showed a similar pattern of expression – an increase followed 
by a fall by 14 days of treatment. 
 
 
Figure  3-52 : Changes in levels of expression of L19, NESTIN, OCT4, OLIG2, 
REX1, and SOX10 during treatment of human fibroblasts with B104-conditioned 
medium at different time points. Human fibroblasts (hFibs, HS27 line) at day 0 had been 
cultured in D10 medium, and were thus untreated. Expression of each genetic marker was 
normalised with respect to the loading control L19 after densitometric analysis of the bands 
was performed. 
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Oct4 : untreated fhMSCs (fhMSCs, day 0) expressed higher levels of Oct4 than other 
cell types (Figure 3-53). Although, Oct4 expression rose slightly 24 hours after exposure to 
B104-CM, it declined by day 4, but rose again by day 14 to higher than pre-treatment levels. 
R197VM neural stem cells did not express Oct4, whilst human fibroblasts expressed low 
levels at all timepoints. 
 
Figure  3-53 : Oct4 expression by cell types used during B104-CM treatment, 
normalised with respect to the loading control L19. ufhMSCs are untreated fhMSCs in D10 
medium. Expression of each genetic marker was normalised with respect to the loading control L19 
after densitometric analysis of the bands was performed. 
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Rex1 : untreated fhMSCs expressed higher levels of Rex1 than treated ones (Figure 3-
54). Culture in a serum-free medium (DMEM + N1 supplement) increased the levels of Rex1 
in fhMSCs. Exposure to B104-CM increased expression of Rex1 by day1, which gradually 
declined to lower than pre-treatment levels by day 14. In contrast to fhMSCs, fibroblasts 
expressed low levels of Rex1, which fell after exposure to B104-CM, but then recovered to 
pre-treatment levels by day 14. R197VM neural stem cells did not express Rex1 (not shown). 
 
Figure  3-54 : Rex1 expression by cell types used during B104-CM treatment, 
normalised with respect to the loading control L19. ufhMSCs are untreated fhMSCs in D10 
medium. 
 
Nestin : fhMSCs expressed much higher levels of nestin than R197VM neural stem 
cells (Figure 3-55). Furthermore, nestin expression was higher in untreated fhMSCs than in 
treated ones at all timepoints except day 14. The expression of nestin in both untreated and 
treated fhMSCs followed the same pattern until day 14, when it declined in untreated 
fhMSCs, but rose in treated ones. As expected, neural stem cells expressed higher levels of 
nestin than fibroblasts. Exposure of neural stem cells to B104-CM did not alter the expression 
if nestin in these cells (Figure 3-55). However, expression fell at day 14, presumably due to 
their continued proliferation, reaching over-confluence and subsequently differentiating. 
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Unexpectedly, human fibroblasts expressed low levels of nestin, which decreased upon 
exposure to B104-CM (Figure 3-55). 
Figure  3-55 : Nestin expression by cell types used during B104-CM treatment, 
normalised with respect to the loading control L19. ufhMSCs are untreated fhMSCs in D10 
medium. 
 
 
CD133 : untreated fhMSCs (day 0) expressed higher levels of CD133, a marker of 
undifferentiated stem cells, than R197VM neural stem cells (Figure 3-56). Although the level 
of CD133 expression fell dramatically with B104-CM treatment, it returned to pre-treatment 
levels by day 14. CD133 expression remained at very low levels in untreated fhMSCs at all 
timepoints. In contrast, the expression of CD133 in neural stem cells increased following 
B104-CM treatment, reached a peak by day 7 and fell again by day 14 (still at higher than pre-
treatment levels) (Figure 3-56). As expected, fibroblasts were not found to express CD133 
(not shown). 
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Figure  3-56 : CD133 expression by cell types used during B104-CM treatment, 
normalised with respect to the loading control L19. ufhMSCs are untreated fhMSCs in D10 
medium. 
 
Olig2 : Levels of expression in untreated fhMSCs rose until 7 days and declined by 
14 days (Figure 3-57). This is in contrast to treated fhMSCs, in which Olig2 expression at 14 
days was higher than at earlier timepoints. R197VM neural stem cells (positive controls for 
oligodendrocytic differentiation) generally expressed higher levels of Olig2 than other cells 
types, except at day 7, when untreated fhMSCs expressed more. In neural stem cells, the 
levels of Olig2 rose slightly at day 1, declined gradually until day 7, and then fell more 
dramatically by day 14 (Figure 3-57). Human fibroblasts (negative controls for 
oligodendrocytic differentiation) generally expressed the lowest levels of Olig2, with the 
expression level remaining roughly constant throughout the duration of the experiment (14 
days) (Figure 3-57). Exposure to B104-conditioned medium initially lead to a down-
regulation of Olig2 (day 1), followed by a gradual recovery to pre-treatment levels by day 14. 
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Figure  3-57 : Olig2 expression by cell types used during B104-CM treatment, 
normalised with respect to the loading control L19. ufhMSCs are untreated fhMSCs in D10 
medium. 
 
Sox10 : Sox10, a marker of immature oligodendrocytes, was not only expressed by 
untreated fhMSCs but also at higher levels than observed in neural stem cells (Figure 3-58). 
Exposure to B104-CM lead to an initial increase in Sox10 expression (day 1) followed by a 
decline. The expression of Sox10 followed a similar pattern in untreated and treated fhMSCs 
until day 14, when it rose dramatically in treated fhMSCs. In neural stem cells, the expression 
levels of Sox10 increased slightly until day 7, and then fell back to pre-treatment levels 
(Figure 3-58). In fibroblasts, exposure to B104-CM lead to a general fall in Sox10 expression 
(Figure 3-58). 
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Figure  3-58 : Sox10 expression by cell types used during B104-CM treatment, 
normalised with respect to the loading control L19. ufhMSCs are untreated fhMSCs in 
D10 medium. 
 
3.7.1.5 Effect of Cell Stress on the Morphology of fhMSCs & Implications for 
Oligodendrocytic Differentiation in B104-CM 
In the present study, freshly thawed B104-conditioned medium (CM) failed to induce 
any morphological changes indicative of oligodendroglial differentiation in fhMSCs and hWJ 
cells. However, when the same batch of B104-CM, which had been stored for a few weeks at 
4oC was used again on fhMSCs (24XY line), they changed morphology within a few days 
from fibroblastic spindle-shaped to bipolar and multipolar (Figure 3-59). This is in agreement 
with earlier studies in this laboratory. However, immunocytochemistry revealed that the cells 
were not immunopositive for any of the oligodendroglial markers probed for (A2B5, O4 and 
GalC; data not shown). Differentiating CG4 cells were used as positive controls and human 
primary fibroblasts (HS27 line) were used as negative controls. 
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Figure  3-59 : Phase-contrast photomicrographs of fhMSCs (24XY line) exposed for 5 
days to B104-CM stored at 4oC for three weeks (at four magnifications). For comparison, 
photomicrographs of primary (non-immortalised) and immortalised CG4 rat oligodendrocytes are 
also shown. Scale bars are 100m. 
 
This indicated that factors accumulating in the B104-CM during storage at 4oC might 
be causing the fhMSCs to retract and assuming neural-like morphologies. It was postulated 
that one of these factors might be glutamate, formed from the breakdown of L-glutamine in 
the culture medium. Glutamate, in high enough concentrations, would be toxic to cells. 
The effects of L-glutamine degradation in the culture medium on the retraction of 
fhMSCs were assessed using a modified published protocol (28) to test whether the 
morphological changes seen previously in the laboratory were due to the exposure to B104-
CM or nutrient degradation. 
24XY fhMSCs were seeded onto uncoated glass coverslips in 24-well plates at a 
density of 20 000 cells per well in triplicate. 
The following ten conditions were tested : 
1. D10 (Made up in DMEM already containing L-glutamine) 
2. DMEM (already containing L-glutamine) + N1 
3. 35% B104-CM freshly thawed + 1% L-glutamine + N1, made up fresh 
4. 35% B104-CM freshly thawed + N1, made up fresh 
5. 35% B104-CM + 1% L-glutamine (added before incubation) incubated for 3 weeks at 
37oC 
6. 35% B104-CM + 1% L-glutamine (added before incubation) incubated at 4oC 
7. DMEM (already containing L-glutamine)  + 5 M glutamate + N1 
8. B104-CM freshly thawed + 5 M glutamate + N1 
9. SSP, 100nM for 210 mins on 25k/24WP well, in DMEM already containing L-
glutamine (No FBS) 
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10. SSP, 100nM for 210 mins on 25k/24WP well, in DMEM already containing L-
glutamine (10% FBS) 
Bipolar cells appeared 5 days after the initiation of B104-CM treatment (Figure 3-60), at 
which point cells were fixed for immunocytochemistry (4% paraformaldehyde at room 
temperature for 10 minutes). Cells were probed for the expression of A2B5 and O4/GalC. All 
conditions revealed negative labelling for these markers of the oligodendrocytic lineage (data 
not shown). Differentiating CG4 cells were used as positive controls and human primary 
fibroblasts (HS27 line) were used as negative controls. 
At the morphological level, interesting changes occurred. Bipolar cells appeared in 
conditions 2 (DMEM already containing L-glutamine + N1), 3 (B104-CM + 1% L-glutamine 
+ N1) and 4 (B104-CM + N1) (Figure 3-60), although there was considerably more cell death 
in 3 and 4, especially towards the edges of wells where the cell density tended to be less. 
There were no bi- or multi-polar cells in condition 5 (B104-CM + 1% L-glutamine 
incubated at 37oC, Figure 3-60), although cells retracted and became ‘spiny’. Again, cell death 
was apparent towards the edges of these wells (more than conditions 3 and 4). 
Considerably more bipolar cells were seen in conditions 6 (B104-CM + 1% L-glutamine 
incubated at 4oC), 7 (DMEM already containing L-glutamine + glutamate + N1) and 8 (B104-
CM + glutamate + N1) with minimal cell death only in condition 6 (Figure 3-60). 
Cell retraction and cell death was apparent in condition 9 (SSP without FBS), although the 
processes of the resulting bipolar cells at 30 minutes and later were different from typical 
bipolar cells in that they were of uneven thickness. At this same timepoint, no bi- or 
multipolar cells could be seen in condition 10 (Figure 3-60). 
Bi- and multipolar cells were observed in condition 10 (SSP + 10% FBS) after 210 
minutes of exposure to the toxin (not shown), accompanied by considerably more cell death 
than other conditions. 
Therefore, FBS delayed cell death upon exposure to staurosporine (SSP) in fhMSCs. 
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Figure  3-60 : Phase-contrast photomicrographs of 24XY fhMSCs exposed to various treatments. All photomicrographs were taken at 5 days, unless 
otherwise indicated. Neural morphologies (bi- and multipolar cells) were seen not only in B104CM-treated cultures but also in DMEM + N1, DMEM + glutamate + N1 and 
SSP. Scale bars are 100m. 
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Additional experiments were carried out in order to mimic the retraction of cells that might 
lead them to assume neural-like morphologies. Passage 5 HS27 primary human fibroblasts, not 
previously reported to have neurogenic potential, were exposed to PEB solution (PBS + EDTA + 
BSA) for 3 hours without any agitation of the medium. The behaviour of the cells was closely 
monitored throughout the treatment. Phase-contrast photomicrographs were taken of the cells (Figure 
3-61). Immunocytochemical labelling of these cell for neural markers used in other neural 
differentiation studies showed that they were immunonegative for those lineage markers (data not 
shown). R197VM hNSCs were used as positive controls to confirm that the antibodies and the 
labelling protocol had worked. Untreated HS27 fibroblasts were used as negative control. 
 
Figure  3-61 : Phase-contrast photomicrographs of HS27 primary human fibroblasts 
exposed to PEB (PBS + EDTA + BSA) for 3 hours. Arrows indicate bi- and multipolar cells. Scale 
bars are 100m. 
 
A further observation was made using passage 30 fhMSCs (24XY line). Five days after 
routine sub-culture, many of the cells assumed neural-like morphologies, as shown below (Figure 3-
62). 
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Figure  3-62 : Phase-contrast photomicrographs of passage 30 fhMSCs (24XY line) after 
routine sub-culture in D10 medium. After 5 days in culture at late passage, cells assumed bi- and 
multi-polar morphologies (arrows) in the absence of any treatment. Scale bars are 100m. 
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Summary : 
1. B104-conditioned medium had a dose- and time-dependent mitogenic effect of CG4 
oligodendrocytic progenitor cells. 
2. No oligodendrocytic (bipolar or multipolar) morphologies were seen in fhMSCs and 
hWJ cells treated with B104-conditioned medium. No positive labelling for 
oligodendrocytic antigenic markers was obtained on these cell types. 
3. The appearance of bi- and multipolar cells was likely due to a combination of sub-
optimal adherence to the culture substrate and the accumulation of toxic metabolites in 
the culture medium. 
4. Untreated and B104-CM-treated fhMSCs expressed neural and embryonic stem cell 
markers. Many of these markers were upregulated 1 day after the initiation of treatment, 
followed by a decrease in expression and a rise by 14 days of treatment. 
5. Cells cultured in the presence of toxic substances such as staurosporine (SSP) and 
glutamate retracted and mimicked the appearance of neural cells. This also occurred 
spontaneously in fhMSCs at late passage, and in fibroblasts treated with EDTA during 
sub-culture. 
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3.7.2 Protocol 5 - VEGF-C/PDGF-A/FGF2-Induced 
Oligodendrocytic Differentiation 
The aim of these experiments was to induce the oligodendrocytic differentiation of 
mesenchymal stem cells from foetal blood and Wharton’s Jelly using a modification of 
published protocols (140, 144, 176). 
The medium was changed twice a week, keeping any loose cells by centrifuging them 
after collecting the medium from dishes and re-seeding them or centrifuging wellplates and then 
aspirating the medium gently. This is so that any cells differentiating into progenitor cells which 
might not adhere well enough to the substrate would not be lost during the medium change. 
After 21 days of treatment, cells were fixed for immunocytochemistry or processed for 
subsequent Western blotting and PCR. Duplicate wells were used for each antibody 
combination to probe each cell type in each condition. 
At day 5 after the initiation of treatment, dramatic morphological changes were 
observed in all cell types (Figure 3-63). The most marked changes were seen in 24XY fhMSC 
cultures, in which the cells became neural-like (Figure 3-63D-F). Cells with altered morphology 
survived and appeared healthy at day 21. 
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Figure  3-63 : Phase-contrast photomicrographs of different cell types after 5 days of 
exposure to DMEM/F12 & Neurobasal medium containing N2 + B27+RA + PDGF-A + FGF2 + 
VEGF-C. Scale bars are 100m. 
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Although no quantification was undertaken for these experiments, there was no 
apparent change in the proportions of A2B5+, nestin+ and III-tubulin+ hWJ cells and fhMSCs in 
untreated (D10 medium) versus treated conditions, although for the first time in the current 
series of experiments, III-tubulin+ cells had neuronal-like morphologies, rather than being 
fibroblast-like during treatment with other factors. There was an increase in the proportions of 
nestin+ and III-tubulin+ hNSCs, the positive control cells (Figure 3-64). 
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Figure  3-64 : Various cell types stained for various neural markers after exposure to 
DMEM/F12 & Neurobasal medium containing N2 + B27+RA + PDGF-A + FGF2 + VEGF-C. Scale 
bars are 100m. 
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All cells were stained with secondary antibodies only as negative controls. All were negative. 
Figure 3-65 shows treated hWJ-18-2-05 cells stained with secondary antibodies only. 
 
Figure  3-65 : hWJ-18-2-05 cells stained using secondary antibodies only (negative 
controls) after exposure to DMEM/F12 & Neurobasal medium containing N2 + B27+RA + PDGF-
A + FGF2 + VEGF-C. Scale bar is 100m. 
Summary : 
1. Treatment of hWJ cells and fhMSCs resulted in dramatic morphological changes that 
indicated neuronal differentiation. 
2. However, there was no apparent change in the proportions of those cells expressing 
neuronal antigenic markers. Nonetheless, cells with neuronal morphologies expressed 
III-tubulin. 
3. As seen in previous experiments, the responses of hWJ cell lines to treatment varied. 
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4 DISCUSSION  
4.1 Isolation & Culture of Human Wharton’s Jelly (hWJ) Cells from 
the Umbilical Cord 
The isolation and expansion in vitro of high-purity hWJ cells were successfully 
achieved making them an accessible source of cells for potential use in the clinic. The efficiency 
with which they could be cryogenically stored and subsequently cultured also makes them ideal 
for therapeutic use. However, the isolation of hWJ cells in the absence of animal or human 
serum will need to be addressed before these cells can safely be used in therapeutic applications. 
4.2 Characterisation of Human Mesenchymal Stem Cells 
4.2.1 Morphology 
The Wharton’s jelly cells isolated in this study and previously published work indicate that 
they are a fibroblastic population of cells sharing morphological and other characteristics of 
typical foreskin fibroblasts and mesenchymal stem cells from other sources including foetal 
blood and adult bone marrow. 
As described for foetal MSCs (Kennea et al., in prep.) non-spindle shaped large flattened 
hWJ cells typical of non-proliferating fibroblasts gradually began to appear and increased with 
serial passaging (Figure 3-1E & F). It was not technically possible to exclude contaminating 
endothelial cells (despite the removal of the umbilical vein and arteries) and amniotic epithelial 
cells during the dissection procedure. MSCs with neurogenic potential have been isolated from 
these tissues (205, 259) and these MSCs have been used in rodent models of Parkinson’s 
disease (121). 
Karyotyping confirmed that no genetic abnormalities had resulted from extended culture in 
any of the cell types and lines used. This also has major implications for their eventual use in 
the clinic. 
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4.2.2 Antigenic Profile 
4.2.2.1 Immunocytochemistry 
There is presently no single antigenic marker capable of distinguishing mesenchymal 
stem cells and they must therefore be identified using a panel of antibodies. Since they share 
epitopes with fibroblasts, endothelial and amniotic epithelial cells, it is not possible to ascertain  
definitively that only cells from the umbilical cord matrix are responsible for the observations in 
this study. However, the fact that the majority of hWJ cells expressed markers associated with 
mesenchymal stem cells (38) (Figure 3-2) suggests that a relatively pure population of hWJ 
cells was successfully isolated.  Primary cultures immediately after isolation consisted of a 
mixture of cell morphologies from the matrix of the umbilical cord (from small and spindle-
shaped to large irregular-shaped with a prominent cytoskeleton), presumably not all stem cells 
and not all proliferative. This is the likely reason for the observation that the proportion of Ki67-
positive cells increased with passage number (Figure 3-2F). Serial passaging resulted in the 
expansion of the proliferative cells and the gradual loss of non-dividing ones. 
For comparison with oligodendrocyte-like cells obtained from mesenchymal cells and for 
use as positive antibody labelling controls, CG4 oligodendrocytic precursors cells were cultured 
and differentiated into mature oligodendrocytes (Figures 3-3 & 3-4). 
 
4.2.2.2 FACS 
As observed in a previous study (38), hWJ cells expressed very low levels of 
haematopoietic cell lineage markers CD34 and CD45 (Table 9). The same study also reported 
that only 10-15% of foetal MSCs isolated from the circulation expressed CD105, recognised by 
the SH2 antibody, as assessed by FACS. The present study replicated this finding using FACS, 
but also found that the same marker was expressed by the vast majority of fhMSCs (not shown) 
and hWJ cells (Figure 3-2C) using immunocytochemistry. It is possible that the detection limit 
of FACS is higher (less sensitive) than conventional immunocytochemistry, allowing more cells 
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to be identified as positive using the latter technique. This may be particularly important for 
CD105, which was very frequently expressed at low levels by many cells from different isolates 
(Figure 3-2C). 
4.2.3 Doubling Time 
The doubling time of hWJ cells obtained by serial passaging was comparable to that of 
fhMSCs, and suggests that they can be rapidly expanded in culture over extended periods. The 
CyQuant proliferation assay produced similar results to doubling time data obtained by serial 
passaging (Figure 3-5 & 3-6). This technique also highlighted the variation between different 
isolates of hWJ cells at the same passage. The reduced doubling times obtained for fhMSCs (30 
hours) by this laboratory (unpublished data, (38) may be due to the higher cell seeding densities 
used in these studies, 5 x 105 cells per 100mm dish and 10 000 cells/cm2, respectively compared 
to 2.5 x 105 per 100mm dish (equivalent to 4300 cells/cm2) in the present study. In our hands, 
fhMSCs and hWJ cells seeded at densities higher than 2.5 x 105 per 100mm dish reached 
confluence too quickly. 
 
4.2.4 Expression of Embryonic Genes (PCR) 
Undifferentiated mouse and foetal human MSCs from multiple sources  express the embryonic 
markers Oct4, Nanog and Rex1 (99, 141, 259), (Figure 3-7). This has important implications for 
their multi-lineage differentiation potential but also requires caution since, like embryonic stem 
cells, they may exhibit post-implantation oncogenic growth patterns. A careful and thorough 
assessment of their safety in experimental implantation models of human neurodegenerative 
conditions is therefore required before they can be used for clinical applications. However, thus 
far there is only one report of  tumour-like growth of murine MSCs (but not human MSCs) 
expressing embryonic makers including SSEA-1 by Dominique Bonnet’s group (3). 
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4.2.5 Telomere Length Assays 
Telomere length is directly proportional to self-renewal capacity and proliferation rate (5).  
In the present study  early passage fhMSCs and hWJ cells were observed to have long telomeres 
followed by a gradual decrease in telomere length coincident with a decline in proliferative 
capacity and self-renewal (Figure 3-8). This suggests that fhMSCs and hWJ cells possess 
limited replicative capacity. This would favour their use clinically compared to embryonic cells 
since they are unlikely to divide uncontrollably after transplantation, 
 
4.3 Mesodermal Differentiation of Human Mesenchymal Stem Cells 
4.3.1 Bone Differentiation Potential 
Alizarin Red S stains calcium-rich extracellular matrix (ECM) deposited by cells 
(http://www-medlib.med.utah.edu/WebPath/webpath.html). The slight increase in labelling in 
untreated hNSCs is therefore not surprising, since these cells synthesise ECM molecules in 
vitro. This increase was more pronounced in BDM2. The same observations were made for 
fhMSCs, but on a greater scale since these cells synthesise more matrix than hNSCs in culture. 
The increase in Alizarin Red S labelling with time in fhMSCs in D10 medium might also 
represent spontaneous differentiation. The amount of labelling of untreated hWJ cells remained 
relatively stable compared to fhMSCs. However, hWJ cells treated with BDM2 accumulated 
more Alizarin Red S stain compared to untreated controls. The fall in the amount of labelling 
may reflect increased cell death after the cells have reached confluence in a medium that 
contains 10% FBS. Different fhMSC lines showed varying abilities to form nodules in BDM2 
(Figure 3-9), which reflects a variation in either the differentiation potential or the response to 
treatment of cells from different isolates. Furthermore, given that cultures were generated from 
foetuses of different ages and sexes, a direct comparison was not possible and would require a 
minimum of three isolates of the same age and sex, which could not be obtained. No bone 
nodule formation was observed in hWJ cell cultures (Figure 3-9). Osteogenic differentiation 
would need to be confirmed by quantitative or semi-quantitative PCR in order to test for any 
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increase in the expression of recognised osteogenic-associated genes, including collagen I, 
osteopontin, cbfa1, osterix, alkaline phosphatase and bone sialoprotein. 
4.3.2 Fat Differentiation Potential 
Oil Red O extraction and quantification, a measure of lipid accumulation, was not a 
reliable indicator of adipogenic differentiation since it was not matched by the amount of 
intracellular lipid globules observed. A recognised marker of adipogenic differentiation (38), 
intracellular lipid globules were observed only in the FDM treated cells (Figure 3-10). 
Adipogenic differentiation would need to be confirmed by quantitative or semi-quantitative 
PCR in order to assess an increase in the expression of recognised adipogenic genes, including 
Fatty Acid Binding Protein-4 (FABP4) and PPARg2. Functional characterisation studies are 
also required, such as catecholamine-regulated lipolysis, and adiponectin and leptin secretion  
(220). The differences in the responses of the three hWJ cell lines (Figure 3-12A-C) reflect the 
variations of cells from different isolates. It is possible that different isolates contain cells with 
varying differentiation potentials and/or different proportions of sub-populations with varying 
potentials. This could be confirmed by performing clonal studies in which cultures of hWJ cells 
derived from single cells are expanded and their differentiation potentials analysed. However, 
given the difficulties in generating proliferative clonal colonies from fhMSCs (and quite likely 
hWJ cells) and obtaining sufficient cell numbers for experiments before the onset of senescence, 
this was not attempted in the present study. Another potential source of variation is the age and 
sex of the donor. In the present study, age was standardised by taking umbilical cords only from 
full-term births without complications. 
 
4.3.3 Chondrogenic Differentiation Potential 
Only Alcian Blue (pH 1.0), a copper-containing cationic phthalocyanine dye, was 
reliable as a marker of chondrogenic differentiation because it increased when the positive 
controls cell type (fhMSCs, the 40mm line) were treated with chondrogenic medium. This 
might be due to sub-optimal labelling conditions, or more likely to the fact that the type of 
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glycosaminoglycans or mucopolysaccharides synthesised in response to treatment and/or the 
amount by the synthesis increased could not be detected by other dyes such as Safranin O. 
Therefore,  PCR analysis would be required to detect the expression of recognised genetic 
markers of chondrogenic differentiation such as collagen types I and II (38, 231). The fact that 
only one hWJ cell line showed indications of chondrogenic differentiation (as determined by 
increased Alcian Blue labelling, Figure 3-13) is important, since it highlights the variations in 
differentiation potential between hWJ cells obtained from different umbilical cords. This is 
possibly a reflection of the heterologous nature of the starting populations of cells, since clonal 
colonies were not isolated and cells were not purified or enriched using FACS or 
immunopanning before the induction of differentiation. For hWJ cells to be used 
therapeutically, their differentiation potential would need to be assessed in vitro in advance. 
This could be avoided by using heterologous hWJ without immune rejection, although the 
safety of such an intervention remains to be tested both in culture and in experimental subjects. 
Chondrogenic differentiation could be enhanced by using additional factors such as BMP2 and 
6 (226, 230). 
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4.4 Protocol 1 - Differentiation of Human Mesenchymal Stem Cells 
into Neural Stem Cells 
Recently, Nistor’s group reported the generation of a highly pure population of 
oligodendrocytic precursors from human ES cells using a medium formulation very similar to 
the one used here - 20 µg/ml insulin, 20ng/ml T3, 2ng/ml bFGF, 20ng/ml EGF, 10µM all-trans 
retinoic acid in DMEM and 1% B27 (197). Therefore, the treatment employed in this study is 
not only a potential neural stem cell induction protocol but could also generate oligodendrocytic 
progenitors. Exposure to EGF and FGF2 has also been reported to generate neural cells from 
whole bone marrow (120). 
Given recent suggestions that apparent transdifferentiation might be explained by a cellular 
response to stress (59, 168, 243), dermal fibroblasts isolated from infants during routine 
circumcision procedures were used as negative controls. These cells are the closest to umbilical 
cord matrix cells from the end of gestation in terms of the developmental age of the donors. 
As reported in previous studies (27, 63, 256), nestin was found to be expressed in untreated 
fhMSCs and hWJ cells. However, whilst the proportion of nestin-positive fhMSCs and hWJ 
cells and the intensity of expression increased in mitogen-supplemented medium (DF/SFEM), 
no change was observed for fibroblasts, suggesting that this change was not due to the removal 
of serum from the culture medium. 
Not all hWJ cell lines responded in the same way to exposure to serum-free mitogen-
supplemented medium. The proportion of nestin+ hWJ-18-2-05 cells increased only slightly 
compared to untreated controls (Figure 3-15). 
The culture of cells in DMEM/F12 medium not supplemented with either serum or 
mitogens served as an additional negative control. The absence of any increase in the proportion 
of nestin+ cells strongly suggests that changes in the expression of this stem cell marker was not 
stress-induced due to the removal of serum during treatment. 
The picture was not so clear for A2B5 expression (Figure 3-17). Although there was a 
slight increase in expression in mitogen-supplemented medium compared to untreated negative 
controls, there was an even greater increase for the 3 lines tested in DMEM/F12 alone. This 
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suggests that the expression of A2B5 might be related to the absence of serum. However, 
fibroblasts did not express A2B5 in any of the conditions tested. A2B5 has not been used in 
published transdifferentiation studies on mesenchymal stem cells, despite being a well-
recognised marker of oligodendrocytic progenitor cells (73). Unsupplemented DMEM/F12 
medium lacking mitogens and inhibitory factors present in serum, may allow mesenchymal cells 
to express A2B5 as a result of unrestricted differentiation. 
It has been reported that undifferentiated bone marrow-derived mesenchymal stem cells 
express the neuronal marker III-tubulin  (27, 63, 256). In agreement with this,  III-tubulin  was 
expressed in  fhMSCs and hWJ cells although the proportion of positive cells (50-70%) was 
surprisingly high (Figure 3-19). The reason for this is unknown, since all immunocytochemical 
protocols had been optimised. Negative control cell types (fibroblasts) did not express this 
marker and positive cells (differentiated neural stem cells) did. The morphology of  hWJ cells 
and fhMSCs which did express this marker was, however, not neurone-like but remained 
fibroblastic suggesting that III-tubulin might not only be expressed but upregulated by such 
cells when stressed by the absence of serum and without neuronal differentiation. The greater 
proportion of positive cells observed in DMEM/F12 alone compared to those in D10 medium 
supports this hypothesis. On the other hand, the presence of mitogens should partially 
compensate for the stress that mesenchymal cells are exposed to upon removal of serum. It was, 
therefore, surprising to find a greater proportion of III-tubulin-positive cells in mitogen-
supplemented medium compared to DMEM/F12 alone. This may be an indication that the 
mitogens used (EGF and FGF-2) promote the expression of this marker in hWJ and fhMSCs 
under serum-free culture conditions. Although no quantification was undertaken, similarly high 
proportions of fhMSCs and hWJ cells expressed MAP2, NSE and NeuN. Human fibroblasts 
were used as negative labelling controls, and R197VM hNSCs were used as positive controls 
(data not shown). The dilutions of all antibodies used were optimised in order to minimise non-
specific labelling. No GFAP-positive mesenchymal cells were seen in any condition at any time, 
unlike most published studies (164, 223). 
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Untreated hWJ and fhMSCs did not express PSA-NCAM (Figure 3-22). The upregulation 
of this marker under different culture conditions varied with not only the cell type but the 
particular line. Results were similar to those obtained for A2B5. A dramatically greater 
proportion of hWJ cells in DMEM/F12 alone expressed PSA-NCAM than those in D10 and 
mitogen-supplemented media. The reason for this is unknown. Unlike the other two hWJ cell 
lines tested, hWJ-18-2-05 cells did not express this marker in mitogen-supplemented medium. 
A relatively low percentage of fhMSCs in DMEM/F12 alone and mitogen-supplemented 
medium expressed PSA-NCAM compared to those in D10 medium. PSA-NCAM has not been 
routinely used in neural differentiation studies on non-neural cells, although it is a well 
recognised marker of stem cells and slightly more mature neuronal progenitors (6). 
hNSCs were an additional positive control for CD105 labelling (using the SH2 antibody), 
since they also are known to express CD105, the VEGF-receptor (177). The proportion of 
CD105+ MSCs and hWJ cells decreased from 90% to 80% in the absence of serum, but was 
similar in DMEM/F12 alone and mitogen-supplemented medium (Figure 3-24). Proportions of 
CD73+ cells (using the SH3 antibody) fell slightly in mitogen-supplemented medium compared 
to those in D10 medium (Figure 3-25). This suggests that the mesenchymal markers CD105 and 
CD73 are down-regulated only slightly in the absence of serum, and that mitogens, instead of 
maintaining the levels of expression of these markers, further down-regulate them in the hWJ 
cells and fhMSCs tested. The hypothesis was that an increase in the proportions of cells 
expressing neural antigenic markers would coincide with a decrease in the proportion of CD105 
and CD73-positive cells. The observed  increase in the proportions of nestin and III-tubulin-
positive cells in mitogen-supplemented medium compared to DMEM/F12 alone and D10 
medium appears to support this, although the increase in the proportions of nestin and III-
tubulin-positive cells were greater than the decrease in SH2 and SH3-positive cells. 
The mitogenic effect of the growth factors used and the survival rate of the cells in the 
absence of serum during the course of these experiments were investigated by counting the 
numbers of cell per field at the same magnification. Unsurprisingly, cell numbers dropped in 
DMEM/F12 alone (Figure 3-26). A mild mitogenic effect as detected for hWJ-27-10-04, and a 
dramatic effect was seen for hWJ-18-2-05 cells. This suggests that EGF and FGF2 combined 
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can be mitogenic for at least 14 days in the absence of serum for hWJ cells and fhMSCs 
previously cultured in 10% serum, although this effect varies with cell line. FGF2 has been 
shown to be mitogenic for bone marrow MSCs (17). 
The similarity of cell numbers between cell types and conditions also suggests that cell 
counts were unlikely to have been affected by the number of cells in each field with the possible 
exception of one cell line (hWJ-18-2-05). The reason for this is unknown. 
4.5 Protocols 2 & 3 - Neuronal Differentiation of Human Mesenchymal 
Stem Cells 
Noggin and sonic hedgehog (Shh) are well recognised inducers of neuronal fate in neural 
stem cells. Gerrard et al., 2005 (90) used noggin to block BMP signalling in ES cells and induce 
their differentiation into neural progenitors which subsequently differentiated into tyrosine 
hydroxylase-expressing neurones. The protocol employed in this study was adapted from this 
publication. Kohyama et al. transfected bone marrow-derived MSCs with noggin to derive 
electrophysiologically active neurones, although only one marker (MAP2) was used to confirm 
neuronal differentiation (132). 
Noggin has also been found to promote the formation of A2B5+ cells in cultures of neural 
precursors derived from ES cells (115). Noggin and FGF2 can maintain the pluripotent state of 
human ES cells (265, 279) and therefore were not used in combination in this study. 
Shh also has a central role in the development of oligodendrocytes in the ventral forebrain 
(250). Similarly to noggin, Shh has also been used to generate dopaminergic neurones from ES 
cells. Nurr1-overexpressing murine ES cells were shown to generate a highly enriched 
population of dopaminergic neurones in the presence of Shh and FGF8, which integrated 
(without forming teratomas) into the brains of 6-hydroxydopamine (6-OHDA)-lesioned rats and 
exhibited electrophysiological properties of mesencephalic neurones (126, 128, 146). The 
protocol employed here was adapted from the latter publication.  
Human ES cells can also generate dopaminergic neurones with similar efficiency. 
Recently, Roy et al. (219) reported the derivation of a high percentage (67.4%) of A9 
nigrostriatal dopaminergic neurones of the type lost in Parkinson’s disease from human ES cells 
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by co-culturing with mesencephalic astrocytes in the presence of FGF8 and Shh. Significantly 
less dopaminergic neurones were obtained when hES cells were co-cultured with astrocytes 
from a different region of the brain. 
Shh has been used to induce the neuronal differentiation of non-neural cells. In synergy 
with retinoic acid (also present in B27 in the present protocol) and in the presence of FGF2, it 
was found to promote the formation of sensory neurones from bone marrow-derived MSCs 
(133). However, the treatment involved the use of toxic reagents such as IBMX and -
mercaptoethanol.  We attempted to differentiate MSCs into neural cells without toxic chemicals 
that would render the protocol clinically inapplicable. Interestingly, the same group found that 
exposure to FGF2 promoted the expression of neuronal antigenic markers in MSCs. 
As reported previously, 5-10% of untreated fhMSCs and hWJ cells expressed nestin 
(Figure 3-29). The absence or lower levels of nestin expressed by untreated cells (serum-free 
medium) after 21 days suggests that the increase in the proportion of nestin+ treated cells was 
not due solely to stress caused by the removal of serum from the culture medium. On the other 
hand, nestin expression may have been upregulated at earlier stages of serum withdrawal. There 
was a notable increase in the proportion of nestin+ cells in Shh+FGF2+FGF8-treated cultures of 
some but not all cell lines. 
Given that the two treatments used in these experiments are designed to induce neuronal 
differentiation, it was not surprising to find no or very little A2B5 and GalC expression (Figures 
3-31 & 3-34) although A2B5 is also recognised as an indicator of early neurones and Shh 
promotes oligodendrogliogenesis. 
The proportion of cells expressing the neuronal marker III-tubulin decreased in response to 
treatment (Figure 3-32). However, given the very high proportion of untreated III-tubulin+ cells, 
this is not a reliable indicator of neuronal differentiation of fhMSCs and hWJ cells. 
 In contrast, these experiments revealed an increase in the proportion of PSA-NCAM+ cells 
(hWJ-27-10-04 only, Figures 3-33 & 3-34). The fact that low numbers of untreated fhMSCs and 
hWJ cells express this marker is important as it suggests that these cultures contain 
subpopulations with the capacity to generate neural cells. Whether these were of mesodermal 
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origin remains unknown. Although the PSA-NCAM+ cells did not exhibit neuronal morphology, 
neural stem cells which express this marker are also often similarly non-neuronal in morphology 
(Figure 3-22). 
Unlike previous protocols tested, the proportion of cells expressing CD105 (detected using 
the SH2 antibody) decreased to varying extents in all lines tested (Figure 3-37). The proportion 
of CD73+ cells (detected by SH3 antibody) also decreased albeit to a lesser extent (Figure 3-39). 
Neurones and neural stem cells express CD105 (177). Therefore, it could be argued that if these 
experiments resulted in neuronal specification, the levels of CD105 expression would not 
decrease to the levels observed (Figure 3-37). 
As observed in experiments using protocol 1, FGF2-supplemented medium had a 
mitogenic effect on fhMSCs and hWJ cells, even in the absence of serum, throughout the 3 
week culture period. The mitogenic effect of FGF2 on MSCs has long been recognised (200). In 
the absence of mitogens but in medium supplemented by B27 (without retinoic acid) and N2, 
cell survival was maintained throughout the duration of treatment. This has important 
implications for the use of MSCs in the clinic setting as it suggests that they can be maintained 
and expanded in culture in the absence of serum for extended periods. 
The limited success of this treatment in generating neurones from fhMSCs and hWJ cells 
may be explained by the requirement of additional, as yet unidentified, factors that play 
important roles in neural induction (240). 
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4.6 Protocols 4 & 5 - Oligodendrocytic Differentiation of Human 
Mesenchymal Stem Cells  
4.6.1 Protocol 4 - B104-CM-Induced Oligodendrocytic 
Differentiation 
The viability of the B104-CM produced was analysed based on its mitogenic effect on CG4 
cells. Although the optimum growth of these cells was obtained using 15-30% B104-CM 
(Figure 3-41), previous experiments suggest that a slightly higher concentration is required for 
non-neural cells possibly due to degradation of factors within the conditioned medium during 
incubation at 37oC. 
 
Based on previous observations made in the laboratory, the lack of oligodendrocytic 
morphological changes with B104-CM treatment of hWJ cells and fhMSCs in the present study 
was surprising (Figure 3-43). These findings are in contrast to observations made in previous 
experiments using fhMSCs. This may be due to re-addition of L-glutamine to culture media in 
the later experiments resulting in an increase in cell survival. All other conditions and materials 
were unchanged compared to previous experiments. In agreement with this, when the above 
experiment was repeated on 24XY fhMSCs using the same batch of B104-CM that had been 
stored at 4oC for three weeks, bi- and multipolar cells appeared within a few days of exposure. 
The degradation of L-glutamine into glutamate, which is toxic to cells, may therefore explain 
the retraction of cells in earlier experiments. In order to test this hypothesis, this experiment was 
repeated using unsupplemented compared to L-glutamine-supplemented B104-CM. Refer to 
Section 4.6.1.1 of the Discussion. 
 
In contrast to previous findings, no morphological change indicative of oligodendrocytic 
differentiation was observed in any cell type at any point. This may be due to the optimised 
extracellular matrix coating procedure used in these later experiments which increased cell 
adherence to the substrate and therefore did not result in retraction upon removal of serum. 
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To confirm that cell confluence, attained as a result of continued cell proliferation in B104-
CM, was not hindering the formation of bi- and multipolar fhMSCs and hWJ cells in B104-CM, 
the growth of cells in B104-CM was examined. This would provide a method for controlling the 
final cell density during treatment. 
Since the cells did not proliferate in DMEM only after culture in D10 medium (Figure 3-
44), proliferation was not due to a residual mitogenic memory effect of serum exposure but 
possibly to the persistent expression of growth factor receptors and presence of corresponding 
factors within the B104-CM. Expression of growth factor receptor appeared to decline after 12 
days in DMEM alone and subsequent exposure to B104-CM did not lead to proliferation of the 
cells, unlike those in DMEM alone for only 6 days. Exposure to B104-CM prolonged the 
mitogenic responsiveness of fhMSCs and hWJ cells to the reintroduction of serum, given the 
slight increase in cell numbers seen after switching from B104-CM to D10 medium. 
It is possible therefore that final cell density may be controlled by an initial period in 
DMEM alone. However, it is also possible that a decrease or absence in growth factor receptors 
may reduce the potential or prevent the differentiation of mesenchymal cells into neural cell 
lineages. After 28 days in culture, no bi- or multipolar cells were observed. A further point to 
note is that many cells cultured in DMEM alone were under stress, indicated by the 
accumulation of lipid globules (Figure 3-45). An alternative explanation is that the absence of 
serum induces these cells to differentiate into mesodermal lineages, including adipogenic 
lineages. 
 
Undifferentiated mouse and foetal human MSCs have been found to express the embryonic 
markers Oct4 and Rex1 (99, 141) (Figure 3-7, 49). Nestin expression by untreated fhMSCs was 
confirmed at the RNA level by PCR (Figure 3-55). Expression of all the markers analysed, 
except CD133, increased upon treatment followed by a decline that was either maintained at 14 
days (Rex1) or increased again. There was no decline at 7 days of treatment in the expression 
levels of Olig2, which continued to increase even at 14 days. 
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In spite of the above changes in expression levels, no coincident morphological changes 
indicative of neural differentiation were observed. With increases a day after the initiation of 
treatment, it is possible that the increase in expression of these genes within 24 hours of 
treatment is induced by stress following the withdrawal of serum. 
 Changes in gene expression levels also occurred in culture in the absence of any other 
treatment but serum withdrawal (in N1 medium, Figure 3-49). It is therefore important to 
include untreated controls at all timepoints during differentiation experiments. It is also possible 
that important changes may have occurred in fhMSCs in D10 medium, however, the sustained 
proliferation of cells and death after over-confluence was achieved (and the resulting difficulties 
in interpretation of the data) made it impossible to analyse the results obtained under these 
culture conditions. Levels of expression of all the genes tested remained relatively stable 
throughout the course of the experiments in treated hNSCs and fibroblasts. 
 
4.6.1.1 Effect of Cell Stress on the Morphology of fhMSCs & Implications for 
Oligodendrocytic Differentiation in B104-CM 
The fact that bi- and multipolar cells appeared in DMEM only (Figure 3-59), a condition 
lacking as a negative control during previous experiments in the laboratory, suggests that the 
appearance of these cells with neural-like morphologies may actually be a result of cell 
retraction upon withdrawal of serum from the culture medium. 
The fact that there was more cell death in the presence of freshly thawed B104-CM, rather 
than less, as expected given the growth factors in B104-CM, suggests that there might be 
cytotoxic factors within the conditioned medium. Another interesting observation was the 
predominance of cell death towards the edges of culture wells, an observation also made in 
previous experiments by Dr Nigel Kennea in this laboratory. This may be due to decreased cell 
density tends around the periphery of wells compared to the centre. Cells further away from the 
centre of wells might be more vulnerable to a toxic element in the medium. Furthermore, these 
cells would be more likely to retract because MSCs secrete extracellular matrix molecules 
which would be less concentrated towards the edges of wells. 
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On the other hand, it could be argued that factors in B104-CM exert their neurogenic 
effects on fhMSCs in a cell density-dependent manner and that cells at a lower density would be 
more likely to differentiate into oligodendrocytes. However, the fact that they did not express 
the appropriate lineage markers and failed to survive or proliferate in culture (even when 
medium was supplemented with FGF2 and PDGF (which support the growth of CG4 
oligodendrocytic progenitors; data not shown) does not support this latter hypothesis. However, 
in previous experiments carried out by Nigel Kennea in this laboratory, no difference in the 
proportions of bi- and multipolar cells treated with B104-CM was found in different conditions 
– uncoated versus fibronectin-coated substrate (no poly-D-lysine was used) or at different cell 
seeding densities. However, in that study, cells with neural morphologies survived for longer 
periods on fibronectin compared to uncoated substrate. This determined the choice of ECM 
coating for the present experiments.  
In the present study, no morphological changes indicative of oligodendrocytic 
differentiation were observed in fhMSCs treated with B104-conditioned medium at different 
cell seeding densities or on different substrates. This indicated that substrate coating and cell 
density did not contribute to the generation of oligodendrocyte-like cells from fhMSCs. In both 
studies, the same fhMSCs (24XY) cell line and passage number were used suggesting that 
factors in the medium are likely to be responsible for the previously observed effect. 
 
The accumulation of toxic factors in the medium is supported by the appearance of bipolar 
cells in the presence of glutamate (Figure 3-60, conditions 7 and 8), which was added in order to 
mimic its formation from the breakdown of L-glutamine. However, the absence of bi- or 
multipolar cells in condition 5 (B104-CM supplemented with glutamine and incubated for three 
weeks at 37oC) appears to contradict this theory.  
A further possibility is that the accumulation of glutamate actually promotes the 
differentiation of fhMSCs into neural cells. Glutamate has been found to promote the survival 
and proliferation of neural precursors (28). However, the absence of positive labelling for neural 
markers does not support this hypothesis. 
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The addition of staurosporine (SSP) partially mimicked the addition of glutamate and 
B104-CM. The effect of this cytotoxin was delayed by the presence of 10% serum. 
The additional experiments with fibroblasts illustrate the point that neural morphologies 
can appear in cells not previously reported to have neurogenic differentiation potential in the 
absence of neurogenic stimuli, but under cell stress in the presence of a calcium-chelating agent 
(EDTA, Figure 3-61). For late passage fibroblasts of the same line, no neurogenic stimulus was 
used (Figure 3-62). Although subtle differences exist between these fibroblastic cells and 
differentiated CG4 cells (Figure 3-59), the absence of oligodendrocytic immunomarker 
expression supports the idea that no oligodendrocytic differentiation took place in this case. 
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4.6.2 Protocol 5 - VEGF-C/PDGF-A/FGF2-Induced 
Oligodendrocytic Differentiation 
The aim of this experiment was to differentiate MSCs derived from WJ and foetal blood 
into oligodendrocytes using a combination of VEGF-C, FGF2 and PDGF-AB.  
LaChapelle et al in 2002 (140) tested the ability of adult lateral ventricle rostral SVZ 
progenitor cells to generate oligodendrocytes by grafting into the brain of neonate shiverer and 
wild-type mice. Injection of the donor with FGF2 or PDGF-AB prior to isolation of the SVZ 
dramatically improved the proliferation (up to 4.5-fold), survival, migration (up to 4-fold) and 
differentiation into myelinating (MBP+) oligodendrocytes and neurones of SVZ-derived PSA-
NCAM+ progenitors post-grafting. Astrocytic differentiation was not affected by growth factor 
treatment. Interestingly, a combination of FGF2 and PDGF-AB led to a total absence of survival 
of the grafted cells. 
Mani et al., 2005 (176) found that VEGF increased proliferation of astrocytes. Exposure of 
astrocytes to VEGF upregulated expression of FGF2, VEGF, GFAP and nestin. These results 
differ from studies by Le Bras and LaChapelle possibly because they used human VEGF165 
(V7259, Sigma), which contains a mixture of different isoforms (A, C and D) rather than a 
specific isoform. 
More recently and in contrast to Mani et al., Le Bras et al., 2006 (144) found that 100ng/ml 
of VEGF-C (but not VEGF-A) promoted proliferation of A2B5+/VEGF-R3+ OPCs but not 
astrocytes in the embryonic mouse optic nerve. It also increased the number of Olig2+ cells in 
cultures of E14.5 mouse ventral forebrain, which also express VEGF-R3. Furthermore, this 
group showed that vegf -/- and vegf +/- mice had 60% less Olig2+ cells in the SVZ and 85% less in 
the optic nerve compared to wildtype animals (vegf +/+). It was also shown that VEGF-C (but not 
VEGF-A) was required for olfactory bulb neurogenesis. 
The protocol used in the present study was modified from Le Bras et al., 2006. 
Interestingly, the protocol employed by Le Bras et al is very similar to that used by another 
group to induce the cardiomyocytic differentiation of adult rodent bone marrow MSCs (278). 
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However, in that and in the present study no spontaneously contracting cardiomyocytic cells 
were observed during treatment. 
Using this protocol for the induction of oligodendrocytic differentiation, fhMSCs but not 
hWJ cells adopted a neuronal morphology in response to treatment (Figure 3-63). However, no 
oligodendrocytic morphology or immunocytochemical labelling was observed. This is the first 
treatment that resulted in the appearance of fhMSC-derived cells with immature neuronal 
morphology that were also immunopositive for III-tubulin, a neuronal marker (Figure 3-64). 
However, since most of the untreated fhMSCs and hWJ cells expressed this antigenic marker, 
this observation is to be interpreted with caution. 
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5 CONCLUDING REMARKS & FUTURE WORK 
Our results suggest that hWJ cells are an ethical and abundant alternative source of stem 
cells compared to fhMSCs obtained from elective abortions. Future experiments with hWJ cells 
will attempt to confirm their mesodermal differentiation potential and analyse in greater detail 
the variations between cells from different umbilical cords and the evaluation of their 
neurogenic potential. 
The embryonic origin of cells isolated for the present study also requires further 
investigation as cells of the outer amniotic membrane were not separated from those of the 
matrix (Wharton’s jelly). Given that the amniotic membrane is of ectodermal origin and also 
contains progenitor cells (9, 199)  whilst cells of the matrix are of mesodermal origin, the 
precise origin of the stem cells cultured in the present study awaits confirmation. 
Some investigators have studied the effects of co-culturing MSCs with astrocytes. Lei et al. 
(2007) (147) co-cultured rat MSCs with mouse foetal brain astrocytes. They found that the 
MSCs expressed GFAP. Wislet-Gendebien et al. (2005) (274) co-cultured adult MSCs with 
cerebellar granule cells to differentiate them into electrophysiologically functional neurones. 
This group found that direct cell-cell interaction was a prerequisite of neural differentiation of 
MSCs. In the same year, another group (85, 86) exposed Wharton’s jelly cells to neuronal 
conditioned medium before treating with Shh and FGF8. This not only generated 12.7% of 
tyrosine hydroxylase-positive cells, but transplantation of these cells into the striatum of rats 
previously made Parkinsonian by unilateral striatal lesioning with the dopaminergic neurotoxin 
6-hydroxydopamine (6-OHDA) partially corrected the lesion-induced amphetamine-evoked 
rotation. 
In this respect, future work on the neurogenic potential of MSCs from Wharton’s jelly 
would need to focus on the effects of diffusible factors from neural stem cells and differentiated 
neurones, astrocytes and oligodendrocytes. The R197VM hNSCs used in this study were 
derived from the human embryonic ventral mesencephalon, the same brain region that Roy et al.  
(219) derived astrocytes to co-culture with ES cells. R197VM hNSCs could easily be 
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differentiated into astrocytes by exposure to serum or complete withdrawal of growth factors. 
These astrocytes could be used for co-culture with hWJ cells to differentiate them into neurones. 
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6 APPENDIX 
 
Figure A1 : Western blot of samples 1-9. Only III-tubulin, Oct4 and Nanog worked well on 
Western blotting, with bands at the expected sizes. 
 
Samples 4, 6 & 9 were reprobed with secondary antibody and normal ECL (not Super 
Signal) was used for lower signal intensities (Figure A2). Only III-tubulin worked well on 
Western blotting, with a band at the expected size of 46kDa. 
 
Nestin          MAP2      SH3         NG2 
1                    2               4   5
200 kb 
46 kb 
III-Tubulin    Oct4        Nanog        SH2        CD133 
            6              7        8         9            3 
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Figure A2 : Western blot of samples 4, 6 & 9 (reprobed), and 10-14. 10, 5B5; 11, MBP 
(pr-diluted); 12, NSE; 13, CNPase; 14, NeuN. 
Nestin    SH2 
 6            9
  5B5    MBP          NSE      CNPase    NeuN 
     10        11           12  13     14
50 kb 
75 kb 
100 kb 
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Figure A3:  Western blots to test antibodies against prolyl-4-hydroxylase (5B5, sample 
10), MBP (11), NSE (12), CNPase (13), NeuN (14), Sox1 (15), III-tubulin on fhMSCs (16), OSP 
(17), Nkx2.2 (18) and Olig2 (19).  Anti-MBP did not work on Western blot. The antibody against 
NeuN (sample 14) recognised multiple bands, as expected, but of greater sizes than expected (Refer to 
Table 1). Untreated fhMSCs (24XY) expressed III-tubulin, given the band at the correct size (46kDa). 
The antibody against Oligodendrocyte-Specific Protein (OSP) recognised an epitope at 22kDa in 
addition to one at 25kDa and one at 70kDa and 100kDa. Antibodies against Nkx2.2 and Olig2 
recognised proteins of the correct sizes. 
 
 
  Sox1    B3Tub        OSP      Nkx2.2    Olig2 
     10        11          12  13   14
100 kb 
160 kb 
200 kb 
25 kb 
46 kb 
60 kb 
20 kb 
32 kb 
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